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ABSTRACT 
Major Histocompatibility Complex (MHC) class II molecules are indispensable arms of the im-
mune system that present extracellular antigens to CD4
+
T cells and initiate the adaptive immune 
response.  MHC class II expression requires recruitment of a master regulator, the class II trans-
activator (CIITA).  How this master transcriptional regulator is recruited, stabilized and degraded 
is unknown.  The 26S proteasome, a master regulator of protein degradation, is a multi-subunit 
complex composed of a 20S core particle capped on one or both ends by 19S regulatory par-
  
ticles.  Previous findings have linked CIITA and MHC class II transcription to the ubiquitin pro-
teasome system (UPS) as mono-ubiquitination of CIITA increases its transactivity whereas poly-
ubiquitination targets CIITA for degradation.  Increasing evidence indicates individual ATPase 
subunits of the 19S regulator play non-proteolytic roles in transcriptional regulation and histone 
modification.  Our initial observations indicate proteasome inhibition decreases CIITA transac-
tivity and MHC class II expression without affecting CIITA expression levels.  Following cyto-
kine stimulation, the 19S ATPase Sug1 associates with CIITA and with the MHC class II enhan-
ceosome complex.  Absence of Sug1 reduces promoter recruitment of CIITA and proteasome 
inhibition fails to restore CIITA binding, indicating Sug1 is required for CIITA mediated MHC 
class II expression.  Furthermore, we identify a novel N-terminal 19S ATPase binding domain 
(ABD) within CIITA.  The ABD of CIITA lies within the Proline/Serine/Threonine (P/S/T) re-
gion of CIITA and encompasses a majority of the CIITA degron sequence.  Absence of the ABD 
increases CIITA half-life, but blocks MHC class II surface expression, indicating that CIITA re-
quires interaction with the 19S ATPases for both its deployment and destruction.  Finally, we 
identify three degron proximal lysine residues, lysines (K):  K315, K330 and K333, and a phos-
phorylation site, serine (S), S280, located within the CIITA degron, that regulate CIITA ubiqui-
tination, stability and MHC class II expression.  These are the first lysine residues identified as 
sites of CIITA ubiquitination that are essential for MHC class II expression.  These observations 
increase our understanding of the role of the UPS in modulating CIITA mediated MHC class II 
transcription and will facilitate the development of novel therapies involving manipulation of 
MHC class II gene expression. 
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THE UBIQUITIN PROTEASOME SYSTEM  
Work in the late 1930‟s by Schoenheimer first indicated the cellular pool of proteins is in 
a “dynamic state” involving constant synthesis and degradation (Olson 1997).  We now know the 
process of protein degradation carried out by the ubiquitin proteasome system (UPS) plays a crit-
ical role in the maintenance of this cellular homeostasis.  Ubiquitination is the term applied to the 
enzymatic cascade that covalently attaches ubiquitin, a 76 amino acid protein, to a substrate pro-
tein.  The 26S proteasome is itself a multi-subunit complex known as the master regulator of pro-
tein degradation.  The role of ubiquitin and the 26S proteasome in protein turnover was compre-
hensively described in 1970s and early 1980s (Hochstrasser 1996; Ciechanover 2009) and in the 
last two decades the ubiquitin proteasome pathway has been demonstrated to play crucial roles in 
cellular activities as diverse as cell cycle regulation, DNA damage repair, signal transduction, 
membrane trafficking, neural development and transcription.  While it is well accepted that 
changes in proteolytic functions of the UPS lead to deregulation of cellular function and disease 
development, recent studies have introduced differential ubiquitination pathways and non-
proteolytic functions of the UPS and have demonstrated their equally significant impact on cellu-
lar function and disease.   
Here, the ubiquitin pathway and the 26S proteasome are discussed with emphasis on the 
process and forms of ubiquitination, the structural components of the 26S proteasome and the 
impact of proteasome diversity.  Furthermore, we summarize recent findings indicating non-
proteolytic roles for components of the UPS in regulating a multitude of cellular processes and 
also indicate their significant impact on disease development.  The complex roles of the UPS in 
these diverse cellular functions impact epigenetics, transcription and post-translational modifica-
tions.  The proteolytic and non-proteolytic roles of UPS discussed herein are intended to provide 
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increased understanding of the significant contributions of the UPS in regulating cellular func-
tions. 
 
THE UBIQUITIN PATHWAY 
The process of protein ubiquitination and degradation was first identified by Aron Cie-
chanover, Avram Hershko and Irwin Rose for which they received the Nobel prize in Chemistry 
(Hershko and Ciechanover 1998).  Ubiquitin, initially termed adenosine triphosphate (ATP) de-
pendent proteolysis factor 1 (APF-1) (Ciehanover, Hod et al. 1978), is a highly conserved, 
8.5kD, 76 amino acid protein which is ubiquitously expressed in eukaryotic cells (Ciechanover 
1998; Hershko and Ciechanover 1998; Yang and Yu 2003; Zhang, Wang et al. 2004; Shmueli 
and Oren 2005; Taylor and Jobin 2005; Xu and Peng 2006).  Although cells have multiple copies 
of ubiquitin genes tandemly arranged without intronic sequences, ubiquitin proteins are ex-
pressed as monomers (Hegde 2004).  However, ubiquitin contains a unique propensity to form 
multimeric chains once attached to target substrates (Ciechanover 1998; Hershko and 
Ciechanover 1998; Yang and Yu 2003; Zhang, Wang et al. 2004; Shmueli and Oren 2005; 
Taylor and Jobin 2005; Xu and Peng 2006).   
Ubiquitination is a multi-step process involving the covalent addition of ubiquitin mole-
cules to lysine residues within target proteins.   Substrate ubiquitination is mediated by an ATP-
dependent enzymatic cascade involving a ubiquitin-activating enzyme (E1), a ubiquitin-
conjugating enzyme (E2) and a ubiquitin-ligase (E3) (Figure 1.1)
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Figure 1.1:  Ubiquitination.    
Ubiquitination is an enzymatic cascade involving a ubiquitin (Ub)-activating enzyme (E1), a Ub-conjugating en-
zyme (E2), and a Ub-ligase (E3).   During ubiquitination, Ub is activated by the E1 Ub-activating enzyme and then 
transferred to an E2 Ub-conjugating enzyme.  The E3 Ub-ligase enzyme recognizes and binds both the target sub-
strate and the Ub-E2 enzyme and transfers Ub to the target substrate.  Ubiquitination of target substrates is asso-
ciated with new cellular functions (via monoubiquitination and lys 63 linked poly-ubiquitination) or degradation 
(via lys 48 linked poly-ubiquitination).  Figure adapted from Hegde et.al., 2004,  Taylor et.al., 2005, Wickliffe 
et.al., 2009, Haglund et.al., 2005. 
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 (Deshaies 1995; Hochstrasser 1995; Hochstrasser 1996; Hershko and Ciechanover 
1998).   E1 is encoded by a single highly conserved gene with two isoforms, E1a and E1b (Cook 
and Chock 1992).  Both E1 isoforms lack specificity for target proteins, but are essential for cel-
lular function as inactivation of E1 is lethal to cells (Ciechanover 1994).  By comparison, there 
are more than 50 genes encoding for E2 and more than 500 genes encoding for E3 (Chen, Seth et 
al. 2006; Lehman 2009), and, as each E2 can interact with multiple E3s, numerous E2/E3 com-
binations make possible increased substrate specificity (Lehman 2009).    
To initiate substrate ubiquitination, the C-terminal glycine residue of free ubiquitin is ac-
tivated by the E1 ubiquitin-activating enzyme.  Ubiquitin activation involves the formation of an 
ubiquitin-adenylate intermediate, the release of PPi, transfer of ubiquitin-adenylate to a cysteine 
residue in E1 via a thiolester bond, and subsequent release of AMP (Deshaies 1995; Hochstrasser 
1995; Hochstrasser 1996).   Activated ubiquitin is transferred to a cysteine residue on the E2 
ubiquitin-conjugating enzyme via a thiolester bond (Deshaies 1995; Hochstrasser 1995; 
Hochstrasser 1996; Hershko and Ciechanover 1998).  Transfer of activated ubiquitin from E2 to 
target protein is orchestrated by an E3 ubiquitin ligase which recognizes the target substrate and 
catalyzes transfer via an isopeptide bond between the C-terminal glycine residue of ubiquitin and 
the ε-amino group of an internal lysine residue of the substrate (Deshaies 1995; Hochstrasser 
1995; Hochstrasser 1996; Hershko and Ciechanover 1998).   
The product of this enzymatic cascade is a mono-ubiquitinated protein.  Mono-
ubiquitination has been linked to roles in transcription via regulation of histones and transcrip-
tion factors (Greer, Zika et al. 2003; Muratani and Tansey 2003; Rasti, Grand et al. 2006; Lassot, 
Latreille et al. 2007; Zhu, Wani et al. 2007) and to various cellular functions including receptor 
transport, viral replication, cell cycle regulation, localization of proteins and DNA repair (Hicke 
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2001; Di Fiore, Polo et al. 2003; Greer, Zika et al. 2003; Gregory, Taniguchi et al. 2003; 
Haglund, Sigismund et al. 2003; Brenkman, de Keizer et al. 2008).  Consecutive addition of ubi-
quitin molecules to internal lysine residues of substrate conjugated mono-ubiquitin leads to the 
formation of poly-ubiquitin chains (Pickart and Fushman 2004).  The formation of poly-ubiquitin 
chains is frequently catalyzed by substrate specific E3 ligases; however, recent studies have 
demonstrated the involvement of an additional conjugating enzyme, E4, in the formation of ly-
sine 48 linked polyubiquitin chains (Koegl, Hoppe et al. 1999).  The first E4 to be identified was 
the yeast protein, ubiquitin fusion degradation protein 2 (UFD2) which catalyzes ubiquitin chain 
extensions (Koegl, Hoppe et al. 1999) and harbors the U-box motif that renders ubiquitin ligase 
activity (Koegl, Hoppe et al. 1999).  Although, poly-ubiquitin chains can be formed at any of the 
seven internal lysine residues (K 6, 11, 27, 29, 33, 48 and 63) in ubiquitin (Johnson, Ma et al. 
1995; Peng, Schwartz et al. 2003; Kim, Kim et al. 2007), in eukaryotes poly-ubiquitination can 
occur via lysine 48 or lysine 63 or can be atypical.  Proteins poly-ubiquitinated via lysine 48 are 
targeted for protein degradation by the 26S proteasome, whereas proteins poly-ubiquitinated via 
lysine 63 are directed towards various cellular processes and are eventually degraded in lyso-
somes (Tan, Wong et al. 2007).  Atypical ubiquitination includes mixed chain ubiquitination, 
heterologous ubiquitination, and multiple mono-ubiquitination (Ikeda and Dikic 2008).  Mixed 
chain ubiquitination occurs when poly-ubiquitin chains are formed via different lysine residues 
within ubiquitin (lysine 29/48 ubiquitin chains for example) (Kim, Kim et al. 2007).  Specific 
pairs of E2 Ub-conjugating enzymes and E3 Ub-ligating enzymes, including the E2 Ubch5 and 
the E3 mouse double minute 2 (Mdm 2), are capable of forming mixed-linkage poly-ubiquitin 
chains (Kim, Kim et al. 2007).  Heterologous ubiquitin chains involve ubiquitin like modifiers 
such as the small ubiquitin like modifier (SUMO) (Tatham, Jaffray et al. 2001) or the neural   
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Figure 1.2:  Ubiquitination status determines protein fate.   
Addition of one ubiquitin to target protein leads to mono-ubiquitination. Multiple additions of single ubiquitin 
moieties to different lysine residues on target proteins is termed multiple mono-ubiquitination. Subsequent 
addition of ubiquitin to internal lysine residues of the previously added ubiquitin moiety is termed poly-
ubiquitination.  Poly-ubiquitination occurs at one of the 7 internal lysine residues in ubiquitin (lys 6, 11, 27, 
29, 33, 48 and 63).  Poly-ubiquitination via lysine 48 is considered to be the typical form of poly-
ubiquitination.  Atypical forms of ubiquitination include homotypic ubiquitination, mixed chain ubiquitina-
tion, heterologous ubiquitination and multiple mono-ubiquitination.  Homotypic ubiquitination occurs when 
poly-ubiquitin chains are formed via the same lysine residues within ubiquitin (for example: a lysine 63 poly-
ubiquitin chain).  Alternatively, mixed chain ubiquitination occurs when poly-ubiquitin chains are formed via 
different lysine residues within ubiquitin (for example: a lysine 29/48 poly-ubiquitin chain).  Formation of 
heterologous ubiquitin chains involves additional ubiquitin like modifiers such as SUMO and NEDD8 in addi-
tion to ubiquitin.  
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precursor cell expressed developmentally down regulated (NEDD8) (Xirodimas, Sundqvist et al. 
2008) in addition to ubiquitin.  Multiple mono-ubiquitination involves the addition of mono-
ubiquitin to multiple lysine residues in target proteins (Liu, Aneja et al. 2008).  A comprehensive 
chart of the various ubiquitination patterns and their known roles in cellular function is shown in 
Figure 1.2.   
 
THE PROTEASOME  
The 26S proteasome is an approximately 2.5 MDa complex composed of more than 31 
subunits which was partially purified from rabbit reticulocytes by Hough et al (1986) and was 
characterized by Waxman and colleagues as a “high molecular weight alkaline protease” which 
was renamed as the 26S proteasome (Hough, Pratt et al. 1986; Waxman, Fagan et al. 1987).  The 
26S is composed of a 20S core particle capped on one or both ends by 19S regulatory particles 
(RP) or PA700 (Figure 1.3) (Hough, Pratt et al. 1987; Hoffman, Pratt et al. 1992; Tanaka 2009).  
The 19S and 20S sub-complexes can exist together or independently of each other in both nuc-
lear and cytoplasmic compartments (Peters, Franke et al. 1994).  Discrepancies exist regarding 
the nomenclature assigned to the 26S, which was originally named based on sedimentation coef-
ficients as measured by density-gradient centrifugation (Tanaka 2009).  Yoshimura and col-
leagues have shown that the sedimentation coefficient of the 26S proteasome in solution is “30S” 
according to physicochemical calculations (Yoshimura, Kameyama et al. 1993).  The difference 
may be due to the “26S” proteasome containing one 19S regulatory particle on either end of the 
20S core while the “30S” proteasome contains two 19S regulatory particles on either end of the 
20S core  
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Figure 1.3:  The 26S Proteasome.   
The 26S proteasome is composed of a 20S proteolytic core and a 19S regulatory particle (RP).  The 20S core par-
ticle is the proteolytic center of the proteasome and is a 670kDa complex composed of 28 subunits.  The core is a 
hollow cylindrical structure composed of two heptameric rings of α subunits and two heptameric rings of β subunits 
(αββα).  Capping one or both of the 20S core are 19 S regulators.  The 19S regulatory particle, also known as “PA 
700” or “Proteasome activator 700,” is a large complex of approximately 700 KDa.  The 19S is composed of a 
“base” component and a “lid” component with nine non-ATPase subunits (Rpn3, Rpn5-9, Rpn11, Rpn12 and 
Rpn15) in the lid and four non-ATPase (Rpn1, Rpn2, Rpn10 and Rpn13) and six ATPase subunits (Rpt1-6) in the 
base.  Polyubiquitinated proteins are tagged for degradation, recognized and unfolded by the 19S ATPases, and are 
translocated to the 20S core.  The 20S cleaves the protein into peptides and free ubiquitin is released.  
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(Tanaka 2009).  For the remainder of this review, „26S‟ will be used to describe the functional 
proteasome with a 19S regulatory particle on either end of the 20S core. 
The 20S Core Particle 
The 20S core particle is a 670kDa complex composed of 28 subunits and is the proteolyt-
ic center of the proteasome (Navon and Ciechanover 2009).  This hollow cylindrical structure is 
composed of two heptameric rings of α subunits and two heptameric rings of β subunits with an 
α 1-7 β 1-7 β 1-7 α 1-7 structure (Burkhardt, Lothar et al. 1992; Groll, Ditzel et al. 1997).  The α-
subunits in the outer rings of the 20S core serve to recognize and direct poly-ubiquitinated sub-
strates into the proteolytic center.  The N-terminus of the α2, α3 and α4 subunits forms a gate that 
protects the opening to the proteolytic center.  Binding of the regulatory 19S particle to the 20S 
core triggers a conformational change in the N-terminus of the α2, α3 and α4 subunits which 
causes the gate to open and allows the passage of proteins into the proteolytic center (Jung, 
Catalgol et al. 2009).  Each of the α-subunits has a highly conserved YRD-motif (Tyr8-Asp9-
Arg10) which functions as a hinge and is essential for the opening and closing of the gate.   
Poly-ubiquitinated proteins targeted for degradation are processed by deubiquitinating 
enzymes (DUBs) before they are channeled into the proteolytic core (Hegde 2004).  The DUBs 
remove the poly-ubiquitin tag from the substrate, following which the protein is channeled 
through the proteolytic core for degradation (Hegde 2004).  This step is crucial to prevent “clog-
ging” of the small proteolytic chamber (13Å) by the poly-ubiquitin chain (Hegde 2004).  Al-
though the 20S proteolytic core has two β rings with seven β subunits in each ring (β 1-7 β 1-7), 
only three β-subunits: β1, β2 and β5, which reside in each of the two β rings, are proteolytically 
active.  These β-subunits have distinct proteolytic activities.  β1 has a peptidyl-glutamyl-peptide-
hydrolyzing, or caspase-like activity (Kisselev, Akopian et al. 1999), which cleaves after acidic 
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amino acids; β2 has a trypsin-like activity which cleaves after basic amino acids, and β5 has a 
chymotrypsin-like activity which cleaves after neutral amino acids (Loidl, Groll et al. 1999; 
Groll and Huber 2004).  The proteolytic activities of the three β-subunits are due to the presence 
of a threonine residue in their N-terminus which acts as a neuclelophile in the hydrolysis of sub-
strate proteins (Jung, Catalgol et al. 2009; Navon and Ciechanover 2009).  In addition to the N-
terminal threonine residue, aspartate 17 and lysine 33 in the three β-subunits are also essential for 
the proteolytic activity of 20S core particle (Jung, Catalgol et al. 2009).  The  result of protein 
degradation via the 26S proteasome are peptides with average lengths of 8-12 amino acids and 
free ubiquitin that is recycled in the ubiquitination process by E1 activating enzyme (Jung, 
Catalgol et al. 2009).    
 
The 19S Regulatory Particle (PA700) 
The 20S core particle is capped on one or both sides by a 19S regulatory particle to form 
the active 26S proteasome.  The 19S regulatory particle is a large 700 KDa complex, also known 
as the “proteasome activator 700” or “PA 700” (Jung, Catalgol et al. 2009; Navon and 
Ciechanover 2009), composed of rings of subunits that make up the “19S base” and the “19S lid” 
of the regulatory particle.  Nine non-ATPase subunits (Rpn3, Rpn5-9, Rpn11, Rpn12 and Rpn15) 
are found in the lid and four non-ATPase subunits (Rpn1, Rpn2, Rpn10 and Rpn13) along with 
six ATPase subunits (Rpt1-6) are found in the base (Jung, Catalgol et al. 2009; Tanaka 2009).  
The six ATPases in the 19S base interact with the α-subunits of 20S core particles and, along 
with the non-ATPases of the 19S base and lid, have various functions in ubiquitin dependent de-
gradation.  Recent studies have also highlighted non-proteolytic role of the 19S ATPases in tran-
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scription regulation which will be discussed in detail in later portions of this review.  Rpt2, Rpt3 
and Rpt5 contain a HbYX motif which enables them to function as “gate opening” subunits 
(Tanaka 2009).    Rpn10 and Rpn13 function as “ubiquitin receptors” (Tanaka 2009), while 
Rpn11 functions as a “deubiquitinating enzyme” in the removal of poly-ubiquitin chains from 
substrate proteins (Tanaka 2009).  Rpn1 and Rpn2, along with the six ATPases, function to trans-
locate substrate proteins into the gate of the 20S proteolytic core (Tanaka 2009).   
 
The 11S Regulatory particle (PA28)  
The 11S regulator, also known as “PA28” or “REG,” also forms a conical cap by binding 
to α-rings on both sides of the 20S core (Jung, Catalgol et al. 2009).  Once PA28 binds the 20S 
core, the complex demonstrates increased degradation of small or midsized poly-peptides and 
unfolded proteins in an ATP-independent manner (Jung, Catalgol et al. 2009; Tanaka 2009).  
PA28 is composed of α, β or γ subunits which share 50% structural homology with each other 
but differ in subcellular localization (Tanaka 2009).  PA28α and PA28β are primarily cytoplas-
mic (Jung, Catalgol et al. 2009; Tanaka 2009) and when bound to the 20S core participate in 
processing polypeptide antigens for Major Histocompatibility Complex (MHC) class I mediated 
immunity; thus their expression is induced by the inflammatory cytokine interferon-γ (IFN-γ) 
(Tanahashi, Yokota et al. 1997).  PA28γ is predominantly localized in the nucleus, is thought to 
play roles in regulating nuclear proteolysis (Jung, Catalgol et al. 2009; Tanaka 2009), and has 
been shown to be important in ubiquitin-independent degradation of proteins involved in cell 
cycle regulation, apoptosis, and mitotic progression (Tanaka 2009).  For example, the cell cycle 
regulator p21
Cip1
 is degraded independently of poly-ubiquitination in a PA28γ-dependent manner 
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(Jung, Catalgol et al. 2009).  As PA28γ is also involved in degradation of lysine-free or lysine-
low native proteins (which cannot be poly-ubiquitinated), PA28γ may also be a key player in de-
gradation of viral proteins low in lysine residues (Jung, Catalgol et al. 2009).  These diverse 
functions of PA28γ are plausibly due to its nuclear localization.    
 
Proteasome Diversity 
In addition to the traditional 26S proteasome (PA700-20S-PA700), Tanahashi and col-
leagues have shown that 11S/PA28 and 19S regulators can bind to either sides of the 20S core to 
form a “Hybrid Proteasome” (PA700-20S-PA28) (Figure 1.4A) (Tanahashi, Murakami et al. 
2000).  IFN-γ increases the expression of PA28α/β (11S), which in turn increases the formation 
of hybrid proteasomes (Tanahashi, Yokota et al. 1997; Tanahashi, Murakami et al. 2000).  The 
hybrid proteasome functions in antigen processing through efficient hydrolysis to generate pep-
tides with unique hydrolysis patterns from those produced by the traditional 26S (Cascio, Call et 
al. 2002; Tanaka 2009).  The “Immunoproteasome” refers to the proteasome that is dedicated to 
processing peptide antigens for MHC class I mediated immunity (Tanaka 1994; Tanahashi, 
Yokota et al. 1997; Tanaka and Kasahara 1998).  IFN-γ upregulates the expression of β1, β2i and 
β5i subunits which replace three homologous catalytic subunits: β1, β2 and β5 of the 20S protea-
some, to form the immunoproteasome (Tanaka 1994; Tanahashi, Yokota et al. 1997; Tanaka and 
Kasahara 1998; Yewdell 2005).  The “Thymoproteasome,” was recently identified by Murata 
and colleagues in cortical thymic epithelial cells  (Figure 1.4B) (Murata, Takahama et al. 2008).  
The thymoproteasome contains a β5t subunit homologous to, and structurally related to, β5 and 
β5i (Murata, Takahama et al. 2008).  Unique features of β5t include that it is encoded by an in-
tronless gene and that it is transcribed and translated only in cortical thymic epithelial cells  
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Figure 1.4 A:  Diversity in the proteasome lid.   
The 20S core particle is capped on one or both sides by 19 S regulatory particles to form the 26S proteasome.  The 
11S regulator, or PA28, forms a conical cap on either end of the 20S core to form the immunoproteasome.  PA28 and 
PA700 can actively bind to either sides of the 20S core to form the hybrid proteasome.  Figure adapted from Jung 
et.al., 2009, Tanaka et.al., 2009.   
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Figure 1.4B:  Diversity in the proteasome base.   
The standard 20S proteasome, or proteolytic core, is composed of four heptameric rings of α 1-7 β 1-7 β 1-7 α 1-7 ar-
rangement.  Upon IFN-γ stimulation, the β1, β2 and β5 subunits of the standard proteasome are replaced by β1i, β2i 
and β5i subunits to form the immunoproteasome.  In specialized thymic epithelial cells, the β1, β2 and β5 subunits 
of the standard proteasome are replaced by β1i, β2i and a unique β5t to form a thymoproteasome.  In the testis-
specific proteasome, the α4 subunit is replaced by a novel subunit, α8.  Figure adapted from Tanaka et.al., 2009.  
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(cTECs) (Murata, Takahama et al. 2008).  The β5t subunit lowers chymotrypsin like activity of 
the proteasome as compared to β5 or β5i.  The thymoproteasome in cTECs produces MHC class 
I ligands of moderate avidity, thus supporting positive selection of CD8
+
 T cells (Murata, 
Takahama et al. 2008; Tanaka 2009).  Lastly, Tanaka and colleagues have identified an α8 sub-
unit homologous to the α4 subunit of the 20S core particle.  Expression of the α8 subunit is re-
stricted to cells and tissues of testis and thus the term “Mammalian Testis-Specific Proteasome” 
has been coined for the proteasome containing an α8 subunit in place of an α4 subunit (Figure 
1.4B) (Tanaka 2009). 
 
ROLES OF THE UPS 
Thus far we have discussed contributions of ubiquitination, the structures elements of 
proteasomal subunits and proteasome diversity to the regulation of multiple cellular pathways 
and to the maintenance of cellular homeostasis.  Proteolytic roles of the UPS in regulating cellu-
lar processes including DNA repair, cell cycle control, membrane trafficking, transcription and 
signal transduction are well known and are highlighted below.  More recently identification of 
non-proteolytic functions of the UPS has identified new pathways of cellular regulation.  The 
complex contributions of the UPS in these diverse cellular functions include roles in epigenetics, 
and transcriptional and post-translational modifications.  The proteolytic and non-proteolytic 
roles of the UPS in regulatory mechanisms and in disease development are also discussed in the 
following sections and are intended to provide a better understanding of the magnitude of contri-
butions of the UPS.  
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Roles in DNA repair 
 
Internal and external genotoxic agents pose a constant threat to the genetic information 
stored in DNA.  In order to combat these threats, cells have DNA damage checkpoints and DNA 
repair mechanisms (Panagiotis, Anna et al. 2009) activated to prevent cells from dividing and 
expressing damaged genes; failure to correct damaged DNA leads to induction of senescence or 
cell death (Sheikh and Fornace 2000; Zamzami and Kroemer 2005).  Thus, DNA repair plays 
crucial roles in maintaining the integrity of DNA encoded genetic material.  Roles of ubiquitin in 
modulating DNA repair pathways was first demonstrated when the DNA repair gene RAD6 was 
shown to encode for a ubiquitin-conjugating enzyme, E2 (Jentsch, McGrath et al. 1987).  Fol-
lowing this, multiple signal transducers involved in DNA damage response and DNA repair have 
been shown to be enzymes either capable of catalyzing ubiquitination or to harbor a ubiquitin 
binding domain.  Herein we will review the roles of UPS in various DNA repair pathways in-
cluding double stranded break repair, nucleotide excision repair, Fanconi Anemia DNA repair, 
and MGMT/ AGT repair pathways.   
Roles for the UPS in double stranded break (DSB) repair have been well documented 
in previous reviews (Motegi, Murakawa et al. 2009; Panagiotis, Anna et al. 2009) that illustrate 
how various DNA repair pathways interact and are regulated by the UPS, with particular empha-
sis on pathways involved in tumors and chemotherapeutic regimes.  Recent studies have identi-
fied a component of the nucleosome remodeling histone deacetylation complex (NuRD), metas-
tasis-associated protein 1 (MTA1), to play novel roles in DSB repair caused by ionizing radiation 
(Li, Ohshiro et al. 2009).  MTA2, an additional member of the MTA family, is a known co-
regulator of cellular growth and apoptosis via deacetylation and inactivation of the tumor sup-
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pressor protein p53 (Li, Divijendra Natha Reddy et al. 2009; Toh and Nicolson 2009).  MTA1 
has recently been shown to be a DNA damage responsive protein involved in DSB repair (Li, 
Divijendra Natha Reddy et al. 2009).  MTA1 competes with Mdm2 (Li, Ohshiro et al. 2009) and 
with the RING domain E3 ligase COP1 (constitutive photomorphogenesis protein 1) to bind to 
p53 to inhibit p53 ubiquitination and/or to repress Mdm2 and COP1 activity, resulting in stabili-
zation of p53 (Li, Divijendra Natha Reddy et al. 2009).  MTA1 also promotes COP1 destabiliza-
tion by promoting its auto-ubiquitination (Li, Ohshiro et al. 2009).  Deficiency of  MTA1 reduc-
es p53 stability and p53-dependent expression of downstream genes, including the ribonucleotide 
reductase, p53R2, which is involved in nucleotide supply for DNA repair (Li, Divijendra Natha 
Reddy et al. 2009).  Thus, MTA1 regulates p53 dependent DNA repair.  MTA1 is targeted for 
ubiquitination by COP1 and is subsequently degraded via the UPS, and over expression of 
MTA1 is has been correlated with tumor formation and increased metastasis in breast cancer (Li, 
Ohshiro et al. 2009; Toh and Nicolson 2009).  In addition to regulating p53 dependent DNA re-
pair process, MTA1 regulates DNA repair independent of p53 by directly binding to the p53-
downstream gene, p21
WAF1
 (Li, Pakala et al. 2010).  A complex of MTA1-HDAC2 co-represses 
p21
WAF1
 expression, resulting in increased levels of proliferating cell nuclear antigen (PCNA) 
during DNA damage response, which negatively impact DNA damage repair (Li, Pakala et al. 
2010).  Additionally, ubiquitination (and deubiquitination) of histones H2A and H2AX, well 
known for roles in chromatin remodeling and transcription, have increasingly been found to play 
important roles in DNA damage responses.  Pinato and colleagues have recently identified a 
novel chromatin associated E3 ligase, RNF168, involved in histone ubiquitination (Pinato, 
Scandiuzzi et al. 2009).  RNF168 is recruited to DSB sites where it preferentially poly-
ubiquitinates H2A and H2AX resulting in the formation of lysine linked 63 poly-ubiquitin chains 
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which stabilize binding of the DSB repair machinery to the damaged site (Doil, Mailand et al. 
2009; Pinato, Scandiuzzi et al. 2009).   
The nucleotide excision repair (NER) pathway is involved in the removal of large ad-
ducts caused by UV damage or by exposure to genotoxic agents (Panagiotis, Anna et al. 2009).  
While roles for the 26S proteasome in NER pathway regulation have also been well documented 
(Motegi, Murakawa et al. 2009; Panagiotis, Anna et al. 2009), recent work has identified novel 
NER-dependent chromatin ubiquitination of H2A induced by UV damage.  (Bergink, Salomons 
et al. 2006; Zhu, Wani et al. 2009).  Although similar chromatin modifications of H2A and 
H2AX have been observed in DSB repair, the mechanisms and signaling involved in NER-
dependent H2A ubiquitination are less understood.  Marteijn and colleagues have shown that 
ubiquitin ligases Ubc13 and RNF8 ubiquitinate H2A (Marteijn, Bekker-Jensen et al. 2009).  
These ligases work downstream of the NER pathway as a depletion of these ligases increases UV 
sensitivity without affecting NER (Marteijn, Bekker-Jensen et al. 2009).  It is interesting to note 
that although double stranded breaks and UV lesions recruit independent repair mechanisms, 
they generate the same epigenetic mark of H2A ubiquitination (Marteijn, Bekker-Jensen et al. 
2009), thus amplifying the DNA damage response.   
Fanconi anemia (FA) is a multi-organ human disorder of the Fanconi Anemia DNA re-
pair pathway in which patients are highly sensitive to DNA inter cross-linking agents such as 
mitomycin C (Smogorzewska, Matsuoka et al. 2007).  Eight proteins form the Fanconi anemia 
complex, a nuclear E3 ubiquitin ligase which mono-ubiquitinates FA protein Fanconi anemia 
group D2 protein (FANCD2) and its paralog, Fanconi anemia complementation group I protein 
(FANCI) both of which are both involved in the FA DNA repair pathway (Smogorzewska, 
Matsuoka et al. 2007).  FANCD2 and FANCI form an “ID complex” that co-localizes to chroma-
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tin upon DNA damage.  Following DNA damage, FANCD2 is phosphorylated at S331 by the S-
phase checkpoint kinase, CHK1 which triggers DNA damage inducible mono-ubiquitination of 
FANCD2 (Zhi, Wilson et al. 2009).  FANCI is subsequently mono-ubiquitinated, DNA damage 
induced foci are formed and additional proteins involved in DNA damage response are recruited.  
Interestingly, FANCD2 and FANCI demonstrate a “dual ubiquitin-locking mechanism” where 
maintenance of mono-ubiquitation of either protein is dependent on the mono-ubiquitination sta-
tus of the other (Smogorzewska, Matsuoka et al. 2007).  Thus phosphorylation and mono-
ubiquitination of the ID complex is required for recruitment to the damage site on chromatin 
where it directs the removal of damaged DNA and DNA repair (Smogorzewska, Matsuoka et al. 
2007).    
Recent studies indicate roles for the UPS in regulating the MGMT or AGT repair 
pathway.  Upon DNA damage by carcinogenic alkylating agents, multiple types of adducts are 
formed including O
6
-methylguanine which causes G:C to A:T mutations in DNA and induces 
cell death.  In such situations, the DNA repair protein human O
6
-methylguanine-DNA methyl-
transferase (MGMT), or the more commonly used O
6
-Alkylguanine-DNA alkyltransferse 
(AGT), participates in a one-time transfer of an alkyl group from DNA to an internal cysteine 
residue (Xu-Welliver and Pegg 2002).  Following alkyl group transfer, modified AGT is recog-
nized and ubiquitinated by an unidentified ubiquitin ligase and targeted for degradation (Xu-
Welliver and Pegg 2002).  The yeast homolog of AGT, DNA repair methyltransferase Mgt1, is 
targeted for proteolysis via two ubiquitin dependent pathways, the N-end pathway and the ubi-
quitin fusion dependent pathway (Hwang, Shemorry et al. 2009).  The two pathways work syn-
ergistically to eliminate persistent Mgt1 following DNA repair and to simultaneously protect 
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DNA from further damage due to accumulated alkyl groups (Hwang, Shemorry et al. 2009; Li, 
Ohshiro et al. 2009).   
Poly-ADP ribose polymerase-1 protein (PARP1), a key regulator of the base-excision re-
pair (BER) pathway, has also been shown to be poly-ubiquitinated via lysine 48 and degraded by 
the 26S proteasome (Tao, Cynthia et al. 2008).  PARP is recruited to single stranded breaks 
where it coordinates with various members of BER pathway including the scaffolding protein 
XRCC1, DNA ligase III, and DNA polymerase β, to remove damaged bases (Panagiotis, Anna et 
al. 2009).  Cleavage of PARP1 by caspases 3 and 7 is a prerequisite to apoptosis and PARP1 is 
poly-ubiquitinated and degraded by the 26S proteasome (Tao, Cynthia et al. 2008).  Upon DNA 
damage, PARP1  poly-ubiquitination is down regulated and thus stabilized PARP1 participates 
in nuclear functions, including DNA repair (Tao, Cynthia et al. 2008).  Martin and colleagues 
have recently identified RNF4 as an ubiquitin ligase for PARP1 that regulates its stability and 
transcriptional activity in response to heat shock (Martin, Schwamborn et al. 2009). Thus stabili-
zation of PARP1 increases its transactivation potential and functions in the DNA damage re-
sponse.   
 
Roles in cell cycle control  
 
Normal cells divide in response to proliferative stimuli including developmental and mi-
totic signals.  The cell cycle involves G1, S, G2 and M phases which are coordinately regulated 
to reduce errors during cell division.  The cell cycle is tightly regulated by checkpoint mechan-
isms which ensure accurate completion of each phase prior to beginning the next.  Activation of 
these checkpoints stalls cell cycle progression and provides time for activation of damage repair 
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mechanisms.  Checkpoint activation frequently involves post-translational modifications includ-
ing phosphorylation and ubiquitination of various proteins, including histone H2AX, scaffold 
protein Mdc1, cell division control protein 20 (Cdc20), and cell division control protein 25 
(Cdc25), at different stages of the cell cycle which in turn activate downstream checkpoint me-
chanisms to ensure cell cycle fidelity (Wickliffe, Williamson et al. 2009).  Alternatively, unique 
cyclin dependent kinases (CDKs) play phase specific regulatory roles in promoting cell cycle 
progression.  Each CDK has a cyclin partner to promote its activity and a CDK-inhibitor (CKI) 
to inhibit its activity.  Periodic synthesis of cyclins determines the capability of CDKs to phos-
phorylate their substrate proteins and subsequent cyclin degradation shuts down CDK activity 
and leads to an exit from mitosis.  Levels of both cyclin-CDK complexes and their CKI inhibi-
tors are maintained by periodic synthesis and UPS mediated degradation.  The role of the UPS in 
the cell cycle extends far beyond protein degradation as the UPS controls progression through 
cell cycle programs as well as the function of cell cycle checkpoints, all to ensure coordination of 
cell proliferation and developmental programs.   
Multiple E2 ubiquitin-conjugating enzymes regulate cell cycle control (Wickliffe, 
Williamson et al. 2009) including roles for ubiquitin conjugating enzyme UbcH10 in the pro-
gression of mitosis and roles for ubiquitin conjugating enzyme 3 (Ubc3)/cell division control 
protein (Cdc34) in controlling progression of the G1-S phase (Whitcomb and Taylor 2009).  The 
E2 UbcH10 co-operates with the E3 ubiquitin ligase anaphase-promoting complex (APC/C) to 
form lysine 11 linked poly-ubiquitin chains on target proteins containing a TEK (threonine-
glutamate-lysine residue) motif (Haas and Wilkinson 2008; Wickliffe, Williamson et al. 2009).  
Lysine 11 linked poly-ubiquitin chains are recognized by proteasomal substrate receptors, fol-
lowing which these APC/C substrates are degraded (Wickliffe, Williamson et al. 2009).  The E2 
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Cdc34 co-operates with the E3 ubiquitin ligase Skp1-culin-F-box complex, SCF, to form lysine 
48 linked poly-ubiquitin chains during the transition from quiescent to proliferative phase and 
the transition from G1 to S phase (Wickliffe, Williamson et al. 2009).  These lysine 48 poly-
ubiquitinated proteins are subsequently degraded by the UPS. 
The BIR repeat-containing ubiquitin-conjugating enzyme (BRUCE) is an E2 ligase in-
volved in cell cycle progression, UPS mediated degradation of which leads to initiation of apop-
tosis (Liu, Goldberg et al. 2007).   BRUCE has been shown to be a “chimeric E2/E3 ubiquitin 
ligase” due to its ability to function as a ubiquitin conjugating (E2) and a ubiquitin ligase (E3) in 
ubiquitinating the pro-apoptotic protein, Smac (Bartke, Pohl et al. 2004).  Reduction in levels of 
BRUCE triggers activation of caspase 3, release of pro-caspase 9 and Smac, and promotion of 
cellular apoptosis, indicating the importance of BRUCE in maintaining cell viability (Liu, 
Goldberg et al. 2007).  Nrdp1 (or RFP41-Ring finger protein 41) is a known E3 ligase that ubi-
quitinates and targets BRUCE for proteasome-mediated degradation (Qiu, Markant et al. 2004; 
Liu, Goldberg et al. 2007).  As BRUCE is essential in regulating cell viability, maintenance of 
appropriate levels of this protein complex is crucial for cell cycle progression (Liu, Goldberg et 
al. 2007).   
Numerous E3 ubiquitin ligases, including the anaphase-promoting complex (APC/C) and 
the Skp1-culin-F-box (SCF), also play vital roles in cell cycle control (Wickliffe, Williamson et 
al. 2009).  The APC/C complex ubiquitinates and targets cyclins A and B for degradation in the 
mitotic stage, thus inhibiting major mitotic kinase, Cdk1 activity (King, Peters et al. 1995) and 
initiating exit from the mitotic phase.  SCF is crucial in the G1 to M transition as SCF ubiquiti-
nates and degrades proteins including the CDK inhibitor p27, cyclin E, cyclin D1 and Sic1 
(Nakayama and Nakayama 2006) (Feldman, Correll et al. 1997; Carrano, Eytan et al. 1999; 
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Koepp, Schaefer et al. 2001; Barbash, Egan et al. 2009).  Of these, p27 is a critical SCF target as 
p27 is the Cdk inhibitor whose degradation is essential for the transition from G1 to S phase 
(Wickliffe, Williamson et al. 2009).   
 
Roles in tumor development 
 
Regulation of the cell cycle plays fundamental roles in the prevention of tumor develop-
ment.  During G1, when cells commit to the next round of the cell cycle, Src and Abl kinases are 
activated and phosphorylate p27 (Wickliffe, Williamson et al. 2009).  Phosphorylated p27 is tar-
geted for further phosphorylation by cyclin E/Cdk2, recognized by an F-box protein of the SCF 
complex, ubiquitinated, and degraded by the 26S proteasome (Wickliffe, Williamson et al. 
2009).  Following p27 degradation, Cdk2 and the transcription factor E2F are activated leading 
to an increase in CDK inhibitors cyclin A and cyclin E as the cell irreversibly enters S phase 
(Wickliffe, Williamson et al. 2009).  Degradation of p27 is a vital checkpoint; it offers directio-
nality to cell cycle progression and also “releases a brake” in the cell cycle (Wickliffe, 
Williamson et al. 2009).  As such, aberrant expression or degradation of both p27 and cyclin E is 
frequently seen in tumors including pituitary tumors, breast carcinoma and oral squamous cell 
carcinoma (Kudo, Kitajima et al. 2005; Nakayama and Nakayama 2006; Porter, Barlow et al. 
2006; Wickliffe, Williamson et al. 2009).  In the case of cyclin E, mutations in the ligase human 
F-box protein (hCdc4), which poly-ubiquitinates cyclin E and targets it for degradation, lead to 
the development of breast cancer (Yu, Ding et al. 2009).  In addition to p27 and cyclin E, the 
UPS mediates degradation of many additional oncogenic proteins involved in cell cycle control, 
including Myc and Myb, β-catenin, S-phase kinase-associated protein 2 SKP2, hypoxia-
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inducible factors, epidermal growth factor receptor (EGFR), and multiple tyrosine kinases 
(Nakayama and Nakayama 2006; Kyoko, Yojiro et al. 2009).  Thus the UPS plays crucial roles 
in ensuring proper cell cycle progression and in inhibiting tumor development. 
Failures in cell cycle regulation are deleterious, as is demonstrated by the development of 
tumors due to deregulation of critical cell cycle control pathways involving tumor suppressor 
protein p53 (Mahalingam, Mita et al. 2009; Polager and Ginsberg 2009).  Dysregulation of p53 is 
a major cause of tumor development, with more than 50% of tumors containing a defective or 
mutated p53 (Irwin and Kaelin 2001).  The p53 family of proteins include tumor repressor pro-
teins p53, p63 and p73 (Irwin and Kaelin 2001) with p53 being the most studied.  Upon stress 
induction, p53 is stabilized, following which it activates cellular responses through transcription-
al activation of genes responsible for angiogenesis, cell-cycle arrest, DNA- repair, or apoptosis 
(Figure 1.5) (Midgley, Owens et al. 1995; Agarwal, Taylor et al. 1998; Carol Prives 1999).  
Thus, p53 activation and levels of expression are tightly regulated and increase in response to 
cellular stresses including DNA damage and oncogene activation (Lane 1992).  Levels of p53 are 
regulated by ubiquitin-mediated degradation by the ubiquitin ligase Mdm2 (Fang, Jensen et al. 
2000) which can both mono- and poly-ubiquitinate p53 (Li, Brooks et al. 2003).  At low levels, 
Mdm2 catalyzes mono-ubiquitination of p53 whereas at elevated levels, Mdm2 catalyzes poly-
ubiquitination and 26S proteasome-mediated p53 degradation (Li, Brooks et al. 2003).  Mono-
ubiquitinated p53 is transported out of the nucleus and serves as a reservoir of p53 which can be 
used under stress conditions.  Alternatively, poly-ubiquitinated p53 is rapidly degraded in the 
nucleus by the 26S proteasome (Li, Brooks et al. 2003; Brooks and Gu 2004).  Thus, a fine-
regulation of MDM2 mediated p53 ubiquitination is crucial in maintaining p53 function.  Muta-
tions in MDM2 leading to deregulation of p53 protein stability and transactivity have been   
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Figure 1.5:   p53 mediated cell cycle control.   
p53 is activated by UV radiation, oncogenes, and DNA-damaging agents.  Upon activation, p53 itself activates DNA 
repair proteins including p21, cyclin B1, and GADD45.  P53 activation drives cell cycle arrest at G1/S and simulta-
neously activates DNA repair mechanisms.  Upon successful repair, cell cycling begins.  Alternatively, if the DNA 
damage is irreparable, p53 initiates apoptosis by inducing gene transcription and through direct interactions with 
mitochondrial proteins.  Thus p53 maintains cellular and genetic stability to prevent tumor growth.  
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demonstrated in 40-80% of late-stage metastatic cancers, in breast cancer, and in endometrial 
cancer (Petroski 2008; Araki, Eitel et al. 2009; Ogino, Nosho et al. 2009; Osamu, Masatsugu et 
al. 2009).  Recent studies have highlighted the importance of p53 family members, p63 and p73 
in tumor development.  While p63 and p73 share little homology with p53 in their transcription 
activation and oligomerization domains, they share high homology in their DNA binding do-
mains with p53, and thus are functionally similar.  p63 and p73 are thus able to transcriptionally 
regulate p53 downstream genes and can induce cell cycle arrest or apoptosis (Pietsch, Sykes et 
al. 2008).  Altered protein expression of p63 and p73 are commonly observed in cancerous 
growths.  For example, 80% of head and neck squamous cell carcinomas demonstrate elevated 
levels of p63 and neuroblastoma, breast cancer, and lung cancer have each displayed mutations 
in p73 or p63 that impaired their transactivation potential (Irwin and Kaelin 2001; Pietsch, Sykes 
et al. 2008).    
In addition to a dysregulated cell cycle, tumor development is directly linked to UPS me-
diated accumulation of oncogenic proteins and degradation of tumor suppressors (Kyoko, Yojiro 
et al. 2009).  In normal cells, oncogenic proteins are poly-ubiquitinated by E3 ligases and tar-
geted for degradation via the 26S proteasome.   Thus these E3 ligases function as anti-oncogenic 
ligases and include the ubiquitin ligase complex APC/C and the ligase SCF.  Likewise, tumor 
suppressor proteins including p53 inhibit cancerous growths and thus prevent tumor onset.  Thus, 
activation of oncogenic E3-ligases that degrade tumor suppressor proteins also leads to cancer-
ous growth and tumors.  Examples of the intricate relationships between E3 ubiquitin ligase and 
target protein turnover in cell cycle regulation and tumor development are the E3 ubiquitin ligase 
Mdm2 and p53; the E3 ubiquitin ligase complex APC/C and cyclin A and B; and the E3 ubiqui-
tin ligase complex SCF and Cyclin E (Figure 1.6).  
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Figure 1.6:  Dysfunction of the UPS leads to tumor growth.   
Tumor development is linked to accumulation of oncogenic proteins and degradation of tumor suppressors. In 
normal cells, oncogenic proteins are poly-ubiquitinated by anti-oncogenic E3 ligases and are degraded via the 
26S proteasome.  Malfunctions in E3 ligases which result in accumulation of oncogenic proteins or that target 
tumor suppressors for degradation, lead to tumor growth.  Figure adapted from Kitagawa et.al., 2009  
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Roles in neurodegenerative disease 
 
The importance of the UPS is further highlighted by the direct relationship between onset 
of neurodegenerative diseases and perturbations in the UPS (Ciechanover, Orian et al. 2000; 
Hegde 2004; Kyoko, Yojiro et al. 2009).  A majority of neurodegenerative diseases show in-
creased protein accumulation in extracellular and/or intracellular compartments of neuronal cells  
(Jung, Catalgol et al. 2009).  This accumulation of proteins is caused by genetic or environmental 
factors in combination with imbalances in anabolic and/or catabolic pathways (Figure 1.7).  Ge-
netic mutations can lead to the production of mutated proteins that have different rates of degra-
dation or a tendency to form persistent cellular aggregates (Jung, Catalgol et al. 2009).  Further-
more, deregulation of gene expression also leads to accumulation of protein aggregates due to 
increased protein synthesis and reduced protein degradation by the 26S proteasome (Jung, 
Catalgol et al. 2009).  Intraneuronal aggregates contain ubiquitinated proteins and accumulation 
of these ubiqutinated aggregates is due to their impaired clearance by the 26S proteasome.  The 
link between the UPS and neurodegerative diseases is further strengthened by observations that 
several mutations linked to neurodegerative disease onset are found in genes that code for pro-
teins involved in the UPS.  Thus the UPS plays an important role in the development of neurode-
generative diseases. 
Alzheimer’s Disease is a neurodegenerative disorder involving the development of 
twisted neurofibrils termed “neurofibrillary tangles” (NFT), which involve extracellular accumu-
lation of toxic β-amyloid aggregates, and the appearance of cellular plaques (Hegde 2004; Jung, 
Catalgol et al. 2009).   
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Figure 1.7:  Intracellular accumulation of proteins during neurodegerative disease.   
Post-translational modifications of proteins due to genetic or environmental factors, or to imbalances in anabolic 
and/or catabolic pathways, leads to an intracellular accumulation of proteins.  Genetic mutations can produce pro-
teins with different rates of degradation or tendencies to form aggregates which persist longer in cells.  Dysregula-
tion of gene expression may also lead to increases in protein aggregates due to increased protein synthesis or re-
duced protein degradation.  Post-translational modifications caused by environmental factors including stress en-
hance protein stability or ability to aggregate.  Figure adapted from Jung et.al., 2009.  
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NFTs result from the accumulation of hyperphosphorylated tau proteins, which form large inso-
luble aggregates called paired helical filaments (PHF) that impair proteasomal function (Hegde 
2004; Jung, Catalgol et al. 2009).  Tau proteins and β-amyloid aggregates are highly poly-
ubiquitinated but are resistant to degradation by the UPS.  Resistance stems from mutation of the 
ubiquitin moiety involved such that there are 19 extra amino acid in C-terminal end of ubiquitin 
caused by “molecular misreading” (Lindsten, de Vrij et al. 2002).  This “molecular misreading” 
involves deletion of 2 nucleotides in the mRNA for the ubiquitin B pre-cursor.  The deletion re-
sults in a +1 frame shift near the C-terminal end of the first ubiquitin and results in a 19 amino 
acid extension.  The 19 amino acid extension prevents the activation and conjugation of the mu-
tated ubiquitin, but the presence of internal lysine residues in mutated ubiquitin still serve as sites 
for addition of ubiquitin molecules (Lindsten, de Vrij et al. 2002).  These additions result in a 
general accumulation of ubiquitinated proteins and cause cell cycle arrest (Lindsten, de Vrij et al. 
2002).  The decreased proteasomal regulation of tau and β-amyloid proteins leads to accumula-
tion of NTF‟s in neurons and eventual development of Alzheimer‟s disease.  
Parkinson’s disease (PD) is another prevalent neurodegenerative disease and has been 
linked to 13 genes: polyubiquitinated α-synuclein, ubiquitin carboxyl-terminal esterase L1 
(UCH-L1), Parkinson disease 7 (DJ-1), the E3 ligases parkin -2, -3, -4, -5, -6, -7, -8, -9, -10  and 
Nuclear receptor subfamiliy 4 group A member2 (NR4A2) (Hegde 2004; Jung, Catalgol et al. 
2009).  Histology reports from PD patients demonstrate a loss of dopaminergic neurons and the 
presence of inclusion bodies, termed Lewy bodies, within brain cells.  Lewy bodies are formed 
due to accumulation of multiple proteins, one of them being poly-ubiquitinated form of mutated 
α-synuclein (Hegde 2004; Jung, Catalgol et al. 2009).  Although the function of α-synuclein pro-
teins is unclear, they are thought to be involved in neuronal plasticity and in the release of neuro-
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transmitters, and mutations in α-synuclein increase neuronal susceptibility to oxidative stress 
(Jung, Catalgol et al. 2009).  In addition to α-synuclein, the E3 ligase Parkin is also found in 
Lewy bodies, and interacts with the Rpn10 subunit of the 19S regulatory particle (Jung, Catalgol 
et al. 2009).  Parkin ubiquitinates the α-synuclein interacting protein synphilin-1 leading to the 
formation of Lewy bodies.  Thus, in some PD cases, mutations in the coding region of Parkin 
lead to development of Parkinsonian syndrome in the absence of Lewy bodies (Davie 2008).  
UCHL-1, a neuronal ubiquitin carboxyl-terminal esterase protein involved in hydrolysis of poly-
ubiquitin chains to release ubiquitin monomers, is also found associated with Lewy bodies.    
Although the presence of Lewy bodies is pathological, the primary reason for develop-
ment of PD is thought to be oxidative stress (Jung, Catalgol et al. 2009).  Accumulation of reac-
tive oxygen species and depletion in ATP levels, affect ubiquitination and protein degradation 
via UPS and thus the functioning of neurons (Jung, Catalgol et al. 2009).  Dopaminergic neurons 
demonstrate reduced expression of 19S/11S regulatory particles and of 20S proteasomal α-
subunits, thus negatively affecting the formation of functional proteasomes (Jung, Catalgol et al. 
2009).  Although the exact mechanism for reduced expression of proteasomal subunits is un-
clear, proteasomal function is clearly affected and likely contributes to the accumulation of Lewy 
bodies within neurons.   
Huntington’s disease (HD) is caused by mutations in the gene Huntingtin and is a pro-
gressive neurodegenerative disease (Hegde 2004; Jung, Catalgol et al. 2009).  Mutations in Hun-
tingtin involve insertion of CAG triplets and leads to the addition of polyglutamine (polyQ) se-
quences at the N-terminus of Huntingtin proteins.  Addition of polyQ chains to Huntingtin has 
also been linked to other neurodegenerative diseases including spinocerebellar ataxias 1, 2, 3, 6, 
7 and 17, spinobular muscle atrophy, and dentatorubro-pallidoluysian atrophy (Jung, Catalgol et 
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al. 2009).  Histologies from HD patients demonstrate abnormal accumulation of polyQ and the 
formation of inclusion bodies, with HD severity depending on the length of polyQ chains (Hegde 
2004; Jung, Catalgol et al. 2009).  In HD and other polyQ diseases, the length of polyQ chains 
ranges from 40-300 residues and this overwhelms the function of the 26S proteasome 
(Venkatraman, Wetzel et al. 2004).  PolyQ chain extensions of Huntingtin protein interact with 
the α-subunits of 20S proteasome thus preventing the binding of 19S regulatory particle, assem-
bly of 26S proteasomes, and protein degradation (Jung, Catalgol et al. 2009).   Failure of protea-
some assembly leads to accumulation of proteins aggregates within neurons and the onset of neu-
rodegeneration.  Additionally, the degradation of the long polyQ chains may produce small pep-
tides that are toxic to the cell (Bennett, Bence et al. 2005).   
 
Roles in protein localization and membrane trafficking 
 
The UPS is intricately involved in protein localization and membrane trafficking (Hicke 
1999; Hicke 2001; Hicke 2001).  The canonical poly-ubiquitin lysine 48 chain targets proteins 
for 26S proteasome-mediated degradation, where as poly-ubiquitin chains formed via lysine 63 
target proteins for diverse cellular activities (Hicke 1999; Lauwers, Jacob et al. 2009).   Levels of 
membrane proteins are maintained by lysine 63 linked poly-ubiquitination which functions as a 
signal for selective trafficking to the lysosomal lumen via multivescicular endosomal (MVE) or 
multivesicular body (MVB) degradation pathways (Raiborg and Stenmark 2009).  This process 
of endosomal sorting is dependent on ubiquitination of membrane proteins, or “cargo” (Raiborg 
and Stenmark 2009).  Ubiquitinated cargo is recognized by the endosomal sorting complex for 
transportation machinery (ESCRT) which blocks recycling of ubiquitinated cargos (Raiborg and 
34 
 
Stenmark 2009).  The ESCRT facilitates sorting of ubiquitinated cargo into endosomal invagina-
tions to form intraluminal vescicles (ILV) which contain the ubiquitinated cargos (Raiborg and 
Stenmark 2009).  Mutations in subunits of ESCRT III lead to intraneuronal accumulation of ubi-
quitinated protein aggregates and development of neurodegenerative diseases including amyo-
trophic lateral sclerosis and frontotemporal dementia (Raiborg and Stenmark 2009).  Additional-
ly, subunits of ESCRTs function as tumor suppressors in human embryonic kidney and ductal 
pancreatic tumors, indicating roles in tumorogenesis (Li, Belogortseva et al. 2008).  Thus, the 
ESCRTs prevent the onset of various neurodegenerative diseases and cancers (Raiborg and 
Stenmark 2009).  Lauwers and  colleagues recently demonstrated roles for lysine 63 linked ubi-
quitination in multivesicular body (MVB) sorting in yeast (Lauwers, Jacob et al. 2009).  Al-
though mono-ubiquitination of the general amino acid permease (Gap1) permease triggers its 
internalization into MVB, lysine 63 linked poly-ubiquitination of Gap1 is crucial for its maximal 
internalization and sorting in the MVB pathway as mono-ubiquitinated Gap1 is efficiently inter-
nalized, but not sorted, in the MVB pathway unless poly-ubiquitinated via lysine 63  (Lauwers, 
Jacob et al. 2009).   
An additional example of role of the UPS in protein trafficking involves EGFR.   Follow-
ing growth factor stimulation, ligand-bound EGFR is rapidly internalized through clathrin-
dependent and independent pathways.  Ligand-dependent endocytosis and sorting of EGFR is 
dependent on its ubiquitination status, and Huang and colleagues have provided new evidence 
for the role of lysine 63 linked poly-ubiquitin chains in this process (Huang, Kirkpatrick et al. 
2006).  EGFR mutants lacking ubiquitination sites undergo internalization; however, their turno-
ver is dramatically affected as a lysine 63 linked poly-ubiquitination event is essential for ubiqui-
tin mediated EGFR lysosomal degradation (Huang, Kirkpatrick et al. 2006).   
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Major histocompatibility (MHC) class I and MHC class II molecules are additional ex-
amples of ubiquitinated membrane proteins (Geetha, Jiang et al. 2005; Duncan, Piper et al. 2006; 
Shin, Ebersold et al. 2006).  MHC class I and II are cell surface glycoproteins that express anti-
genic peptides and are involved in the inflammatory response.  MHC class I proteins bind and 
present cytosolic peptides, including viral peptides; thus viruses frequently downregulate MHC 
class I expression in order to evade immune surveillance (Duncan, Piper et al. 2006).  For exam-
ple, cells infected with Kaposi‟s sarcoma-associated herpesvirus express viral protein K3 which 
is an ubiquitin ligase.  K3 poly-ubiquitinates MHC class I via lysine 63 additions, resulting in 
endocytosis and degradation of MHC class I and a reduction in cell surface presentation of viral-
ly derived peptides (Duncan, Piper et al. 2006).  Ubiquitination of MHC class II plays a crucial 
role in the development of dendritic cells.  In immature DC cells, the cytoplasmic tail of the 
MHC class II β-chain is ubiquitinated, which facilitates the endocytosis and sequestration of 
MHC class II in the MVB (Shin, Ebersold et al. 2006).  E3 ligases; modulator of immune recog-
nition (cMIR) and membrane-associated RING-CH (MARCH1) poly-ubiquitinate lysine 225 on 
the cytoplasmic tail of the MHC class II β-chain and therefore decrease MHC class II cell surface 
expression by regulating trafficking through the endosomal compartment (Ohmura-Hoshino, 
Matsuki et al. 2006; Ohmura-Hoshino, Matsuki et al. 2009).  When an immature dendritic cell 
encounters foreign stimuli, the dendritic cell matures and dramatically increases cell surface ex-
pression of MHC class II (van Niel, Wubbolts et al. 2008).  Upon maturation, ubiquitination of 
MHC class II is reduced through deubiquitination which stabilizes the surface expression of 
MHC class II on mature dendritic cells (Shin, Ebersold et al. 2006).  Thus, the rapid increase of 
MHC class II on the mature dendritic cell surface is due to rapid changes in the localization of 
MHC class II from endosomes to the cell surface. 
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Roles in Transcription 
 
Transcriptional regulation involves a synchronized interplay of multiple protein com-
plexes which must be recruited to, and ultimately removed from, DNA.  Though intensive stu-
dies have been undertaken to elucidate the mechanisms involved, how cells perform the tasks 
required to initiate, maintain and terminate transcription remains largely enigmatic.  Swaffield 
and colleagues first linked the proteasome to transcription regulation in 1992 by identifying mu-
tations in Rpt6 (Sug1) and Rpt4 (S10b) capable of rescuing a mutant Gal4 transactivator pheno-
type in yeast (Swaffield, Bromberg et al. 1992).  Rpt6 (Sug1) was later demonstrated to be a 
subunit of the 26S proteasome (Rubin, Coux et al. 1996), a seminal finding that encouraged oth-
ers to investigate roles for the proteasome in transcription regulation.  Peters and colleagues 
showed localization of the intact 26S, the 19S regulatory particle, and the 20S proteolytic core in 
both cytoplasmic and nuclear components in multiple cell types, including Xenopus laevis oo-
cytes (Peters, Franke et al. 1994), indicating the 26S, 19S and 20S could each exist separately 
and might play independent roles in the regulation of transcription.  To date, Sikder and col-
leagues have demonstrated association of subunits of the 19S and/or 20S proteasome with in 
excess of 6400 genes (Sikder, Johnston et al. 2006).  Components of the UPS have now been 
linked, via proteolytic and non-proteolytic roles, to transcription factor and co-factor processing, 
chromatin modifications, initiation, elongation and termination.  In this section we will highlight 
the many functions of UPS in transcriptional regulation. 
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Regulation of transcription factors  
 
Recent findings have shed light on the roles played by the 19S ATPases in regulating 
mammalian gene transcription.  In 2006, Rasti and colleagues established a non-proteolytic role 
for 19S ATPases in adenovirus E1A-dependent transcription.  S8 (Sug1) is recruited to the ade-
noviral promoter and enhances transcription by interacting with the transactivation domain of 
viral transcription factor E1A.  The 20S proteolytic core also interacts with E1A, but has distinct 
roles in mediating efficient E1A transactivation (Rasti, Grand et al. 2006).  Zhu and colleagues 
next identified non-proteolytic roles for the 26S in p53 mediated stress responses as p53 recruit-
ment to p21waf1 responsive promoters is enhanced upon proteasome inhibition (Zhu, Wani et al. 
2007).  p53 physically interacts with the 19S proteasomal ATPase Sug1 and is recruited to 
p21waf1 responsive promoters along with Sug1 and the S1 (a non-ATPase component of 19S) 
component of the 19S regulatory particle (Zhu, Wani et al. 2007).    
Lassot and colleagues have also demonstrated proteolytic and non-proteolytic roles of the 
proteasome in regulating HIV-1 transcription (Lassot, Latreille et al. 2007).  In the absence of the 
HIV-1 transactivator Tat, proteolytic activity of the 26S proteasome limits basal levels of tran-
scription from HIV-1 promoters (Lassot, Latreille et al. 2007).  Upon expression, Tat recruits the 
proteasome-associated protein PAAF-1 which facilitates separation of the 19S lid and the 20S 
core and thus switches the proteasome to a non-proteolytic mode (Lassot, Latreille et al. 2007).  
Following dissociation of the 19S lid, Tat recruits the 19S lid, but not the 20S proteolytic core, to 
the promoter in a PAAF dependent process (Lassot, Latreille et al. 2007).  Once recruited to the 
HIV-1 promoter, the 19S regulatory particle plays a non-proteolytic role in facilitating transcrip-
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tional elongation and HIV-1 transcription (Nelbock, Dillon et al. 1990; Shibuya, Irie et al. 1992; 
Bres, Kiernan et al. 2003; Lassot, Latreille et al. 2007).   
The UPS has also been implicated in regulating retinoic acid (RA)-mediated transcription 
(Ferry, Gianni et al. 2009).  Sug1 physically interacts with the retinoic acid receptor, a transcrip-
tional coactivator, and is recruited to RA-target promoters in order to facilitate the recruitment of 
additional complexes (vom Baur, Zechel et al. 1996; Gianni, Bauer et al. 2002; Ferry, Gianni et 
al. 2009).  We have recently established the importance of Sug1 in regulating the transcription of 
MHC class II molecules (Bhat, Turner et al. 2008).  Sug1 binds to the MHC class II proximal 
promoter and to the master regulator of MHC class II transcription, CIITA, via interactions inde-
pendent of the 20S proteolytic core (Bhat, Turner et al. 2008).  In the absence of Sug1, MHC 
class II transcription is dramatically decreased and CIITA recruitment at the MHC class II pro-
moter is abolished (Bhat, Turner et al. 2008).  The 20S proteasome is also recruited to the MHC 
class II promoter following prolonged cytokine stimulation, suggesting the 26S proteasome may 
be reassembled at active promoters.   
 
Mono-ubiquitination of transcription factors 
 
The role of ubiquitin in transcription activation was first demonstrated by Salghetti and 
colleagues who showed ubiquitination of the transactivation domain of viral protein-16 (VP-16) 
by the Met-30 ubiquitin ligase is essential for transactivity (Salghetti, Caudy et al. 2001).  Mono-
ubiquitination of LexA-VP16 (the fusion product of the LexA DNA binding domain and the 
VP16 transactivation domain) was later demonstrated to enhance recruitment of positive tran-
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scription elongation factor (PTEFb) to target promoters (Kurosu and Peterlin 2004).   We have 
demonstrated that CIITA, the master regulator of MHC Class II transcription, has increased 
transactivity and promoter binding when mono-ubiquitinated (Greer, Zika et al. 2003) and others 
have demonstrated enhanced degradation of CIITA upon poly-ubiquitination (Schnappauf, Hake 
et al. 2003).  Levels of the potent stress-responsive tumor repressor and transactivator p53 are 
tightly regulated through the actions of multiple E3 ligases including Mdm2, COP1, ADP-
ribosylation factor-binding protein1 (ARF-BP1), E6 associated protein (E6-AP), p300 and topoi-
somerase I-binding RING protein (Topors) (Kim, Wu et al. 2009).  Under steady state condi-
tions, E3 ligases maintain low levels of p53 through poly-ubiquitination and degradation 
(Scheffner, Huibregtse et al. 1993; Haupt, Maya et al. 1997; Honda and Yasuda 1999; Weger, 
Hammer et al. 2002; Grossman, Deato et al. 2003).  During cell stress, E3 ligases including 
Mdm2 and COP1, mono-ubiquitinate p53 thus increasing p53 transactivity and stability 
(Kubbutat, Jones et al. 1997; Lai, Ferry et al. 2001; Lin, Ozaki et al. 2005).   
The HIV-1 transactivator Tat is also regulated by ubiquitination (Bres, Kiernan et al. 
2003).  The E3 ligase Hdm2 positively regulates Tat-mediated transcription through the addition 
of lysine 63 linked poly-ubiquitin chains which increase Tat transactivity without affecting turn-
over (Bres, Kiernan et al. 2003).  Mono-ubiquitination of the atypical nuclear receptor DAX-1 
(dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1) is 
implicated in transcriptional repression during steroidogenesis (Ehrlund, Anthonisen et al. 2009).  
Ring finger protein 31 (RNF31) is a E3 ubiquitin ligase that targets DAX-1 and is crucial for re-
gulating DAX-1 activity and stability (Ehrlund, Anthonisen et al. 2009).  Foxhead box O4 
(FOXO4) is a transcription factor involved in cellular responses to oxidative stress (van der 
Horst, de Vries-Smits et al. 2006) that is also modified by multiple post-translational modifica-
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tions, including mono-ubiquitination, in response to stress.  Mono-ubiquitinated FOXO4 translo-
cates to the nucleus with increased transactivity (van der Horst, de Vries-Smits et al. 2006; 
Brenkman, de Keizer et al. 2008) and Mdm2, a well known regulator of cell cycle control,  has 
been identified as an E3 ligase responsible for mono-ubiquitination of FOXO4 (Brenkman, de 
Keizer et al. 2008).  Finally, apoptosis-antagonizing transcription factor (AATF) is also involved 
in cell cycle regulation and has been shown to interact with tumor susceptibility gene protein 
(TSG101), a subunit of the ESCRT subunit, upon activation by hormones. TSG101 functions as 
a ubiquitin conjugating enzyme (E2) and increases mono-ubiquitination of AATF (Burgdorf, 
Leister et al. 2004).  Mono-ubiquitination stabilizes AATF, increases its transactivity, and posi-
tively regulates cell cycle progression (Burgdorf, Leister et al. 2004).   
Regulation of the ubiquitination status of activators is critical in the control of transcrip-
tion factor promoter function.  How mono-ubiquitination of transactivators “licenses” their acti-
vation, and how this status is balanced with poly-ubiquitination and degradation, has been the 
focus of intense investigation.  Studies in yeast on Gal4-dependent genes first indicated that 19S 
proteasomal ATPases bind to the Gal4 activation domain independently of both the non-ATPase 
19S subunits and the 20S proteolytic core (Gonzalez, Delahodde et al. 2002).  Binding of the 19S 
ATPases to active promoters leads to increases in efficient transcription initiation and elongation 
(Ferdous, Gonzalez et al. 2001; Ferdous, Kodadek et al. 2002; Gonzalez, Delahodde et al. 2002; 
Ferdous, Sikder et al. 2007).  In 2007, Ferdous and colleagues demonstrated a non-proteolytic 
“destabilizing” function of the APIS (19S ATPase proteins independent of 20S) complex involv-
ing an ATP-dependent, rapid, and reversible disassociation of the transactivator-promoter com-
plex which was inhibited in presence of mono-ubiquitin (Ferdous, Sikder et al. 2007; Archer, 
Delahodde et al. 2008).   
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Figure 1.8: Role of mono-ubiquitin in protecting activator from “Stripping Activity” of Proteasomal ATPase  
Protein-DNA destabilization process is initiated by the extraction of APIS complex (ATPases and Rpn1 and Rpn2) 
from the 26S proteasome leaving 20S and 19S lid subunits. APIS complex bound to activation domain of activator 
via Rpt4/Rpt6 would start to unfold the protein and thus perform its “stripping activity” to inhibit transcription.  
Mono-ubiquitination of DNA binding domain of activator would block the “stripping activity” of APIS as this ubi-
quitin moiety would interact with Rpn1 and Rpt1 following which the interaction between activation domain and 
Rpt4/Rpt6 is disrupted by allosteric mechanism.  The APIS complex then proceeds to execute its function in promo-
ter escape and transcription elongation.  Figure adapted from Archer et.al., 2008.   
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The destabilizing activity of the APIS complex was dependent on direct interaction the 19S   
ATPase Sug1/Rpt6 and Sug2/Rpt4 with activation domains of Gal4 protein and the presence of 
ATP (Ferdous, Sikder et al. 2007; Archer, Delahodde et al. 2008).  Destabilization is initiated by 
the extraction of the APIS complex (the 19S ATPases and non-ATPases Rpn1 and Rpn2) from 
the 26S proteasome leaving 20S and 19S lid subunits behind.   When the APIS complex binds to 
the activation domain of an activator via Rpt4/Rpt6, the APIS begins to unfold the protein, this 
acts as a “stripping activity” that inhibits transcription (Archer, Burdine et al. 2008) (Figure 1.8).   
Interestingly, the destabilizing activity of APIS is inhibited when Gal4 is mono-ubiquitinated or 
is genetically fused with mono-ubiquitin (Ferdous, Sikder et al. 2007; Archer, Delahodde et al. 
2008).  Mono-ubiquitination of the DNA binding domain of Gal4 thus blocks the “stripping ac-
tivity” of APIS.  The mono-ubiquitin moiety interacts with Rpn1 and Rpt1, and via allosteric 
hindrance, disrupts the interaction between the activation domain and Rpt4/Rpt6 (Archer, 
Burdine et al. 2008) (Figure 1.8).   Finally, Kim and colleagues have established the presence of 
similar mechanisms in mammalian transcription, where p53 mediated regulation of p21waf1 ex-
pression is shown to be negatively modulated by the “stripping activity” of 19S proteasomal 
ATPases (Kim, Wu et al. 2009).   
To summarize the complex contributions of subunits of the 19S proteasome to transcrip-
tion; initial findings have demonstrated that subunits of the APIS complex bind and recruit tran-
scription factors to promoters where they enhance transcription initiation and elongation 
(Ferdous, Kodadek et al. 2002; Rasti, Grand et al. 2006; Zhu, Wani et al. 2007; Bhat, Turner et 
al. 2008; Truax, Koues et al. 2009).  Further studies have shown mono-ubiquitination of tran-
scription factors increases transactivation; however, the mechanisms involved in this process 
were unclear (Salghetti, Caudy et al. 2001; Greer, Zika et al. 2003; van der Horst, de Vries-Smits 
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et al. 2006).  Recent studies have elucidated additional non-proteolytic roles of the 19S ATPase 
Sug1 and the APIS complex involving stripping of non-mono-ubiquitinated transcription factors.  
Sug1/Rpt6 binds to unmodified transcription factors and performs a “stripping activity” to halt 
transcription (Gonzalez, Delahodde et al. 2002; Ferdous, Sikder et al. 2007; Archer, Burdine et 
al. 2008; Archer, Delahodde et al. 2008; Ferdous, O'Neal et al. 2008; Kim, Wu et al. 2009).  In 
the presence of mono-ubiquitin, Sug1/Rpt6 binding to transcription factor is inhibited, allowing 
and transcription initiation (Archer, Burdine et al. 2008).  Together, these studies shed light on 
non-proteolytic and proteolytic roles of Sug1, the APIS complex, and mono-ubiquitin in mod-
ulating transcription.     
 
Regulation of elongation 
 
Both degradative and non-degradative roles of the 26S proteasome are important in regu-
lating elongation (Ferdous, Gonzalez et al. 2001).  Gcn4, Gal4 and Ino2/4 yeast transcription fac-
tors require UPS-mediated proteolytic activity in order to mediate transactivation, as proteasome 
inhibition decreased transcription of downstream genes (Lipford, Smith et al. 2005).  Tempera-
ture sensitive mutations in the E3 ligase SCF, or lysine 48 to arginine mutations of ubiquitin, 
both block Gcn4 mediated transcription of target genes although Gcn4 was abundant at the target 
promoters.  Finally, proteasome inhibition causes a reduction in RNA pol II recruitment to mul-
tiple promoters regulated by Gcn4, Gal4 and Ino2/4, further indicating the importance of the pro-
teolytic function of UPS in regulation of efficient transcription elongation (Lipford, Smith et al. 
2005).   
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The 19S proteasomal ATPase subunits have been shown to play roles in pol II dependent 
yeast elongation that are independent of the 20S proteasome.  Initial observations indicated that 
absence of the 19S decreases transcription elongation whereas absence of the proteolytic 20S 
increases transcription elongation
 
(Ferdous, Gonzalez et al. 2001; Ferdous, Kodadek et al. 2002; 
Gillette, Gonzalez et al. 2004; Lipford, Smith et al. 2005).  These data signified that while the 
two subunits of proteasome can function independently of each other, each is essential for proper 
transcription elongation and termination (Ferdous, Gonzalez et al. 2001; Ferdous, Kodadek et al. 
2002; Gillette, Gonzalez et al. 2004; Lipford, Smith et al. 2005).  The APIS complex has also 
been shown to be essential for efficient transcription elongation by RNA pol II, although the ex-
act mechanism by which the APIS complex aids transcription elongation is unknown (Ferdous, 
Gonzalez et al. 2001; Ferdous, Kodadek et al. 2002).  Ferdous and colleagues have demonstrated 
roles for the 19S ATPase Sug1 in RNA pol II mediated elongation as Sug1 physically interacts 
with the yeast elongation factor Cdc8 and mutations in Sug1 lead to defective elongation 
(Ferdous, Gonzalez et al. 2001).  Finally, studies in yeast indicate the existence of a holo-RNA 
pol II  composed of a core RNA pol II and a mediator complex which enables enhanced tran-
scription activity of the core RNA pol II (Kim, Bjorklund et al. 1994).  In this study, the 19S 
ATPase Sug1  was identified as a subunit of the mediator complex, providing additional support 
for a role for Sug1 in transcription initiation and elongation (Kim, Bjorklund et al. 1994).  Thus, 
proteolytic and nonproteolytic activities of proteasome are necessary for efficient RNA pol II 
mediated elongation.   
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Regulation of epigenetics 
 
Ezhkova and colleagues first demonstrated roles for 19S ATPase heterodimer subunits 
Rpt6 (Sug1) and Rpt4 (S10b) in yeast chromatin remodeling (Muratani and Tansey 2003).  Bind-
ing of functional Rpt6 and Rpt4 to chromatin links histone H2B ubiquitination to the activating 
modifications of histone H3 lysine 4 (H3K4) and H3K79 methylation as mutations in Rpt6 and 
Rpt4 prevent methylation of H3K4 and H3K79 but do not affect H2B ubiquitination (Ezhkova 
and Tansey 2004).  Mono-ubiquitination of histone H2B may direct the stable recruitment of 19S 
ATPases to chromatin, where the ATPases facilitate recruitment of methyl transferases to his-
tones leading to histone H3K4 and H3K79 methylation and open chromatin (Ezhkova and 
Tansey 2004; Collins and Tansey 2006).   
Lee and colleagues have demonstrated links between 19S ATPases and the Spt-Ada-
Gcn5-acetyltransferase (SAGA) complex, a co-activator involved in yeast transcription initiation 
(Lee, Ezhkova et al. 2005).  SAGA physically interacts with Rpt6 (Sug1) and this interaction fur-
ther enhances recruitment of the SAGA complex to transcription factors and target promoters 
(Lee, Ezhkova et al. 2005).  The SAGA complex catalyzes histone H3 acetylation and thus plays 
crucial roles in opening chromatin structure for transcription initiation (Lee, Ezhkova et al. 
2005).  Mutations in Rpt6 (Sug1) lead to reduced H3 acetylation due to decreases in promoter 
recruitment of general control of amino-acid synthesis 5 (GCN5), a histone acetylase component 
of SAGA (Lee, Ezhkova et al. 2005).  The deubiquitinase Ubp8 of the SAGA complex is a struc-
turally non-essential component of SAGA which has been implicated in deubiquitination of his-
tone H2B, as disruption of the ubp8 gene leads to a significant increase in histone H2B ubiquiti-
nation (Daniel, Torok et al. 2004).  Ubp8 physically associates with upstream activation se-
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quence of GAL10 gene when radiation sensitivity protein 6 (Rad6) dissociates, and this process 
has been shown to be essential for trimethylation of histone H3K4 (Daniel, Torok et al. 2004).  
In sum, these data indicate the 19S ATPases mediate initial chromatin reorganization events by 
modulating various post-translational modifications to regulate transcription at yeast promoters.   
We have investigated roles played by the 19S ATPases in epigenetic modifications occur-
ring at MHC class II and CIITA mammalian promoters.  Sug1 physically interacts with histone 
acetyltransferase CREB-binding protein (CBP) and recruits CBP to the MHC class II promoter 
(Koues O.I. 2008).  Recruitment of Sug1, and subsequent recruitment of CBP, to the promoter is 
essential for histone H3 acetylation, as knocking down Sug1 decreases histone H3 acetylation 
and reduces MHC class II expression (Koues O.I. 2008).  We have also demonstrated roles for 
Sug1 and additional 19S ATPases in activating methylation events at the MHC class II HLA-
DRA gene (Koues, Dudley et al. 2009).  Sug1 modulates chromatin activation events including 
histone H3 trimethylation at lysine4 and histone H3 dimethylation at arginine 17 at both MHC 
class II and CIITA promoters (Koues, Dudley et al. 2009).   
The 19S ATPases exist as heterodimeric complexes of Sug1-S10b, S7-S4, and S6a-S6b.  
Evidence that these heterodimers exist in the nucleus independent of the non-ATPase 19S lid 
subunits (Richmond, Gorbea et al. 1997; Russell, Steger et al. 1999; Adams 2003) suggests these 
heterodimers may also have roles independent of the 26S proteasome.  We have shown that the 
19S ATPase S6a regulates cytokine inducible expression of MHC class II by regulating expres-
sion of its master regulator CIITA (Agnieszka D.Truax 2009).  This regulation is likely at the 
level of transcription as knocking down S6a reduces acetylation at histone H3 and H4 preferen-
tially at lysine 18 on histone H3 and lysine 8 on histone H4 (Agnieszka D.Truax 2009).  S6b the 
19S ATPAse that heterodimerizes with S6a, was determined to have parallel functions to S6a in 
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regulating histone acetylation events and to be dependent on S6a for these functions (Agnieszka 
D.Truax 2009), indicating S6a and S6b may function as heterodimers in regulating epigenetic 
events at mammalian promoters.  Thus, the UPS plays important roles in regulating the dynamics 
of transcription by controlling the assembly of regulatory complexes and the turnover of tran-
scription factors and cofactors involved in multiple stages of transcription.  This regulation is 
further complicated by the multiple regulatory mechanisms employed by UPS and observations 
that components of the 26S proteasome have differential association and involvement in different 
stages of transcription.   
 
MHC CLASS II AND IMMUNE SYSTEM 
Immune system 
Proper functioning of the adaptive immune system requires fine regulation of various 
immune proteins.  One of the major determinants of the immune response is the major histocom-
patibility complex (MHC).  MHC are cell surface glycoproteins involved in antigen presentation 
(Kvist and Levy 1993).   MHC class I is constitutively expressed by all nucleated cell types 
(York and Rock 1996), while constitutive expression of MHC class II is restricted to antigen pre-
senting cells (APCs) (Matheux and Villard 2004).   Cytokines including interferon-γ (IFN-γ) and 
tumor necrosis factor-α (TNF-α) upregulate MHC class II expression on almost all other cell 
types (Weber and Rosenberg 1988; Matheux and Villard 2004).  The antigens presented by the 
two classes of MHC differ in that MHC class I presents cytosolic antigen on the cell surface to 
activate CD8
+
 T cells (cytotoxic T cells) (Rock 1996) while MHC class II presents processed 
exogenous antigens on the cell surface to activate CD4
+
 T cells (Matheux and Villard 2004).   
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Activation of CD4
+
 T cells is required for cell mediated and antibody mediated immune 
responses (Glimcher and Kara 1992).  Due to the crucial roles in adaptive immunity played by 
MHC class II molecules, deficiencies in MHC class II expression lead to the development of 
bare lymphocyte syndrome (BLS) (Reith and Mach 2001), an autosomal recessive disease fatal 
in early childhood.   Severe combined immunodeficiency (SCID) is also an outcome of MHC 
class II deficiency (Reith and Mach 2001).   SCID patients lack CD4
+ 
T cells and, in the absence 
of these T cells, many B cells also fail to function, thus SCID patients are severely immunocom-
promised.   Overexpression of MHC class II is associated with increased vulnerability to the de-
velopment of autoimmune diseases including multiple sclerosis, rheumatoid arthritis and myo-
cardial infarction (Swanberg, Lidman et al. 2005).  In addition, MHC class II molecules play 
critical roles in anti-tumor immunity as tumor specific CD4
+
 T cells help recruit and activate 
CD8
+
 T cells at the tumor sites (Wang 2003) and tumor cells frequently decrease MHC class II 
expression to evade immune recognition (Guy, Krajewski et al. 1986).  Because MHC class II is 
a critical regulator of adaptive immune response, its expression is tightly regulated (Benoist and 
Mathis 1990).   
          
Regulation of MHC class II  
There are three types of MHC class II proteins expressed in humans HLA -DR, -DP and -
DQ (Trowsdale 2001) expression of which is regulated primarily at the level of transcription 
(Benoist and Mathis 1990; Glimcher and Kara 1992).  The MHC class II proximal promoter con-
tains a conserved cis-acting region consisting of W (or S), X1, X2 and Y boxes (Benoist and 
Mathis 1990; Reith and Mach 2001).  Ubiquitous transcription factors including regulatory factor 
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X (RFX5, RFX-AP, RFX-ANK) (Steimle, Durand et al. 1995; Ting and Trowsdale 2002) 
(Nagarajan, Louis-Plence et al. 1999) (Masternak, Barras et al. 1998), cAMP responsive element 
binding protein (CREB) (Moreno, Beresford et al. 1999) and nuclear nactor-Y (NF-Y) 
(Mantovani 1999) bind respectively to the X1, X2 and Y elements to form the “enhanceosome 
complex”(Ting and Trowsdale 2002) (Figure 1.9).  Although recruitment of these transcription 
factors is essential for MHC class II transcription, it is not sufficient (Masternak, Muhlethaler-
Mottet et al. 2000).  MHC class II transcription initiation requires recruitment of the master regu-
lator CIITA to the enhanceosome complex (Steimle, Otten et al. 1993; Mach, Steimle et al. 1996; 
Muhlethaler-Mottet, Otten et al. 1997; Masternak, Muhlethaler-Mottet et al. 2000).  CIITA does 
not directly bind to DNA but acts as a co-factor that binds the pre-assembled enhanceosome 
complex (Fontes, Jiang et al. 1997; Mahanta, Scholl et al. 1997; Kretsovali, Agalioti et al. 1998; 
Moreno, Beresford et al. 1999; Zhu, Linhoff et al. 2000; Jabrane-Ferrat, Nekrep et al. 2003) 
(Zhu, Linhoff et al. 2000).  Upon cytokine stimulation, CIITA is recruited to the MHC class II 
proximal promoter and co-ordinates multiple steps to initiate MHC class II transcription (Zhu, 
Linhoff et al. 2000).  Chromatin remodeling enzymes including BRG1ATPase (Mudhasani and 
Fontes 2005) and histone acetyltransferases (CBP/p300) are recruited by CIITA to open the 
chromatin structure (Drozina, Kohoutek et al. 2005) (Wright and Ting 2006).  Various basal 
transcription factors and cyclin dependent kinases (CDKs), which phosphorylate the C-terminal 
domain of RNA polymerase II (RNA pol II), are also recruited in a CIITA dependent fashion; 
following which MHC class II transcription initiates (Spilianakis, Kretsovali et al. 2003).   
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Figure 1.9: MHC class II HLA-DRA promoter.   
MHC class II proximal promoter region has a conserved cis-acting region consisting of W (or S), X1, X2 and Y 
boxes.  Ubiquitous transcription factors including regulatory factor X (RFX5, RFX-AP, RFX-ANK), cAMP res-
ponsive element binding protein (CREB) and nuclear factor-Y (NF-Y) bind to the X1, X2 and Y elements re-
spectively to form the “enhanceosome complex”.  MHC class II transcription requires recruitment of master reg-
ulator, class II transactivator (CIITA) to the enhanceosome complex.  CIITA does not directly bind to DNA but 
acts as a co-factor that binds the pre-assembled enhanceosome complex and recruits kinases that phosphorylate 
RNA pol II to initiate transcription.  
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CIITA interaction with the enhanceosome complex and transcription factors is further enhanced 
by phosphorylation by c-AMP-dependent protein kinase (PKA) (Chang CH 2002; Sisk, 
Nickerson et al. 2003).  Transcription initiation then occurs, however elongation is soon paused 
due to the presence of negative transcription elongation factor (N-TEF) and DRB-sensitive in-
ducing factor (DSIF) (Kanazawa and Peterlin 2001; Peterlin and Price 2006).  To enable proper 
transcription elongation, CIITA binds to the CycT1 subunit of positive transcription elongation 
factor (P-TEFb) complex, following which the P-TEFb complex is recruited to the MHC class II 
promoter (Kanazawa, Okamoto et al. 2000).  The cdk9 subunit of P-TEFb complex phosphory-
lates N-TEF and releases the paused complex leading to elongation (Kohoutek, Blazek et al. 
2006; Oven, Brdickova et al. 2007). These multiple interactions are crucial steps in the initiation 
of MHC class II transcription and their regulation plays a critical role in initiation of the immune 
response.  The steps involved in activation of MHC class II transcription are well understood, but 
how CIITA itself is recruited, stabilized and degraded at the MHC class II proximal promoter 
region remains unknown.   
 
CIITA, The Master Regulator of MHC class II 
 CIITA is a non-DNA binding co-factor that is absolutely required for initiation of MHC 
class II genes (Masternak, Muhlethaler-Mottet et al. 2000).  CIITA is not only essential for MHC 
Class II transcription, but also plays crucial roles in transcriptional regulation of additional di-
verse immune response genes including IL-4 (Sisk, Gourley et al. 2000), IL-10 (Yee, Yao et al. 
2005), E-cathepsin (Yee, Yao et al. 2004), MMP-9 (Nozell, Ma et al. 2004), plexin (Wong, 
Brickey et al. 2003) and Fas ligand (Gourley and Chang 2001).  As CIITA plays critical roles in 
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regulating expression of multiple immune response genes, it is inevitable that CIITA might play 
a role in disease development.  A selection from the many diseases in which CIITA has been im-
plicated include head and neck cancer (Meissner, Whiteside et al. 2009), small cell lung cancer 
(Yazawa, Kamma et al. 1999), Erwings sarcoma (Dagmar, Alfons et al. 2009), autoimmune 
Adisson‟s disease (Skinningsrud, Husebye et al. 2008), and artherosclerosis (Buttice, Miller et al. 
2006).  Due to the role of CIITA in regulating expression of multiple genes and in development 
of multiple diseases, intense studies have focused on understanding CIITA regulation.  Despite 
this, due to the complex structure of CIITA and the roles CIITA plays in transcriptional regula-
tion of multiple genes in various cell types, much regarding CIITA regulation remains unknown.  
CIITA is an 1130 amino acid protein with four functional domains: an N-terminal transcriptional 
acidic activation domain (AAD), a proline/serine/threonine rich (P/S/T) domain which is re-
quired for CIITA transactivity, a GTP-binding domain (GBD), and a C-terminal leucine rich re-
gion (LRR) that is required for localization (Tosi, Jabrane-Ferrat et al. 2002)  (Figure 1.10).  
CIITA has three nuclear localization sequences (NLS) that are required for nuclear translocation 
and activity (Cressman, O'Connor et al. 2001).  The P/S/T rich region of CIITA contains a pro-
teolytic signal site called a degron, specific sequences that frequently target proteins for degrada-
tion (Drozina, Kohoutek et al. 2006).  CIITA is expressed from three distinct promoters (pI, pIII 
and pIV) to ensure the presence of CIITA in different cell types under different conditions 
(Muhlethaler-Mottet, Otten et al. 1997).  CIITA isoform I (IF1) is expressed from pI in dendritic 
cells and macrophages, isoform III (IF III) is expressed from pIII in B cells, and isoform IV (IF 
IV) is expressed from pIV in IFN-γ induced cells (Muhlethaler-Mottet, Otten et al. 1997).  Al-
though transcriptional control of CIITA is well understood, the post-translational code (different 
combinations of post-translational modifications) of CIITA remains to be explored. 
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Figure 1.10:  Schematic representation of domain structure of CIITA protein.   
CIITA is a 1130 amino acid long protein with four functional domains, the N-terminal transcriptional acidic activa-
tion domain (AAD) required for CIITA transactivity, proline/serine/threonine rich (P/S/T) domain required for bind-
ing to various factors and cofactors, GTP-binding domain (GBD) and C-terminal leucine rich region (LRR) required 
for its localization and oligomerization.  CIITA has three nuclear localization sequences (NLS) that are required for 
its nuclear translocation and its activity.   The P/S/T rich region of CIITA contains proteolytic signal sites called 
degrons (D) that are specific sequences that target proteins for ubiquitination at proximal lysine residues and degra-
dation. This figure is adapted from Ting J.T. and Trowsdale J., 2002.   
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Post-translational modification of CIITA 
Transcription factors bind to specific sites on promoters to initiate transcription of target 
genes.  Therefore, transcription factors and co-activators are highly regulated in order to allow 
fine-tuning of gene expression (Kodadek, Sikder et al. 2006).  Regulation of CIITA is achieved 
through multiple levels of control including genetic, transcriptional and post-translational path-
ways.  Amongst these regulations, post-translational regulation is the most crucial as in order to 
perform; CIITA is highly modified (Cressman, Chin et al. 1999; Spilianakis, Papamatheakis et 
al. 2000; Cressman, O'Connor et al. 2001; Sisk, Nickerson et al. 2003; Satoh, Toyota et al. 2004; 
Drozina, Kohoutek et al. 2006).   
Post-translational modifications including phosphorylation (P), ubiquitination (Ub) and 
acetylation (Ac) have been shown to regulate CIITA activity (Cressman, Chin et al. 1999; 
Spilianakis, Papamatheakis et al. 2000; Cressman, O'Connor et al. 2001; Sisk, Nickerson et al. 
2003; Satoh, Toyota et al. 2004).  A comprehensive table of the various post-translational mod-
ifications of CIITA and their known roles in cellular function is shown in Table 1.1.  Phosphory-
lation at serine 384 (S834) and serine 1050 (S1050) in the LRR domain of CIITA leads to a re-
duction in MHC Class II expression (Li, Harton et al. 2001).  Alternatively, phosphorylation at 
serine 374 (S374) and serine 375 (S375), that lie between the P/S/T and GBD domains of CIITA, 
increases MHC class II expression (Sisk, Nickerson et al. 2003).  These different phoshorylation 
events are catalyzed by PKA, thus it is thought that PKA activates CIITA at the MHC class II 
proximal promoter by phosphorylating S374 and S375 and inactivates CIITA by phosphorylating 
S834 and S1050 (Dummer, Bastian et al. 1996; Li, Harton et al. 2001; Sisk, Nickerson et al. 
2003; Wu, Kong et al. 2009).  Xu and colleagues have demonstrated that kinases GSK1 and CKI 
both phosphorylate serine 373 (S373) and serine 377 (S377), and that these phosphorylation 
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events increase CIITA mediated collagen transcription without affecting MHC class II expres-
sion, indicating that these post-translational modifications play alternative roles in modulating 
CIITA transactivity (Xu, Harton et al. 2008).  The P/S/T domain of CIITA also has multiple 
phosphorylation sites, and Greer and colleagues have shown that CIITA is phosphorylated at 
sites serines 286, 288 and 293 (S286, S288 and S293), and that these phosphorylation events re-
gulate CIITA nuclear localization but not oligomerization (Greer, Harton et al. 2004).  Following 
this observation, Voong and colleagues subsequently identified ERK1/2 as the kinase involved in 
phosphorylating these sites (Voong, Slater et al. 2008).   
Acetylation, a reversible post-translational modification, has also been shown to regulate 
CIITA activity.  Histone acetyl transferases p300 and PCAF acetylate lysine 141 (K141) and ly-
sine 144 (K144) in the N-terminus of CIITA and increase MHC Class II expression (Spilianakis, 
Papamatheakis et al. 2000).  Histone deacetylases (HDACs) catalyze the removal of acetyl 
groups and have also been shown to modulate CIITA transactivity.  HDAC2 mediated deacetyla-
tion of CIITA targets it for degradation and thus reduces CIITA mediated gene expression whe-
reas SIRT1 mediated deacetylation enhances CIITA transactivity (Kong, Fang et al. 2009; Wu, 
Kong et al. 2009).  Finally, CIITA has been shown to have an intrinsic histone acetyl transferase 
activity that resides in its N-terminus, although target proteins for this activity remain to be iden-
tified (Raval, Howcroft et al. 2001).   
The posttranslational modification of mono-ubiquitination has been shown to increase 
CIITA transactivity (Greer, Zika et al. 2003).  Upon mono-ubiquitination, CIITA demonstrates 
increased association with the enhanceosome complex at the MHC class II promoter where it 
drives increased MHC class II transcription (Greer, Zika et al. 2003).  CIITA has also been 
shown to be degraded by polyubiquitination and the ubiquitin-proteasome pathway (Schnappauf, 
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Hake et al. 2003).  Although these studies have demonstrated ubiquitination to be a regulatory 
mechanism of CIITA transactivity, sites of ubiquitination in CIITA remain unknown.  Identify-
ing ubiquitination sites is a significant task as CIITA has multiple ubiquitination sites (42 lysine 
residues).  Although much is known about the post-translational modifications of CIITA, how 
CIITA is recruited to, stabilized on and eventually removed from the MHC class II promoter re-
mains enigmatic.   
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Table 1.1 Post-translational code of CIITA  
Post-translational modifications Sites of     
modifications 
Effect of modifications 
Phosphorylation S834, S1050 Inhibition of MHC class II transcription 
Phosphorylation S286, S673, 
S942, S943, 
S944, S1128 
Not determined 
Phosphorylation S374, S375 Increase MHC class I transcription, interaction 
with co-activator p300 and oligomerization 
Phosphorylation S373, S377 Inhibition of collagen transcription by interacting 
with co-repressor Sin3B 
Phosphorylation S286, S288, 
S293 
Inhibition of MHC class II transcription and Nuc-
lear export 
Phosphorylation S293 Repression of CD36 
Ubiquitination Not determined Increase in MHC class II transcription 
Acetylation K141, K144 Enhance nuclear localization of CIITA and in-
crease MHC Class II expression 
Deacetylation Not determined HDAC2 mediated deacetylation decreases CIITA 
stability and its interaction with RFX5 
Deacetylation Not determined SIRT1 mediated deacetylation increases MHC 
class II transcription 
Note: This table is adapted from Adapted from Wu X. et.al., 2009 
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SUMMARY 
The master regulator of degradation, the 26S proteasome, regulates transcription through 
proteolytic and non-proteolytic pathways.  The 19S regulatory particle and the 20S proteolytic 
core of the 26S proteasome can function independently of each other and each component has 
distinct roles in transcription regulation (Ferdous, Kodadek et al. 2002; Gonzalez, Delahodde et 
al. 2002; Rasti, Grand et al. 2006; Zhu, Wani et al. 2007).  The 19S proteasomal ATPases asso-
ciate with actively transcribing genes in yeast (Gonzalez, Delahodde et al. 2002; Auld, Brown et 
al. 2006) and have been shown to regulate the elongation process carried out by RNA-
polymerase II (Ferdous, Gonzalez et al. 2001; Ferdous, Kodadek et al. 2002).  The role of the 
19S proteasomal subunit in transcription is widely studied in yeast, it remains unclear if the 19S 
proteasomal subunits play similar roles in mammalian gene transcription.   
Because MHC class II plays a crucial role in initiating the adaptive immune response to 
infection and in anti-tumor responses, it is of utmost importance to understand how MHC class II 
transcription and CIITA stability and activity are regulated.  It is known that mono-ubiquitination 
of CIITA increases its transactivity and that CIITA is eventually degraded via the ubiquitin-
proteasome pathway (Greer, Zika et al. 2003; Schnappauf, Hake et al. 2003).  These findings link 
CIITA and regulation of MHC class II transcription to the ubiquitin proteasome system (UPS).  
In the light of the novel non-proteolytic roles of various 26S proteasomal subunits in transcrip-
tion regulation in yeast, it is probable that these subunits have roles to play in MHC class II gene 
transcription.  Thus, studying the roles played by the UPS in regulating MHC class II transcrip-
tion will not only aid in the development of novel therapies to manipulate MHC class II gene ex-
pression but will also further our knowledge of the roles of ubiquitin and 19S proteasomal sub-
units in mammalian gene transcription.  
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SUMMARY 
Emerging evidence in yeast suggests roles for ATPases of the 19S proteasome as media-
tors of transcriptional systems through their association with actively transcribed promoters, faci-
litation of clearance of paused elongation complexes and recruitment of coactivators.  Although 
19S subunits also regulate mammalian transcription, their role in recruiting transcription factors 
remains unclear.  Here, we demonstrate for the first time a role for the 19S proteasome ATPase 
Sug1 in regulating transcription of the critical adaptive immune gene, MHC class II.  Sug1 asso-
ciates with the class II transactivator, CIITA, and with the MHC class II proximal promoter.  In 
the absence of Sug1, HLA-DR promoter activity and MHC class II transcription are decreased.  
Critically, CIITA association with the MHC II promoter is dramatically decreased when Sug1 
expression is reduced, even under conditions of proteasome inhibition.  In contrast to the rapid 
promoter association of the 19S subunit, a 20S proteasome subunit associates with the MHC 
class II proximal promoter following prolonged cytokine stimulation and its association corres-
ponds with pronounced promoter disassociation of CIITA.  Taken together, these data demon-
strate that both 19S and 20S subunits of the 26S proteasome play specific and critical roles in 
regulating CIITA activity and MHC class II transcription.  
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BACKGROUND 
 MHC class II gene products encode cell-surface glycoproteins that bind and present 
antigenic peptides derived from extracellular proteins.  Molecules of the MHC class II complex, 
HLA-DR, HLA-DP and HLA-DQ in humans, present these antigenic peptides specifically to 
CD4
+
 T helper lymphocytes, resulting in initiation of T helper cell activation and proliferation.  
This basic premise forms an essential arm of the adaptive immune response and is critical to the 
activation of both cellular and antibody mediated immune mechanisms (Glimcher and Kara, 
1992).  Tight regulation of MHC class II protein expression is necessary for control of the adap-
tive immune response and for the prevention of autoimmune diseases.  MHC class II expression 
is regulated primarily at the level of transcription of MHC class II genes (Benoist and Mathis, 
1990) (Reith and Mach, 2001) by a group of cis acting elements, W(or S), X1, X2 and Y boxes 
commonly referred to as the W-X-Y module, that are highly conserved among promoters of 
MHC class II genes (Glimcher and Kara, 1992).  The W-X-Y module is recognized and bound 
by the trimeric RFX and NFY complexes (Steimle et al., 1995; Ting and Trowsdale, 2002) (Na-
garajan et al., 1999) (Mantovani, 1999) (Masternak et al., 1998) and by CREB (Moreno et al., 
1999) (Muhlethaler-Mottet et al., 2004).  These transcription factors are ubiquitously expressed 
and, while their binding is insufficient for MHC class II expression (Masternak et al., 2000), they 
form a platform that recruits the Class II Transactivator (CIITA) to the proximal promoter, a step 
required for MHC class II expression (Steimle et al., 1993).   
Unlike the requisite MHC class II transcription factors mentioned above, CIITA gene ex-
pression proceeds and parallels that of MHC class II (Ting and Trowsdale, 2002).  CIITA does 
not bind directly to the MHC class II promoter, but it is known as the master regulator of MHC 
class II transcription as its association with the pre-assembled enhanceosome complex coordi-
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nates several additional steps leading to transcriptional initiation (Moreno et al., 1999) (Zhu et 
al., 2000) (Masternak et al., 2000) (Bewry et al., 2007).  CIITA directs MHC class II transcrip-
tion initiation through interactions with the BRG1 ATPase of the hSWI/SNF remodeling com-
plex (Mudhasani and Fontes, 2002) and through promoter recruitment of histone acetyltransfe-
rases (p300, CBP, pCAF and SRC-1) (Drozina et al., 2005; Wright and Ting, 2006), components 
of the basal transcriptional machinery (Fontes et al., 1997) (Mahanta et al., 1997) and kinases 
that phosphorylate the carboxyl terminus of RNA polymerase II (Spilianakis et al., 2003).  Phos-
phorylation of CIITA further increases its interactions with the co-activator CBP/p300, with 
RFX and with CIITA itself, thus increasing MHC class II promoter activity (Sisk et al., 2003). 
Therefore, interactions of CIITA with the MHC class II enhanceosome complex, with the basal 
transcriptional machinery, and with chromatin remodeling enzymes play a critical role in regulat-
ing MHC class II transcription.   
Localization of the enhanceosome proteins, chromatin remodeling enzymes, basal tran-
scriptional machinery and CIITA at the transcribing MHC class II proximal promoter makes this, 
as are most promoters, a complex regulatory region.  How cells manage to regulate and recruit 
multiple protein:protein interactions like these has become an increasingly important question.  
Recent evidence has supported a role for components of the 26S proteasome as mediators of the 
assembly of transcriptional systems in yeast.  The 26S proteasome is a multi-protein complex 
that regulates the degradation of polyubiquitinated proteins and consists of two basic parts:  a 
20S proteolytic core complex and a 19S regulatory particle (Baumeister et al., 1998).  The 19S 
can be further divided into base and lid subunits.  The base is composed of six homologous AAA 
ATPases (S4, S6a, S6b, S7, Sug1(Sug1) and S10b) and three non-ATPases (S1, S2 and S5a) 
while the lid is composed of eight non-ATPase subunits (Ciechanover, 1998).  Studies in yeast 
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have demonstrated that ATPase components of the 19S proteasome play a role in activating gene 
transcription.  The ATPases associate with actively transcribed genes where they may link pro-
moter recruitment of transcription factors to their eventual degradation by polyubiquitination and 
the proteasome (Makino et al., 1999) (Gonzalez et al., 2002). In yeast, the most novel implica-
tions for a role for the proteasome in regulating transcription come from observations that 19S 
ATPases directly associate with genes that are actively being transcribed.  These ATPases, but 
not other proteins from the 19S lid or the 20S proteolytic core, have been shown to bind to the 
yeast Gal4 activation domain in vitro, suggesting that components of the 19S complex, and not 
the 26S holoenzyme, are intimately involved with transcription (Gonzalez et al., 2002).  In addi-
tion, the 26S proteasome associates with RNA polymerase II (RNA Pol II) (Gillette et al., 2004) 
and is critical for efficient RNA Pol II mediated elongation (Ferdous et al., 2001).  In fact, spe-
cific inhibition of activity of the 19S subunit decreases elongation while inhibition of the 20S 
subunit increases elongation, indicating that a balance between these two subunits and their ac-
tivities may be important for transcriptional regulation in yeast (Gillette et al., 2004) (Ferdous et 
al., 2001) (Ferdous et al., 2002).  While most research to date has been performed in yeast sys-
tems, several very recent publications have highlighted the significance of the 19S in regulating 
transcription in mammalian cells.  The 19S ATPase Sug1 is recruited to the viral transcription 
factor E1A and enhances transcription from viral promoters during Adenoviral infection of hu-
man cells (Rasti et al., 2006).  Sug1 also associates with the p53 transcription factor and is re-
cruited to p53 responsive p21
waf1
 promoters in a manner that correlates with p53 recruitment 
(Zhu et al., 2007).  Finally, the HIV-1 trans-activator protein, Tat, regulates the conversion of the 
26S proteasome into separate 19S and 20S components by recruiting a proteasome-associated 
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protein, PAAF-1, which results in decreased proteasome activity and increased association of 
multiple 19S, but not 20S, subunits with the HIV-1 promoter (Lassot et al., 2007) 
While the evidence for 19S involvement in mammalian transcription is tantalizing, many 
unanswered questions remain.  It is primarily unclear if 19S subunits play a role in recruiting 
transcription factors to promoters and, if so, how these factors are targeted for recruitment.  To 
understand the role of the proteasome system in regulating transcription of MHC class II genes, 
we investigated the role of the 19S ATPase subunit Sug1 in regulating CIITA activity, promoter 
recruitment and MHC class II transcription.   Our data show that Sug1 associates with CIITA 
and with the MHC class II proximal promoter.  Sug1 plays important roles in regulating CIITA 
activity and MHC class II expression, in part by regulating promoter recruitment of CIITA.  The 
20S proteasome is also strongly recruited to the proximal promoter, but only following pro-
longed cytokine stimulation, suggesting that the entire 26S proteasome is recruited to the MHC 
II proximal promoter at various times during active transcription.  Our data show for the first 
time that CIITA, the master regulator of MHC class II transcription, is in turn regulated by com-
ponents of the master regulator of protein destruction, the 26S proteasome.  These data define 
novel roles for proteasomal subunits in transcriptional programs regulated by CIITA and offer 
further insights into the function of the proteasome in mammalian transcription. 
 
MATERIALS AND METHODS 
Cell culture:  HeLa cells (human epithelial) from ATCC (Manassas, VA) were maintained using 
high-glucose Dulbecco modified Eagle (DMEM) medium (Mediatech Inc., Herndon, VA) sup-
plemented with 10% FCS, 50U/ml of penicillin, 50μg/ml of streptomycin and 2mM of L-
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glutamine.  The cells were maintained at 37°C with 5% CO2.  Raji cells (Burkitts lymphoma-
derived cell line) from ATCC were maintained in Roswell Park Memorial Institute (RPMI) Me-
dia (Mediatech) supplemented with 10% FCS, 50U/ml of penicillin, 50μg/ml of streptomycin 
and 5mM of L-glutamine at 37°C with 5% CO2. 
Plasmids: The following plasmids used were described previously: Flag-CIITA, pCDNA3 and 
HLA-DRA-Luc (Cressman et al., 1999; Cressman et al., 2001; Greer et al., 2003). The C-Myc 
Sug1 construct was a generous gift from Dr. A.Wani (30). 
Transient transfection and luciferase reporter assays:  HeLa cells were plated at 5x10
4
 
cells/well density (60% confluency) in 6-well plates and were incubated for 18 hours at 37°C.  
Transfection of indicated plasmids was carried out using Fugene 6 (Roche, Indianapolis, IN) ac-
cording to the manufacturer‟s instructions.  18 hours following transfection, cells were lysed 
with 100μl of 1x cell culture lysis reagent (Promega, Madison, WI).  Following addition of cell 
lysis reagent, cells were scraped and the lysed cell suspension was centrifuged for 2 minutes at 
12,000 rpm (Thermo electron 851, Thermo INC, Needham Heights, MA) at 4°C and luciferase 
assays were performed according to the manufacturer‟s instructions.  Luciferase reporter assays 
on Sug1 knockdowns.  HeLa cells were plated as above, transfected with 1.0μg of siRNA (diluted 
in buffer EC-R, Qiagen) using the RNAi transfection reagent (Qiagen) according to manufactur-
er‟s instruction.  Following 30 hours of siRNA transfection, Flag-CIITA, HLA-DRA-Luc and 
pCDNA3 plasmids were transfected, the cells were lysed as above and luciferase assays and 
western blots were performed.  10% of total lysates were normalized for protein concentration, 
separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted with mAb to Sug1 
(Novus Biologicals, Littleton, CO) and secondary goat anti-mouse horseradish peroxidase (HRP) 
conjugated antibody (Promega).   
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Generation of siRNA duplexes:  Short interfering RNA duplexes were used for transient 
knockdown of Sug1 expression.  siRNA sequences were designed with a GC content of 35-55% 
containing dTdT overhangs and were blasted using NCBI nucleotide BLAST.  The target se-
quence of siRNA used was 5‟-AAGGTACATCCTGAAGGTAAA-3‟ (Qiagen, Valencia, CA).  
siRNA for Lamin protein was used as a positive control siRNA (Qiagen) and scrambled se-
quence siRNA was used as a negative control (Qiagen; Santa Cruz Biotechnology, Santa Cruz, 
CA). 
RNA expression:  HeLa cells were plated at a cell density of 4x10
5
 cells/plate. Cells were har-
vested, washed with cold PBS, centrifuged at 3,000rpm at 4°C for 5 minutes, and total RNA was 
prepared with 1ml of TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer‟s 
instructions.  RNA was reconstituted in 60μl DEPC water (MP Biomedical, LLC, Aurora, OH) 
and stored at -80°C.  The Omniscript reverse transcription kit (Qiagen) was used to make 20μl of 
cDNA from 1μg of RNA.  Gene specific antisense primers (Sigma, Saint Louis, MO) were used 
for reverse transcription (RT).  Q-PCR was done in an eppendorf microcycler.  PCR reactions for 
all reactions included an initial 10 minute incubation step at 65°C followed by a 60 minute incu-
bation step at 37°C according to the manufacturer‟s instructions (Qiagen).  Real-time PCR reac-
tions were carried out on an ABI prism 7900 (Applied Biosystems, Foster City, CA).  MHC class 
II and CIITA promoter IV probes were labeled 5‟with 6-carboxyfluorescein (FAM) reporter dye 
and 3‟ with N,N,N,N-tetramethyl-6-carboxyrhodamine (TAMRA) quencher dye. The primer and 
probe sequences are as follows: MHC class II sense sequence, 5‟-AA GCCAACCTGGAAAT-
CA-3‟; antisense sequence, 5‟-GGCTGTTCGTGAGCAC AGTT-3‟; probe sequence, 5‟-6 FAM-
CTCCGATCACCAATGTACCTCCAGA-TAMRA-3‟; human CIITA pIV sense sequence, 5‟-
GGGAGAGGCCACCAGCAG-3‟ ; antisense sequence,5‟-GCTCCAGGTAGCCACCTTCT-3‟ ; 
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probe sequence, 5‟-6 FAM-CTGTGAGCTGCCGCTGTTCCC-TAMRA-3‟.  The housekeeping 
gene 18S ribosomal RNA was used to normalize mRNA values. 18S rRNA probes were labeled 
with tetrachloro-6-carboxyfluorescein (TET) reporter dye at the 5‟ end and with TAMRA 
quencher dye at the 3‟ end. Primer and probe sequence for 18S rRNA are as follows: sense se-
quence, 5‟-GCTGCTGGCACCAGACTT-3‟; antisense sequence, 5‟- CGGCTACCACATCCA 
AGG-3‟; probe sequence,  5‟-6 TET-CAAATTACCCAC TCCCGACCCG-TAMRA-3‟.   Pre-
sented values from real-time PCR reactions were calculated on the basis of standard curves gen-
erated for each gene, were run in triplicate reactions and were analyzed using the SDS 2.0 pro-
gram. RNA Expression in Sug1 Knockdowns.  HeLa cells were plated at a cell density of 4x10
5
 
cells and 18 hours later were transfected with siRNA.  24 hours following siRNA transfection, 
cells were stimulated with IFN-γ (25μg/ml) for 20 hours.  Cells were harvested and 15% of the 
cells were lysed with 1% Nonidet P-40 buffer ( NP-40:1M Tris pH 8.0, 1M KCl, 10% NP40, 
0.5M EDTA, 5M NaCl, 1M DTT, dH2O) with protease inhibitor and were analyzed by western 
blot for Sug1 knockdown as above.  The remaining fraction of cells was subjected to RNA ex-
traction as described above.   
Co-immunoprecipitation:  In transiently transfected cells.  HeLa cells were plated at a cell den-
sity of 8 x10
5
 in 10cm tissue culture plates.  Following cell adhesion, cells were transfected using 
Fugene 6 (Roche) as indicated with 5μg of Flag-CIITA and/or 5μg c-Myc-Sug1 or transfection 
reagent alone.  20 hours following transfection, cells were untreated or were stimulated with 
IFN-γ (25μg/ml) for four hours.  Four hours following stimulation, or 24 hours following trans-
fection, cells were lysed in RIPA lysis buffer (RIPA: 1M trispH8.0, 5M NaCl, 10% NP-40, 5% 
DOC, 10% SDS, 1M DTT, dH2O) with protease inhibitors for 30 minutes on ice.  Lysates were 
centrifuged, normalized for protein concentration, pre-cleared with 50 μl mouse IgG (Sigma-
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Aldrich, Saint Louis, MO) and immunoprecipitated with 50ul of anti-c-Myc agarose beads (Sig-
ma-Aldrich) or with 5µg anti-CIITA (Santa Cruz Biotechnology).  Immune complexes were de-
natured with Leammli buffer, boiled and separated by SDS-PAGE gel electrophoresis.  Gels 
were transferred to nitrocellulose and individually immunoblotted with anti-Flag or anti-Myc 
monoclonal antibodies (Sigma-Aldrich). HRP conjugates were detected with Supersignal West 
Pico Chemiluminescent substrate to determine associations between Sug1 and CIITA.  Equal 
loading was determined in non-immunoprecipitated lysates by immunoblot of total protein.  En-
dogenous co-immunoprecipitations.  15 x 10
6 
Raji B cells were lysed in RIPA lysis buffer (RI-
PA: 1M trispH8.0, 5M NaCl, 10% NP-40, 5% DOC, 10% SDS, 1M DTT, dH2O) with protease 
inhibitors for 30 minutes on ice.  Lysates were centrifuged, normalized for protein concentration, 
pre-cleared with 50μl mouse IgG (Sigma-Aldrich, Saint Louis, MO) and immunoprecipitated 
with 10μg of mAb against Sug1. Positive control samples were immunoprecipitated with 10µg of 
mAb against CIITA and negative control samples were immunoprecipitated with 10μg of mouse 
IgG (Upstate Biotechnology).  Isolated immune complexes were denatured with Leammli buffer, 
boiled and separated by SDS-PAGE gel electrophoresis.  Gels were transferred to nitrocellulose 
and individually immunoblotted for endogenous CIITA.  Equal loading was determined in non-
immunoprecipitated lysates by immunoblot of total protein for CIITA.   
Chromatin immunoprecipitation (ChIP):  HeLa cells were plated at a cell density of 2x10
6
 
and, at the end of IFN-γ stimulation, cells were crosslinked with 1% formaldehyde for 10 mi-
nutes at room temperature and crosslinking was stopped by the addition of 0.125 M glycine for 5 
minutes at room temperature.  Cells were lysed in SDS lysis buffer (1% SDS, 10mM EDTA, 
50mM Tris pH 8.0, dH20) and protease inhibitor for 30 minutes on ice and sonicated at constant 
pulse to generate an average of 500-750 bp sheared DNA.  ChIP assays were performed as pre-
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viously described (Greer et al., 2003).  Briefly, the sonicated lysates were precleared with sal-
mon-sperm coated agarose beads (Upstate Biotechnology) and half of the lysate was immuno-
precipitated with 10μg of antibody to CIITA or individual proteasome components overnight at 
4°C. The remaining half of the lysate was used as a control and was immunoprecipitated with 
control antibody.  Following an additional 2 hour immunoprecipitation with 50μl of salmon-
sperm coated agarose beads, samples were washed for 5 minutes at 4°C with the following buf-
fers:  Low salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 150mM 
NaCl, dH20), High salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris pH 8.0, 
500mM NaCl, dH20), LiCl buffer (0.25M LiCl, 1% NP40, 1% DOC, 1mM EDTA, 10mM Tris 
pH 8.0, dH20) and 1xTE buffer and were eluted with SDS elution buffer (1% SDS, 0.1M NaH-
CO3, dH2O).  Following elution, crosslinks were reversed overnight with 5M NaCl at 65°C and 
immunoprecipitated DNA was isolated using phenol:chloroform:isopropanol mix (Invitrogen) as 
per the manufacturer‟s instructions.  Isolated DNA was analyzed by real-time PCR using primers 
spanning the W-X-Y box of the MHC class II HLA-DRA promoter. MHC-II HLA-DRA promoter 
primers and probe sequences are as follows: MHC-II promoter probe, 5‟-6 FAM- 
CTGGACCCTTTGCAAGAACCCTTCCC-TAMRA-3‟; sense primer, 5‟-
TCCAATGAACGGAGTATCTTGTG T-3‟; and antisense primer, 5‟-
TGAGATGACGCATCTGTTGCT-3‟.  Values were calculated based on standard curves gener-
ated.  Chromatin immunoprecipitation in Sug1 knockdowns.  HeLa cells were plated at a cell 
density of 8x10
5
 in 15cm tissue culture plates and were transfected with Sug1 siRNA. Cells were 
treated with proteasome inhibitor MG132 for 4 hours and then harvested.  Nine% of the total cell 
volume was lysed with 1% Nonidet P-40 buffer with protease inhibitor and analyzed by western 
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blot for Sug1 knockdown as described.  The remaining fraction of cells was subjected to ChIP as 
described above. 
RESULTS 
Proteasome inhibition reduces CIITA-mediated MHC class II transcription.   
If components of the 26S proteasome positively regulate MHC class II gene transcription 
in a degradation-independent manner as has been proposed in yeast, then inhibition of the 26S 
proteasome should decrease, rather than increase, transcription.  We used transient transfection 
to test the effect of the potent 26S proteasome inhibitor MG132 on the activation of the human 
MHC class II promoter, HLA-DRA, associated with a luciferase (Luc) reporter gene by CIITA.  
As shown in Figure 2.1A, transfection of HeLa cells with MHC class II HLA-DRA-Luc reporter 
and increasing amounts of CIITA resulted in dose dependent increases in HLA-DRA promoter 
activity, while treatment with the proteasome inhibitor MG132 for 16 hours decreased HLA-DRA 
promoter activity.  Controls were transfected with the HLA-DRA reporter construct and empty 
pCDNA3 vector in the absence or presence of MG132.  Inhibition of proteasome activity re-
sulted in impaired CIITA mediated transcription of its downstream gene.  Thus, we hypothesized 
that a component of the 26S proteasome is required for full CIITA transactivation. 
We next assessed the effects of proteasome inhibition on the activation of endogenous 
MHC class II HLA-DRA genes.  We stimulated HeLa cells with IFN-γ to induce expression of 
CIITA (Pattenden et al., 2002) and determined the effects of proteasome inhibition on endogen-
ous MHC class II transcription by simultaneously treating with MG132 for 4 additional hours.  
Real-time RT-PCR conducted on mRNA isolated from these cells showed that proteasome inhi-
bition decreased IFN-γ induction of MHC class II mRNA expression (Figure 2.1B).   
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Figure 2.1: Proteasome inhibition represses CIITA mediated MHC class II transcription.  
(A) Proteasome inhibition decreases CIITA transcriptional activity. HeLa cells were transfected with MHC II 
HLA-DRA-Luc reporter construct and increasing amounts of CIITA. Controls were transfected with reporter, empty 
pCDNA3 vector and were both untreated (black bars) and treated (grey bars) with the proteasome inhibitor MG132. 
Luciferase assays were performed in triplicate and data are presented as fold increase in the luciferase activity. Re-
sults presented represent the mean ± S.D. and are representative of three independent experiments. (B) and (C) Pro-
teasome inhibition results in decreased levels of MHC class II mRNA but does not affect levels of CIITA 
mRNA. HeLa cells were either unstimulated (NT) or were stimulated with IFN-γ for 20 h and were simultaneously 
treated (grey bars) with MG132 for 4 h. Control cells were stimulated with IFN-γ, but did not receive MG132 treat-
ment (black bars). Levels of MHC class II mRNA were measured by real-time PCR and were normalized to 18S 
rRNA. Real-time PCR was performed in triplicate and results, which are representative of three experiments, 
represent the mean ± S.D.  
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This reduction in MHC class II mRNA expression does not reflect stabilization of a gen-
eral repressor or RNAase as CIITA mRNA expression levels remained stable in presence or ab-
sence of MG132 (Figure 2.1C).  These results indicate that proteasome activity is required for 
optimal MHC class II expression in the presence of intact chromatin and under conditions of 
physiological CIITA induction and further suggest an important proteolysis-independent role of 
the proteasome in regulating MHC class II transcription.   
 
The 19S ATPase subunit Sug1 physically interacts with CIITA in vivo.   
19S subunits play a critical role in binding ubiquitinated proteins and directing these pro-
teins to the hydrolase activity of the 20S catalytic core (Rubin et al., 1998).  The base component 
of the 19S has been shown to exist as a separate functional species, the APIS complex, apart 
from the 19S lid.  The yeast 19S ATPase subunit and APIS complex member Rpt6 associates 
with both active and inactive yeast genes and undergoes substantial enrichment at multiple pro-
moters under gene activation (Ezhkova and Tansey, 2004; Ferdous et al., 2001).  Rpt6 stimulates 
promoter escape and elongation and is required for transcription of several stress induced pro-
teins in yeast (Sulahian et al., 2006) and has been found to interact with transcription factors in-
cluding the TFIID subunits TAFII90 and TBP (Sun and Allis, 2002; Yanagi et al., 2000), the 
XPB (Weeda et al., 1997) and Tfb2 (Sun et al., 2002) subunits of TFIIH, the Cdc68 subunit of 
the transcription elongation factor FACT (Sun et al., 2002) and the Rpb1 subunit of pol II (Sun et 
al., 2002).  Given the interactions of Rpt6 with various transcription factors, we sought to deter-
mine if its mammalian homolog, Sug1, is involved in regulating MHC class II transcription.  In 
order to address specific mechanisms by which Sug1 might interact with the MHC class II  
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Figure 2.2: The 19S ATPase Sug1 associates with CIITA.  
(A) HeLa cells were transfected with Flag-CIITA and c-Myc-Sug1 as indicated. Cells were lysed and immunopreci-
pitated (IP) with anti-c-Myc agarose beads (lanes 1 and 2). IP samples were immunoblotted (IB) for Flag-CIITA. 
Lysates were IB for Flag-CIITA and c-Myc. (B) Raji cells were lysed and immunoprecipitated with mAb against 
CIITA as a positive control (lane 1), with rabbit IgG as a negative control (lane 2) and with mAb against Sug1 (lane 
3). IP (top panel) and lysate (bottom panel) samples were immunoblotted with antibody against endogenous CIITA. 
(C) HeLa cells were transfected with c-Myc-Sug1 (lanes 2–4). Twenty hours following transfection, cells were sti-
mulated with IFN-γ as indicated. Four hours following stimulation, cells were lysed and immunoprecipitated with 
anti-CIITA mAb (lane 1, negative control; lanes 2 and 3, experimental) or anti-Myc-Sug1 as a positive control (lane 
4). IP (top panel) and lysate (bottom panel) samples were immunoblotted for Myc-Sug1. All results reported in this 
figure are representative data of five experiments.  
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promoter, we examined interactions of Sug1 with CIITA.  Sug1 and CIITA immunoprecipitated 
both from HeLa cells overexpressing tagged and versions of the proteins (Figure 2.2A) and    
endogenously from Raji B cells (Figure 2.2B).  Association of endogenous CIITA and overex-
pressed Sug1 was enhanced upon stimulation with IFN-γ (Figure 2.2C), and thus parallels in-
creased transcription of MHC class II genes (Piskurich et al., 2006).  Equal transfection and load-
ing of cell lysates was confirmed by immunoblot (IB) analysis of total protein (Figure 2.2A-C, 
lower panels).   
 
The 19S proteasome Sug1 subunit is recruited to the endogenous MHC class II promoter in 
parallel to CIITA.   
Yeast 19S ATPases, including Rpt6, associate with the GAL1/10 promoter and the GAL1 
gene upon stimulation of transcription (Gonzalez et al., 2002).  In mammalian cells, the Rpt6 
homolog Sug1 is recruited to p21
waf1
 promoters in response to ultraviolet-induced DNA damage 
(Zhu et al., 2007).  To determine if Sug1 directly associates with the endogenous MHC class II 
promoter, and to compare this association with that of CIITA, we performed ChIP assays on an 
endogenous MHC class II (HLA-DRA) promoter (Figure 2.3).  First, to evaluate CIITA associa-
tion with the MHC class II proximal promoter, HeLa cells were stimulated with IFN-γ, immuno-
precipitated with antibody to endogenous CIITA, and analyzed by real-time PCR with primers 
spanning the W-X-Y box of the MHC class II HLA-DRA promoter.  Endogenous CIITA asso-
ciated with the HLA-DRA promoter by 4 hours of stimulation with IFN-γ; association dramatical-
ly increased by 24 hours, decreased and remained through 65 hours of IFN-γ stimulation and was 
rapidly declining at 95 hours (Figure 2.3A).   
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Figure 2.3: The 19S ATPase Sug1 associates with the MHC class II proximal promoter.  
A and B, ChIP assays were performed in HeLa cells stimulated with IFN-γ for 0 to 95 h. Lysates were immunopre-
cipitated (IP) with control antibody, antibody to endogenous CIITA (A) or to endogenous Sug1 (B), and associated 
DNA was isolated and analyzed via real-time PCR using primers spanning the W–X–Y box of the MHC class II 
HLA-DRA promoter. Real-time PCR values were normalized to the total amount of HLA-DRA promoter DNA added 
to the reaction (input). Input values represent 5% of the total cell lysate. IP values are presented as fold increase in 
the MHC class II promoter DNA relative to unstimulated IP samples. Control IP values for (A) and (B) were 
0.5 ± 0.05. Values for control IP's, CIITA and Sug1 IP's represent mean ± S.E.M. of (n = 3) independent experi-
ments.  
 
76 
 
These in vivo kinetic data are consistent with published results demonstrating that ele-
vated levels of histone acetylation remain at the MHC class II promoter for a minimum of 48 
hours following IFN-γ stimulation (Beresford and Boss, 2001).  Low levels of Sug1 associated 
with the HLA-DRA promoter by 30 minutes of stimulation with IFN-γ; association peaked at 4 
hours and low but reproducible Sug1 association was sustained throughout 95 hours of IFN-γ 
stimulation (Figure 2.3B).  These findings indicate that Sug1 is inducibly recruited to MHC 
class II proximal promoters. 
 
The 20S proteasome is recruited to the MHC class II proximal promoter following pro-
longed IFN-γ stimulation.   
The 20S contains fourteen subunits that assemble as a stack of four rings, two alpha and 
two beta rings, each having seven distinct subunits arranged in a barrel structure:  alpha 1-7, beta 
1-7, beta 1-7 and alpha1-7.  The alpha subunits form the outer rings and, although they have no 
catalytic activity, they are critical for interactions of the 19S regulator with the 20S core and thus 
for assembly of the intact 26S proteasome (Baumeister et al., 1998).  In yeast, components of the 
20S catalytic core of the 26S proteasome are recruited to actively transcribing genes, potentially 
to remodel transcription complexes or to degrade transcription factors once transcription of the 
gene has been initiated (Gillette et al., 2004) (Morris et al., 2003).  In mammalian cells, the 20S 
subunit alpha 4 is present at the HIV-1 promoter and coding regions under low transactivation 
conditions (Lassot et al., 2007).  To determine if the 20S directly associates with the endogenous 
MHC class II promoter, we performed ChIP assays on an endogenous MHC class II (HLA-DRA) 
promoter using antibodies against endogenous alpha 4 (Figure 2.4).   
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Figure 2.4: The 20S proteasome associates with the MHC class II proximal promoter following extensive IFN-
γ stimulation.  
ChIP assays were carried out in HeLa cells stimulated with IFN-γ for 0–95 h. Lysates were immunoprecipitated (IP) 
with control antibody or antibody to the endogenous alpha four component of the 20S and associated DNA was iso-
lated and analyzed via real-time PCR using primers spanning the W–X–Y box of the MHC class II HLA-DRA pro-
moter. Real-time PCR values were normalized to the total amount of HLA-DRA promoter DNA added to the reac-
tion (input). Input values represent 5% of the total cell lysate. IP values are presented as fold increase in the MHC 
class II promoter DNA relative to unstimulated CIITA IP samples. Control IP values were 0.5 ± 0.5. Values for con-
trol and alpha four I IP's represent mean ± S.E.M. of (n = 3) independent experiments.  
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In contrast to CIITA and Sug1, alpha 4 required 65 hours of IFN-γ stimulation to asso-
ciate with the MHC class II proximal promoter, indicating that the 20S core does not associate 
with the MHC class II promoter during initiation of transcription (Figure 2.4). These results 
support our observations that CIITA and alpha 4 do not interact following short periods of IFN-γ 
stimulation (data not shown).  Interestingly, low Sug1 association with the MHC class II proxim-
al promoter throughout the time course demonstrates the potential for reconstitution of the intact 
26S proteasome.  Indeed, early association of 19S ATPase Sug1 but delayed association of 20S 
with the MHC class II promoter suggests that these two proteasome components might be me-
diating distinct events.   
 
The 19S ATPase Sug1 is required for CIITA activation.   
Mutation of the yeast 19S ATPase Rpt6 results in a block in transcription of long tran-
scripts and prevents transcription of multiple insult induced genes (Sulahian et al., 2006).  In 
mammalian cells, decreased expression of Sug1 blocks transactivation of the HIV-1 transactiva-
tor protein Tat (Lassot et al., 2007).  Our observations of cytokine inducible association of Sug1 
with CIITA and of Sug1 with the MHC class II proximal promoter indicate a potential role for 
Sug1 in the regulation of CIITA. To investigate potential roles for Sug1 in MHC class II tran-
scription, we designed a siRNA duplex to specifically knockdown endogenous Sug1 expression 
(Figure 2.5A, lower panels).  siRNA-mediated reduction of endogenous Sug1 decreased Sug1 
expression by approximately 95-99% relative to cells transfected with scrambled control siRNA 
sequence (Figure 2.5A, middle panel).  The reduction of Sug1 expression by siRNA is not af-
fected by the presence of transfected CIITA (Figure 2.5A, bottom panel).   
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  Figure 2.5: The 19S ATPase Sug1 is required for optimal CIITA activity and MHC class II gene expression.  
(A) Reduced expression of Sug1 in siRNA transfected cells decreases the transcriptional activity of CIITA. HeLa cells 
were transfected with scrambled siRNA control or Sug1 specific siRNA duplexes and were co-transfected 48 h later 
with HLA-DRA-Luc and CIITA. Luciferase activity is reported as fold activation relative to that of the luciferase re-
porter alone (top). Luciferase readings were normalized to lysate protein concentrations as determined by Bradford 
assay. Luciferase assays were performed in triplicate and results represent the mean ± S.D. (n = 3). Western blots 
showed 95 % knockdown efficiency of Sug1 (bottom). (B) and (C) Reduced expression of Sug1 in siRNA trans-
fected cells decreases endogenous MHC class II mRNA expression but not CIITA mRNA expression. Twenty-
four hours following Sug1 siRNA expression, HeLa cells were unstimulated or were stimulated with IFN-γ for 20 h. 
Control cells were transfected with scrambled control siRNA sequence. Fractions of cell lysates were analyzed for 
Sug1 expression by Western blot (bottom) or for levels of MHC class II mRNA or CIITA mRNA by real-time PCR 
(top). Western blots show 90–95% knockdown of endogenous Sug1. Levels of MHC class II mRNA and CIITA 
mRNA were measured by real-time PCR and were normalized to 18S rRNA. Real-time PCR was performed in tripli-
cate and results represent the mean ± S.D. Results are representative data of four experiments.  
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In cells transfected with the negative control siRNA, CIITA efficiently activated an MHC class 
II driven luciferase reporter, whereas in cells transfected with Sug1-specific siRNA, CIITA acti-
vation of the MHC class II promoter was reduced (Figure 2.5A, top).   
 
The 19S ATPase Sug1 is required for MHC class II mRNA expression.   
We addressed the role of Sug1 in regulating endogenous MHC class II expression by us-
ing real-time PCR to measure endogenous MHC class II mRNA in HeLa cells.  Twenty hours 
following Sug1 or control siRNA expression, HeLa cells were stimulated with IFN-γ. Fractions 
of cell lysates were analyzed for Sug1 expression by western blot (Figure 2.5B, bottom) or for 
levels of MHC class II mRNA by real-time PCR (Figure 2.5B, top).  Loss of expression of Sug1 
decreased the expression of endogenous MHC class II, further indicating a functional relation-
ship between Sug1 and CIITA.  As a control for the specificity of the effects on MHC class II 
mRNA levels, we addressed the role of Sug1 in regulating endogenous CIITA expression.   
Twenty hours following Sug1 or scrambled control siRNA expression, HeLa cells were stimu-
lated with IFN-γ, lysed and analyzed for Sug1 expression (Figure 2.5C, bottom) or for levels of 
CIITA mRNA (Figure 2.5C, top).  Real-time PCR analysis indicated that the levels of CIITA 
induced by IFN-γ were not affected by Sug1 siRNA.  Therefore, the effects of decreased expres-
sion of Sug1 on physiologically induced MHC class II expression were not due to decreased ex-
pression of CIITA.   
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CIITA recruitment to the MHC class II proximal promoter is dramatically decreased in 
the absence of Sug1.   
The above data strongly suggest that Sug1 enhances the transcription of MHC class II 
genes in a degradation independent manner.  Though obviously required for efficient and effec-
tive transcription, we do not know the function of Sug1 during transcription of MHC class II 
genes.  One possibility is that the Sug1 ATPase generates necessary energy to drive assembly of 
the large, multiprotein enhanceosome complex at the proximal promoter.  There is precedence 
for this scenario as related ATPases in the Clp/HSP 100 chaperone family found in bacteria, mi-
tochondria and chloroplasts, are involved in both degradation and remodeling processes (Ottosen 
et al., 2002).  Therefore, a scenario by which Sug1 may control MHC class II transcription is by 
recruiting or stabilizing CIITA at the proximal promoter.  To determine whether Sug1 regulates 
association of endogenous CIITA with the enhanceosome complex at the MHC class II promo-
ter, we used siRNA duplexes to specifically knock down endogenous Sug1 expression in HeLa 
cells and then performed ChIP experiments to detect endogenous CIITA associated with the 
promoter.  siRNA-mediated knock down of Sug1 resulted in an approximate 90% decrease in 
endogenous Sug1 expression (Figure 2.6, right panels).  Association of endogenous CIITA with 
the MHC class II proximal promoter was decreased in the absence of Sug1, indicating that Sug1 
plays a critical role in regulating MHC class II transcription by recruiting and/or stabilizing CII-
TA (Figure 2.6, left panel).   
Proteasome inhibition results in decreased levels of HLA-DRA promoter activity (Figure 
2.1A), but does not reduce the level of CIITA transcripts in IFN-γ induced cells (Figure 2.1C).  
To determine the effects of proteasome inhibition on CIITA binding to the MHC class II prox-
imal promoter, CIITA ChIPs were performed.  In the presence of wild-type levels of Sug1, 
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  Figure 2.6:  CIITA recruitment to the MHC class II proximal promoter is dramatically decreased in the ab-
sence of Sug1.  
HeLa cells were transfected with scrambled siRNA control or with Sug1 specific siRNA duplexes and 24 h later 
were stimulated with IFN-γ for 18 h or left untreated (NT). Cells were harvested and 9% of the lysate was removed 
for Western blot analysis of endogenous Sug1 expression. Western blots shows 90% knockdown of Sug1 (right pan-
el). The remaining lysate was immunoprecipitated with control antibody or antibody to endogenous CIITA (left pan-
el) and associated DNA was isolated and analyzed via real-time PCR as above. Real-time PCR values were norma-
lized to the total amount of HLA-DRA promoter DNA added to the reaction (input). Input values represent 5% of the 
total cell lysate. Data are presented as fold increase in the MHC class II promoter DNA relative to unstimulated CII-
TA IP samples. Control IP values were 1.0 ± 0.025. Values for control and CIITA IP's represent mean ± S.E.M. of 
(n = 3) independent experiments. Statistical significance was determined by Student t-test and the p-value was calcu-
lated to be <0.001.  
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treatment of IFN-γ stimulated cells with the proteasome inhibitor MG132 results in increased 
binding of CIITA to the promoter when compared to non-MG132 treated cells (Figure 2.7 grey 
bars versus Figure 2.6 grey bars).  Despite the increased levels of CIITA binding, MHC mRNA 
expression is ultimately reduced (Figure 2.1B), indicating that MG132 also negatively impacts 
non-proteolytic components of the proteasome that are involved in transcriptional regulation.   
The addition of a siRNA-mediated knock down of Sug1 resulted in an approximate 95% 
decrease in endogenous Sug1 expression (Figure 2.7, right panels).  To determine weather or 
not blocking 26S proteasome activity would also enhance CIITA promoter recruitment in the 
absence of Sug1, we treated Sug1 knockdown cells with MG132 with or without the addition of 
IFN-γ prior to performing CIITA ChIPs.  In the absence of Sug1, CIITA association with the 
MHC class II proximal promoter in MG132 treated cells remained low upon IFN-γ stimulation 
(Figure 2.7, left).  These data indicate that Sug1 functions specifically to stabilize CIITA at the 
MHC class II proximal promoter as proteasome inhibition in the absence of Sug1 could not re-
store CIITA promoter association.   
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  Figure 2.7:  Proteasome inhibition does not reconstitute CIITA promoter association in the absence of Sug1.  
HeLa cells were transfected with scrambled siRNA control or with Sug1 specific siRNA duplexes and 24 h later 
were stimulated with IFN-γ for 18 h or left untreated (NT). All cells were treated with the proteasome inhibitor 
MG132 4 h prior to cell harvest. ChIP assays and Western blots were performed as above to determine CIITA pro-
moter association (left panel) and extent of Sug1 knockdown (right panels). Real-time PCR values obtained from 
ChIP assays were normalized to the total amount of HLA-DRA promoter DNA added to the reaction (input). Input 
values represent 5% of the total cell lysate. Data are presented as fold increase in the MHC class II promoter DNA 
relative to unstimulated CIITA IP samples. Control IP values were 2.0 ± 0.5. Values for control and CIITA IP's 
represent mean ± S.E.M. of (n = 2) independent experiments. Statistical significance was determined by Student t-
test and the p-value was calculated to be <0.01. 
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DISCUSSION 
Our data has provided evidence suggesting a model in which 19S and 20S components of 
the 26S proteasome associate with the MHC class II proximal promoter at different stages of 
transcription where they both positively and negatively regulate CIITA mediated transcription.  
In support of this model, ChIP analysis demonstrates that low levels of the 19S ATPase Sug1 
rapidly associate with the MHC class II proximal promoter within 4 hours of cytokine stimula-
tion.  Following 4 hours of cytokine stimulation, CIITA is also recruited to the MHC class II 
promoter.  CIITA and Sug1 also co-precipitate, thus suggesting that a regulatory interaction ex-
ists between these two proteins.  The 20S alpha 4 subunit also associates with the MHC class II 
promoter, but requires 65 hours of cytokine stimulation to do so.  Association of the 19S Sug1 
subunit peaks at the MHC class II promoter between 4 and 24 hours, then declines and shows 
low but reproducibly sustained for 95 hours; indicating potential reassembly of the 26S protea-
some at the less transcriptionaly active promoter.  CIITA association with the MHC class II pro-
moter remains relatively stable until 65 hours of IFN-γ stimulation, after which time CIITA pro-
moter association begins to decline; also suggesting local assembly of a functional 26S.   
Our observations correlate 20S recruitment to and CIITA loss from the promoter, and are 
consistent with a role for the reconstituted 26S proteasome in mediating transcriptional termina-
tion by degrading promoter bound CIITA.  Previous studies have demonstrated that CIITA re-
mains bound to the MHC class II proximal promoter for extended periods of time following sti-
mulation with inflammatory cytokines.  Our results suggest that assembly of the 26S proteasome 
at the MHC class II promoter serves to degrade promoter bound CIITA and to suppress MHC 
class II transcription.  It has recently been reported that the 20S proteasome associates with the 
promoter region of adenovirus (Ad) early region genes and that the Ad transactivator 13S E1A 
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utilizes the 19S and 20S proteasomes independently and at several points during transcription to 
regulate Ad transcription (Rasti et al., 2006). Several studies in yeast have suggested that the 20S 
is associated with actively transcribing genes indicating that the 20S proteasome is required for 
transcriptional elongation (Ferdous et al., 2001; Gillette et al., 2004; Gonzalez et al., 2002).  Re-
cruitment of the 20S to 3‟ coding regions of MHC class II genes in a transcription dependent 
manner remains to be determined.  However, our reporter assays show that proteolytic function 
is required for efficient transcriptional activation by CIITA and therefore for cytokine inducible 
MHC class II expression.  It is therefore possible that the proteasome functions both proteolyti-
cally and non-proteolytically at promoter and coding regions of MHC class II during different 
stages of transcription.   
   Data presented within this report provide further evidence that the19S proteasome   
ATPase Sug1 regulates MHC class II transcription by controlling CIITA promoter association.  
We determined by ChIP that Sug1 associates with the MHC class II promoter and showed by 
immunoprecipitation that Sug1 binds CIITA.  Using RNAi, we established a role for endogenous 
Sug1 in CIITA transactivation in reporter assays.  The ability of CIITA to regulate transcription 
from the MHC class II proximal promoter is reduced in cells where Sug1 expression has been 
reduced by RNAi.  Consequently, expression of MHC class II mRNA is also reduced in the ab-
sence of Sug1, however CIITA expression remains stable, indicating selectivity in transcriptional 
systems regulated by Sug1.  We also demonstrate by ChIP that in the absence of Sug1, severely 
reduced levels of CIITA bind the MHC class II promoter.  Although diminished, MHC class II 
transcription still occurs despite very low levels of CIITA binding the MHC class II promoter in 
the absence of Sug1.  These data further implicate the importance of degradation (Drozina et al., 
2006) in regulating MHC class II transcription as even small amounts of CIITA function to in-
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itiate transcripts from this promoter.  In data not shown, we have demonstrated that each of the 
additional 19S lid ATPases binds the MHC class II promoter and plays a positive role in regulat-
ing MHC class II transcription.  The combined actions of these ATPases in the 19S lid likely 
play overlapping roles in regulating CIITA recruitment and MHC class II transcription.  A full 
understanding of the mechanistic contributions of individual components of the proteasome in 
regulating MHC class II will require further in depth studies of the events and molecular interac-
tions occurring at this promoter.   
We propose that the following series of events occurs to regulate MHC class II transcrip-
tion:  following cytokine stimulation, Sug1 is recruited to the proximal promoter where it then 
recruits and/or stabilizes CIITA.  Following extensive gene activation, the 20S catalytic core is 
recruited to the proximal promoter where the 26S proteasome may be reassembled resulting in 
degradation of local cofactors, including CIITA.  As proteasome inhibition restored CIITA asso-
ciation but not CIITA function at the MHC class II proximal promoter, additional roles for the 
26S proteasome in regulating CIITA activity must be fully explored.   
Although roles for 19S ATPases in mammalian transcription have been suggested pre-
viously (Lassot et al., 2007; Rasti et al., 2006; Zhu et al., 2007), mechanisms of action and inde-
pendent function of the 19S lid, the APIS complex and/or 19S ATPases on promoters are unclear 
and remain to be fully addressed.  Observations in yeast that 19S ATPases link histone ubiquiti-
nation and histone methylation (Ezhkova and Tansey, 2004) and that the 19S recruits histone 
modifying enzymes to promoters (Lee et al., 2005) suggest that the 19S may independently regu-
late transcription by controlling chromatin modifications.  A model of proteasome subcomplexes 
performing different functions at different locations on a gene is supported by the observation in 
yeast that although 26S proteins are associated with a majority of genes, proteins from the 19S 
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lid or 20S core, but not both, crosslink individually to several hundred genes (Auld et al., 2006; 
Sikder et al., 2006).  It is also important to note that the 26S disassociates into 19S and 20S com-
ponents in yeast cells (Babbitt et al., 2005) and in mammalian nuclear extracts (Lassot et al., 
2007), indicating that the 19S or 19S subcomplexes could independently regulate discrete states 
of the transcription cycle.  The contextual contributions of individual 19S subunits, the 20S and 
26S proteasome to mammalian transcriptional processes remain to be determined and will likely 
reflect both the differences in function and regulation of target genes. 
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SUMMARY 
Major histocompatibility class II (MHC class II) molecules are glycoproteins that present 
extracellular antigens to CD4
+
 T cells and are essential for initiation of adaptive immune res-
ponses.  MHC class II expression requires recruitment of a master regulator, the class II transac-
tivator (CIITA), to the MHC class II promoter.  We and others have previously linked CIITA to 
the ubiquitin proteasome system (UPS) by demonstrating that mono-ubiquitination of CIITA in-
creases its transactivity whereas polyubiquitination of CIITA leads to its degradation.  We have 
further shown that the 26S proteasome also has non-proteolytic roles in MHC class II transcrip-
tion as 19S ATPase subunits of the 26S proteasome positively regulate MHC class II transcrip-
tion and are necessary for stable promoter binding of CIITA.  Although these basic requirements 
of the proteasome to initiate MHC class II transcription are known, how CIITA is recruited, sta-
bilized and degraded remains unclear.  Here, we identify a novel N-terminal 19S ATPase binding 
domain of CIITA.  The ATPase binding domain lies within the P/S/T region of CIITA and en-
compasses a majority of the CIITA degron sequence.  Absence of the ATPase binding domain 
increases the half-life of CIITA, but blocks MHC class II surface expression, indicating that CII-
TA requires interaction with the 19S ATPases for both appropriate deployment and destruction.  
 
BACKGROUND 
 MHC class II molecules are cell surface glycoproteins which present extracellular anti-
gens to CD4
+
T helper cells and elicit specific adaptive immune responses (Matheux and Villard 
2004).  MHC class II expression is essential for protection against invading pathogens, and also 
serves in anti-tumor responses as tumor specific CD4
+ 
T cells are often required for CD8
+
 T cell 
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activation (Marzo, Kinnear et al. 2000).  In addition to these important functions, MHC class II 
molecules play critical roles in tolerance induction and transplant rejection (Harton and Ting 
2000).  Over-expression of MHC class II is thus correlated with increased vulnerability to the 
development of autoimmune diseases including multiple sclerosis, rheumatoid arthritis and myo-
cardial infarction (Swanberg, Lidman et al. 2005) and a lack of MHC class II expression results 
in the fatal disease, Bare Lymphocyte Syndrome (Harton and Ting 2000).  Due to these and other 
critical roles played by  MHC class II molecules in regulating adaptive immune responses and 
disease susceptibility, MHC class II gene expression is tightly regulated (Benoist and Mathis 
1990).   
MHC class II transcription requires recruitment of ubiquitously expressed transcription 
factors including the regulatory factor X complex (RFX), (Steimle, Durand et al. 1995; Ting and 
Trowsdale 2002), (Nagarajan, Louis-Plence et al. 1999), (Masternak, Barras et al. 1998), the 
cAMP responsive element binding protein (CREB) (Moreno, Beresford et al. 1999) and the nuc-
lear factor-Y complex (NFY) (Mantovani 1999) which bind respectively to the X1, X2 and Y 
gene elements to form the “enhanceosome complex” (Steimle, Otten et al. 1993; Mach, Steimle 
et al. 1996; Ting and Trowsdale 2002).  The enhanceosome complex is required, but is insuffi-
cient to initiate MHC class II transcription (Steimle, Otten et al. 1993; Mach, Steimle et al. 1996; 
Muhlethaler-Mottet, Otten et al. 1997).  Transcription is however initiated when the master regu-
lator, the class II transactivator (CIITA) is recruited to the preformed enhanceosome complex 
(Steimle, Otten et al. 1993; Mach, Steimle et al. 1996; Masternak, Muhlethaler-Mottet et al. 
2000).  CIITA binding to the enhanceosome complex orchestrates a sequence of events to recruit 
transcription factors and co-factors to initiate transcription of MHC class II genes (Mahanta, 
Scholl et al. 1997; Kretsovali, Agalioti et al. 1998; Masternak, Muhlethaler-Mottet et al. 2000; 
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Zhu, Linhoff et al. 2000).  Although these basic requirements for initiating MHC class II tran-
scription are fairly well understood, how CIITA is recruited, stabilized and degraded remains 
unclear. 
The 26S proteasome is a complex long known to be responsible for the destruction of a 
majority of cellular proteins, including transcription factors.  The 26S proteasome is composed 
of a 20S proteolytic core which contains the protease active sites and a 19S regulatory particle 
(RP) that caps either end of the core (Ciechanover 1994; Hendil, Kristensen et al. 1995; Coux, 
Tanaka et al. 1996).  The 20S proteolytic core is composed of 4 stacked rings of 7-α, 7- α‟, 7-β 
and 7-β‟ subunits (Hendil, Kristensen et al. 1995; Coux, Tanaka et al. 1996; Hochstrasser 1996) 
which receive and degrade poly-ubiquitinated proteins recognized by the 19S (Lam, Lawson et 
al. 2002; Husnjak, Elsasser et al. 2008; Schreiner, Chen et al. 2008).  The 19S consists of a base 
subunit composed of six ATPase subunits (S4, S6a, S6b, S7, Sug1 and S10b) and three non-
ATPase subunits (S1, S2 and S5a), and a lid subunit which consists of eight non-ATPase sub-
units (Ciechanover 1998).   
The 26S proteasome has recently been found to be intimately associated with the initia-
tion of transcription of many genes (Makino, Yoshida et al. 1999; Ferdous, Kodadek et al. 2002; 
Gonzalez, Delahodde et al. 2002; Muratani and Tansey 2003; Hegde 2004; Rasti, Grand et al. 
2006; Sulahian, Sikder et al. 2006; Zhu, Wani et al. 2007; Bhat, Turner et al. 2008) and it is now 
clear that multiple proteins of the 19S proteasome play a variety of roles in transcription.  In 
yeast, ATPase components of the 19S proteasome associate with actively transcribing genes and 
regulate the elongation process carried out by RNA-polymerase II (Ferdous, Gonzalez et al. 
2001; Ferdous, Kodadek et al. 2002).  Subunits of the 19S but not the 20S have been shown to 
associate with Gal4 activators and Gal responsive promoters (Gonzalez, Delahodde et al. 2002).  
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Specific inhibition of the 19S leads to a decrease in RNA pol II mediated elongation, but inhibi-
tion of the 20S increases RNA pol II mediated elongation, indicating that these sub complexes 
play a role in transcription independent of both each other and of proteolytic activity (Ferdous, 
Gonzalez et al. 2001; Ferdous, Kodadek et al. 2002; Gillette, Gonzalez et al. 2004).  Moreover, 
in mammals, the 19S ATPase Sug1 (S8/Trip1 in humans and Rpt6 in yeast), has been shown to 
interact with transcription factors including E1A, p53 and HIV-tat and to be recruited to respon-
sive gene promoters (Rasti, Grand et al. 2006; Lassot, Latreille et al. 2007; Zhu, Wani et al. 
2007).  We have previously demonstrated the importance of Sug1 in MHC Class II expression 
(Bhat, Turner et al. 2008).  That CIITA failed to bind to the MHC class II promoter in the ab-
sence of Sug1 indicates a role for Sug1 in CIITA recruitment and stabilization (Bhat, Turner et 
al. 2008).  Sug1 recruits histone modifying enzymes at the MHC class II promoter and positively 
regulates histone acetylation and methylation events at MHC class II genes (Koues O.I. 2008; 
Koues, Dudley et al. 2009).  In addition to its requirement for MHC class II expression, Sug1 
interacted with CIITA in vivo (Bhat, Turner et al. 2008).  Finally, we recently demonstrated the 
19S ATPase S6a has regulates CIITA transcription by controlling histone modifying events at 
the CIITA interferon gamma (IFN- ) responsive promoter, CIITA pIV (Agnieszka D.Truax 
2009).  In sum, these studies indicate that the 19S ATPases play critical roles in the regulation of 
multiple genes, including CIITA mediated MHC class II expression.   
Prior observations from our lab and others have linked MHC class II transcription and the 
ubiquitin-proteasome pathway.  In this study we sought to map the binding of the 19S ATPase 
Sug1 to CIITA to further determine the role of the ATPases in MHC class II gene expression.  
We have identified a novel N-terminal ATPase binding domain in CIITA required for CIITA 
binding to the 19S ATPases.  This ATPase binding domain lies within the P/S/T region of CIITA 
94 
 
and encompasses a majority of the degron site.  Absence of this domain increases the half-life of 
CIITA, but dramatically decreases MHC class II surface expression.  These findings pose an in-
teresting conundrum:  CIITA is dependent on interactions with the 19S for activation and promo-
ter binding, but interaction with 19S ATPases also leads to proteasome mediated degradation of 
CIITA.    
 
MATERIALS AND METHODS: 
Cell culture: HeLa cells (human epithelial) from ATCC (Manassas, VA) were maintained using 
high-glucose Dulbecco modified Eagle (DMEM) medium (Mediatech Inc., Herndon, VA) sup-
plemented with 10% FCS, 50U/ml of penicillin, 50μg/ml of streptomycin and 2mM of L-
glutamine.  The cells were maintained at 37°C with 5% CO2.  
Plasmids:  Full length Flag CIITA, truncation mutants flag CIITA 1-224aa, 1-335aa, 1-444aa, 1-
949aa, deletion mutant flag CIITA (Δ132-301aa) and pCDNA3 plasmids were kindly provided 
by Dr. J. Ting.  The pGEX-GST Sug1 and Myc Sug1 constructs were a generous gift from Dr. A. 
Wani.  Site specific mutants flag CIITA 1-335aa K1R (K315R), flag CIITA 1-335aa K2R 
(K330, 333R) and flag CIITA 1-335aa K3R (K315, 330, 333R); deletion mutant flag CIITA 
(Δ132-301) 1-335aa; and truncation mutant flag CIITA 1-301aa were generated using Quick-
Change Lightening site-directed mutagenesis kit (Stratagene, La Jolla, CA).  Specific primers 
with the desired mutations were designed using the Stratagene primer design tool.  Mutagenesis 
reactions were performed as per the manufacturer‟s protocol.  Mutagenesis was confirmed by 
sequence analysis and expression of constructs was analyzed by western blot.    
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GST-protein production and purification:  BL21 star (DE3) competent cells (Invitrogen, 
Carlsbad, CA) were transformed with pGEX constructs.  Transformed colonies were selected 
and inoculated in 3ml LB
+
 Amp
+
 1% glucose.  Three ml preps were transferred into 100ml LB
+
 
Amp
+
 1% glucose and incubated at 37°C for 4 hrs.  Following incubation, cells were pelleted and 
fresh LB
+
 Amp media was added.   IPTG was used to induce protein expression.  Cells were pel-
leted at the end of 4hrs and resuspended in STE buffer (10mM Tris-Cl pH7.5, 10mM NaC, 1mM 
EDTA)  with 1mM PMSF, 5mM DTT and 1.5% Sarkosyl.  Following incubation, cells were so-
nicated and centrifuged.  The supernatant containing soluble proteins was aliquoted into low re-
tention eppendorph tubes and stored -  C.  
GST pull-down assay:  HeLa cells were transfected with 5µg of flag CIITA using Fugene6 
(Roche, Indianapolis, IN) as per the manufacturer‟s protocol.  HeLa cell extracts were prepared 
by lysing cells in 1% Nonidet P-40 buffer ( NP-40:1M Tris pH 8.0, 1M KCl, 10% NP40, 0.5M 
EDTA, 5M NaCl, 1M DTT, dH2O) supplemented with complete EDTA-free protease inhibitors 
(Roche) on ice.   One ml of GST-tagged protein preps were incubated with pre-washed 50% 
GST slurry beads for 30 min at room temperature and then for 90 min at 4° C to allow for max-
imal binding.  Following incubation, beads were washed twice with cold phosphate buffered sa-
line (PBS) containing 1mM PMSF.  Pooled HeLa cell lysates were added to GST-tagged protein-
bound beads and incubated at room temperature for 30 min and then at 4° C for 90 min to allow 
for maximal exposure of cellular proteins to GST-tagged proteins bound GST beads.  Following 
incubation, beads were washed twice with cold PBS containing 1mM PMSF.  Bead complexes 
were denatured with Leammli buffer, boiled and separated by SDS-PAGE gel electrophoresis.  
Gels were transferred to nitrocellulose and individually immunoblotted with anti-flag (Sigma-
Aldrich, Saint Louis, MO).   HRP conjugates were detected with Immobilon Western Chemilu-
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minescent substrate (Milipore, Billerica, MA) to determine associations between Sug1 and CII-
TA.  Equal loading was determined in lysates immunoblotted with anti-flag (Sigma-Aldrich) or 
anti-GST monoclonal antibodies (Abcam, Cambridge, MA). 
Co-immunoprecipitation assay:   HeLa cells were plated at a cell density of 8 x10
5
 in 10 cm 
tissue culture plates.  Following cell adhesion, cells were transfected as indicated with 5μg of 
flag CIITA full length, truncation or deletion constructs or pCDNA control and/or 2μg myc Sug1 
or myc control plasmids.  Twenty hours following transfection, cells were lysed in 1% Nonidet 
P-40 buffer supplemented with complete EDTA-free protease inhibitors (Roche) on ice.  Lysates 
were centrifuged, normalized for protein concentration, pre-cleared with 50 μl mouse IgG (Sig-
ma-Aldrich) and immunoprecipitated with 30µl of anti Myc agarose beads (Sigma-Aldrich).  
Immune complexes were denatured with Leammli buffer, boiled and separated by SDS-PAGE 
gel electrophoresis.  Gels were transferred to nitrocellulose and individually immunoblotted with 
anti-flag or anti-myc monoclonal antibodies (Sigma-Aldrich). HRP conjugates were detected 
with Immobilon Western Chemiluminescent substrate (Milipore) to determine associations be-
tween Sug1 and CIITA.  Bradford assays were used to normalize for protein and equal loading 
was determined in non-immunoprecipitated lysates. 
Half-life assay:  HeLa cells were plated at a cell density of 8 x10
5
 in 10cm tissue culture plates.  
Following cell adhesion, cells were transfected with 5μg of flag CIITA ATPase binding domain 
(Δ132-301) deletion construct or flag CIITA.  Twenty hrs following transfection, cells were 
treated with 100µM cycloheximide for 0-7 hrs.  At the end of cycloheximide treatment, cells 
were lysed in 1% Nonidet P-40 buffer supplemented with complete EDTA-free protease inhibi-
tors (Roche) on ice.  Lysates were centrifuged and normalized for protein concentration.  As a 
control, HeLa cells were transfected with flag CIITA (Δ132-301) deletion construct or flag CII-
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TA construct and treated with 100µM cycloheximide and MG132 (EMD Biosciences, San Di-
ego, CA)  for 7 hrs to stop new protein synthesis and protein degradation.  Proteins were dena-
tured with Leammli buffer, boiled and separated by SDS-PAGE gel electrophoresis.  Gels were 
transferred to nitrocellulose and individually immunoblotted with anti-flag antibodies (Sigma-
Aldrich).  HRP conjugates were detected with Immobilon Western Chemiluminescent substrate 
(Milipore) to determine half-life of CIITA constructs.  Bradford assay was used to normalize for 
protein and equal loading was determined in lysates.  Western blots from half-life assays were 
quantified using Multi-Gauge V3.1 and plotted as percent (%) protein remaining (after 2, 4, 5, 6 
or 7 hours of cycloheximide treatment as compared to 0hr cycloheximide treatment)  v/s hours of 
cycloheximide treatment.   
Flow cytometry:  HeLa cells were plated at a cell density of 8 x10
5
 in 10cm tissue culture 
plates.  Following cell adhesion, cells were transfected with flag CIITA ATPase binding domain 
(Δ132-301) deletion construct or with flag CIITA.  Forthy eight or seventy two hrs following 
transfection, cells were trypsinized and washed with PBS.  Following the wash, the cells were 
resuspended in incubation buffer (0.5% bovine serum albumin in PBS w/v) and 10µg Phycoeryt-
hrin (PE)-labeled anti-human HLA-DR (clone L243, Biolegend, San Diego, CA) antibody or PE 
mouse IgG2a κ isotype control antibody (Biolegend) was added to the cell suspension and ro-
tated at 4° C.  Following antibody incubation, cells were washed twice with PBS, fixed with 2% 
paraformaldehyde and stored at 4°C.  MHC class II cell surface expression was measured by 
FACS-Canto (Becton Dickinson, San Jose, CA) and analyzed using FlowJo.  All samples were 
analyzed using 10,000 events per sample.  1/10
th
 of the HeLa cells harvested for flow analysis 
were lysed in 1% Nonidet P-40 buffer supplemented with Complete EDTA-free protease inhibi-
tors (Roche) on ice.  Proteins were denatured with Leammli buffer, boiled and separated by 
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SDS-PAGE gel electrophoresis.  Gels were transferred to nitrocellulose and individually immu-
noblotted with anti-flag antibodies (Sigma-Aldrich).  HRP conjugates were detected with Immo-
bilon Western Chemiluminescent substrate (Millipore) to determine half-life of CIITA con-
structs.  Bradford assay was used to normalize for protein and equal loading was determined in 
lysates.   
 
RESULTS 
CIITA interacts with the C-terminal end of Sug1 independent of Sug1 ATPase activity 
Sug1 is an ATPase subunit of the 19S regulatory particle of the 26S proteasome (Rubin, 
Coux et al. 1996; Fraser, Rossignol et al. 1997; Makino, Yamano et al. 1997).  Our previous stu-
dies have demonstrated the importance of Sug1 in MHC class II expression (Bhat, Turner et al. 
2008).  We initially observed that CIITA, the master regulator of MHC class II gene expression, 
interacts with Sug1 in vivo and fails to be recruited to the MHC class II promoter in the absence 
of Sug1 (Bhat, Turner et al. 2008), suggesting a role for Sug1 in CIITA recruitment and/or stabi-
lization.  To further understand the importance of the role of Sug1and the 19S regulatory particle 
in CIITA regulation, interactions between CIITA and in vitro translated Sug1 were mapped using 
glutathione S-transferase (GST) tagged wild type Sug1 and Sug1 truncation mutants.  Sug1 is a 
406 amino acid protein with coiled coil structure in its N-terminal end (Fraser, Rossignol et al. 
1997) and with 3‟-5‟ DNA helicase activity and ATPase activity in its C-terminal domain 
(Fraser, Rossignol et al. 1997; Makino, Yamano et al. 1997).   
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Figure 3.1:  CIITA interacts with the C-terminal end of Sug1 independent of Sug1 ATPase activity.   
(A)  Schematic representation of Sug1 truncation mutants.  Sug1 is a 406aa protein with ATPase activity located 
near the C-terminus.  Shown are GST tagged full length Sug1, Sug1 N- and C-terminal truncation mutants, and the 
Sug1 ATPase mutant.  (B)  Glutathione S-Transferase (GST) pull-down assay.   HeLa cells were transfected with 
flag CIITA and HeLa cell lysates were prepared using NP40 lysis buffer.  GST bead slurries were incubated with 
GST tagged protein preps, washed and incubated with HeLa cell lysates.  Western blot analysis was performed and 
the bead-bound complexes were immunoblotted (IB) using anti-flag antibody (left panel).  Lysate blots (right panels) 
demonstrate expression of flag CIITA in pooled HeLa cell lysates (top, right) and GST tagged (bottom, right) pro-
teins.  Results are representative of 3 experiments.   
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Lysine 196 in the C-terminal end of Sug1 lies in the Walker A box and mutation of lysine 196 
leads to loss of ATPase and helicase activity of Sug1(Fraser, Rossignol et al. 1997) without af-
fecting its assembly into the 19S base or the overall structure of the proteasome (Rubin, 
Glickman et al. 1998) (figure 3.1A).  GST pull down assays indicate that CIITA interacts pri-
marily with the C-terminal domain of Sug1 (figure 3.1B).  Interaction with CIITA is also largely 
independent of the ATPase activity of Sug1, activity which is non-essential for the role of Sug1 
in chromatin remodeling at the MHC class II promoter (figure 3.1B) (Koues, Dudley et al. 
2008). 
 
Amino acids within the PST domain of CIITA are critical for Sug1 binding 
While transcriptional regulation of CIITA is well understood, less is known about the 
post-transcriptional modifications and interactions that control CIITA activity and half life.  CII-
TA is an 1130 amino acid long non-DNA binding co-factor with four functional domains: an N-
terminal transcriptional acidic activation domain (AAD), a proline/serine/threonine rich (P/S/T) 
domain, a GTP-binding domain (GBD), and a C-terminal leucine rich region (LRR) (Masternak, 
Muhlethaler-Mottet et al. 2000) (Tosi, Jabrane-Ferrat et al. 2002).  CIITA also has three nuclear 
localization sequences (NLS) that are required for its nuclear translocation and activity 
(Cressman, O'Connor et al. 2001) .  The P/S/T domain of CIITA contains a proteolytic signal site 
termed a degron, which typically targets proteins for degradation (Drozina, Kohoutek et al. 2006) 
(figure .32A).  Interactions between Sug1 and CIITA were initially mapped using flag tagged 
CIITA C-terminal truncations (figure 3.2B).  CIITA truncation 1-949aa, which lacks the leucine 
rich region, associated with Sug1 (figure 3.2C) with the same affinity as full length CIITA (data 
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not shown), indicating that the LRR domain of CIITA is not required for interactions with Sug1.  
Further analysis indicated that CIITA truncation 1-444aa associated with Sug1 while CIITA 
truncation 1-224aa failed to associate (figure 3.2D) and that the interaction of Sug1 with CIITA 
1-444aa was independent of Sug1 ATPase activity (Supplementary figure 3.7).  These data nar-
rowed ATPase independent Sug1 binding to the amino terminus of CIITA.  In order to further 
narrow the region of association, CIITA truncation 1-335aa was used.  CIITA truncations 1-
444aa and 1-335aa associated with Sug1, while truncation 1-224aa again failed to associate (fig-
ure 3.2 E).  These data indicate that the C-terminus, including the GBD, NLS2 and 3, and the 
LRR domains of CIITA are not involved in Sug1 interactions.  CIITA truncation 1-224aa failed 
to bind Sug1 and lacks most of the Proline-Serine-threonine rich (P/S/T) region, a region fully 
present in the 1-335aa truncation which bound CIITA.  Together, these data indicate the P/S/T 
region of CIITA is important for CIITA- Sug1 interactions.  
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The interaction of Sug1 within the PST domain of CIITA is unaffected by mutating mul-
tiple lysine residues 
Figure 3.2: Amino acids within the PST domain of CIITA are critical for Sug1 binding  
(A) Schematic representation of functional domains of CIITA.  CIITA is a 1130aa protein.  CIITA has four major 
functional domains, an N-terminal transcriptional acidic activation domain (AA) required for CIITA transactivity, a 
proline/serine/threonine rich (P/S/T) domain whose function is undetermined, a GTP-binding domain (GBD) and a C-
terminal leucine rich region (LRR) required for localization.  CIITA also has three nuclear localization sequences 
(NLS 1-3) that are required for nuclear translocation and activity and the P/S/T rich region of CIITA contains a pro-
teolytic signal site termed a degron which typically targets proteins for degradation via unknown mechanisms.  This 
figure is adapted from Ting J.T. and Trowsdale J., 2002.  (B)  Schematic representation of N-terminal truncation 
constructs of CIITA.  Flag CIITA truncation constructs 1-224, 1-335, 1-444 and 1-949aa were used to map associa-
tion of Sug1 with CIITA.  (C, D, E)  Sug1 interacts within 224-335aa of CIITA.  Co-Immunoprecipitation (Co-IP) 
assays.  HeLa cells were co-transfected as indicated with flag tagged truncations of CIITA 1-949aa, 1-444aa, 1-335aa 
or 1-224aa, and either myc Sug1 or myc control.  Cells were harvested, lysed in NP40 buffer, precleared and IP‟d 
with anti-myc antibody.  Western blot analysis was performed and the immunoprecipitated (IP‟d) samples were IB 
using anti-flag antibody.  Lysate blots indicate equal expression of myc Sug1 and flag CIITA.  Results shown are 
repr se tative of 3 experiments.  
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The P/S/T region of CIITA contains a highly conserved proteolytic site termed a degron 
which typically targets host proteins for degradation (figure 3.3A) (Drozina, Kohoutek et al. 
2006).  These N-terminal degron sites can serve as recognition sites for E3 ubiquitin-ligases 
(Tasaki, Mulder et al. 2005) which ubiquitinate target proteins on nearby lysine residues.  The 
region between 224 and 335aa of CIITA contains three lysine residues which we have shown to 
be potential sites of CIITA ubiquitination (data not shown).  Mono-ubiquitination of CIITA in-
creases CIITA transactivity, increases CIITA binding to P-TEFb and upregulates MHC class II 
expression (Drozina, Kohoutek et al. 2005) (Greer, Zika et al. 2003).  Mono-ubiquitination has 
recently been shown to protect target proteins from the “stripping” activity of bound 19S protea-
somal ATPases and thus to provide a stimulatory effect on protein activity (Archer, Burdine et 
al. 2008; Archer, Delahodde et al. 2008).  If the three lysine residues located immediately down-
stream from the degron site serve as sites for mono-ubiquitination, they may protect CIITA from 
“stripping” activity of 19S proteasomal ATPases and/or affect ATPase binding.  If so, then mu-
tating these sites to arginine would block ubiquitination and thus potentially the binding of 19S 
ATPases.  To determine the effects of loss of these ubiquitination sites on CIITA binding to 
Sug1, lysines 315, 330 and 333 in CIITA truncation 1-335aa were mutated to arginine (figure 
3.3A, bottom 3 schematics).  Co-immunoprecipitation assays indicate that the mutant 1-335 
K315, 330, 333R associated with Sug1 with the same intensity as the 1-335aa truncation (figure 
3.3B).  These data indicate that these three lysine residues are not involved in Sug1 interactions, 
although modifications at these sites may be important for CIITA activity.  
.   
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Figure 3.3: The interaction of Sug1 within the PST domain of CIITA is unaffected by mutating multiple lysine 
residues.   
(A) Schematic representation of 1-335 CIITA lysine mutants.  Site-directed mutagenesis was performed to mu-
tate lysine residues 315, 330 and 333 to arginine.  The mutants generated were flag CIITA 1-335aa and flag CIITA 
1-335aa K3R (K315, 330, 333R).  (B) Sug1 binding to CIITA is not impaired by mutating lysines 315, 330 and 
333.  Co-IP.  HeLa cells were co-transfected as indicated with flag tagged CIITA 1-335aa or the flag CIITA 1-335aa 
lysine mutant and myc Sug1 or myc control.  Cells were harvested, lysed in NP40 buffer, precleared and IP‟d with 
anti-myc antibody.  Western blot analysis was performed and the IP‟d samples were IB using anti-flag antibody.  
Lysate blots indicate equal expression of myc Sug1 and flag CIITA.  Results shown are representative of 3 experi-
ments.  
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19S ATPases associate with amino acids 132-301 of the PST domain of CIITA 
Proline rich domains in transcription factors are linked to their DNA binding ability and 
activation potential (Mermod, O'Neill et al. 1989; Harton and Ting 2000).  CIITA has a proline 
rich region (within the P/S/T region), but it is a non-DNA binding transcription factor with an N-
terminal transcription activation domain (Steimle, Otten et al. 1993; Zhou and Glimcher 1995; 
Kretsovali, Agalioti et al. 1998).  Thus, functional importance of the P/S/T  domain of CIITA 
remains unclear (Harton and Ting 2000).  Here we have shown that amino acids within the P/S/T 
domain are crucial for interactions between Sug1 and CIITA.  We observed that mutating mul-
tiple degron proximal lysine residues within amino acids 224-335 (K315, K330, and K333) did 
not affect Sug1 binding.  The region between amino acids 224 and 335 of CIITA contains just 
the serine and threonine rich domains.  Thus, we deleted amino acids 132-301aa in the 1-335 
truncation construct of CIITA (figure 3.4A) to determine if the deletion of proline rich amino 
acids 132-301 in the P/S/T domain would affect interaction of CIITA with Sug1.  Co-
immunoprecipitation assays indicate that deletion of amino acids 132-301 in the CIITA P/S/T 
domain leads to a loss of Sug1 association (figure 3.4B).  Sug1 is one of six ATPases of the 19S 
regulatory particle that exist as heterodimers; Sug1/S10b, S7/S4 and S6a/S6b (Richmond, 
Gorbea et al. 1997; Adams 2003).  We next assayed to determine if additional ATPases of the 
19S proteasome associate within aa132-301 of CIITA.  Co-immunoprecipitation assays indicate 
that S7 and S6a also fail to associate with the Δ132-301aa construct of CIITA (figures 3.4C, D).  
These data suggest the 19S ATPases associate as a hexameric complex to this newly identified 
ATPase binding domain of CIITA.   
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Figure 3.4:  19S ATPases associate with amino acids 132-301 of the PST domain of CIITA.   
(A) Schematic representation of N-terminal truncation and deletion constructs of CIITA.  Flag CIITA (Δ132-
301) 1-335aa deletion construct and flag CIITA 1-301, 1-335 and 1-444 aa truncation constructs were used to further 
narrow the association of Sug1 with CIITA.  (B) The 19S ATPases Sug1, S7 and S6a fail to bind (Δ 132-301) 1-
335aa CIITA.  Co-IP.  HeLa cells were co-transfected as indicated with flag tagged truncation or deletion constructs 
of CIITA and myc tagged 19S ATPase (myc Sug1, myc S7, myc S6a) or myc control.   Cells were harvested, lysed 
in NP40, precleared and IP‟d with anti-myc antibody.  Western blot analysis was performed and the IP‟d samples 
were IB using anti-flag antibody.  Lysate blots demonstrate expression of myc 19S ATPase and flag CIITA.   All 
results shown are representative of 3 experiments.  
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Deletion of amino acids 132- 301 stabilizes CIITA 
Deletion of the ATPase binding domain of CIITA (132-301aa) leads to a loss of 19S  
ATPase association.  The region of CIITA between 132-301aa also encompasses a degron site 
which typically targets proteins for degradation.  To further understand the functional importance 
of the ATPase binding domain on CIITA stability, half-life assays were performed using cyclo-
heximide chase.  Half-life studies indicate that full length CIITA with an ATPase binding do-
main deletion (Δ132-301) was significantly more stable (>40%) than wild-type full length CIITA 
(figure 3.5 B-C).  Cells treated for 7 hours with cycloheximide and the proteasome inhibitor 
MG132 show reconstitution of CIITA expression (figure 3.5 B, lane 7).  Together, these studies 
demonstrate binding of 19S ATPases to the CIITA ATPase binding domain is required for nor-
mal CIITA turnover. 
 
Cell surface expression of MHC class II is abolished by deletion of amino acids 132-301 
As deletion of the ATPase binding domain (amino acids 132-301) of CIITA increases 
CIITA stability, we next assayed for the effect of this deletion on MHC class II cell surface ex-
pression.  Flow cytometry results indicate that following 48hrs or 72hrs of WT CIITA transfec-
tion, MHC class II cell surface expression was dramatically increased (figure 3.6A-i-B-i).  The 
robust increase in MHC class II surface expression was abolished when the ATPase binding do-
main deletion construct of CIITA was transfected (figure 3.6A-ii-B-ii), indicating the removal of 
amino acids 132-301 is deleterious to CIITA mediated MHC class II expression.  No MHC class 
II expression was observed when mouse IgG2a κ isotype control antibody was used (supple-
mentary figure 3.8).   
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Figure 3.5:  Deletion of the ATPase binding domain (amino acids 132- 301) stabilizes CIITA.   
(A) Schematic representation of ATPase binding domain deletion constructs.  Half-life assays were performed 
using the full length flag CIITA (Δ132-301) deletion construct and flag full length CIITA.   (B-C) The ATPase 
binding domain deletion construct of CIITA is more stable than full length CIITA.  HeLa cells were transfected 
with flag CIITA (Δ132-301) deletion construct or flag CIITA and were then treated with cycloheximide for 0-7 hrs.  
Following cycloheximide treatment, cells were harvested and western blot analysis was performed to determine the 
half-life of transfected CIITA.  As a positive control, HeLa cells were transfected with flag CIITA (Δ132-301) dele-
tion construct or flag CIITA and were treated with both cycloheximide and proteasome inhibitor MG132 for 7 hrs 
(last lane).  Results shown are representative of 3 experiments.  (C) Densitometry and quantitation of data in A.  
Western blots from half-life assays were quantified using Multi-Gauge V3.1 and plotted as percent (%) protein re-
maining (after 2, 4, 5, 6 or 7 hours of cycloheximide treatment as compared to 0hr cycloheximide treatment) v/s 
hours of cycloheximide treatment.  Flag CIITA (Δ132-301) is represented by a solid black line and flag CIITA is 
represented by a dotted black line.  Results shown are average of 3 experiments.   
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Figure 3.6:  Cell surface expression of MHC class II is abolished by deletion of the ATPase binding domain.   
(A, B) Hela cell MHC class II surface expression is dramatically induced upon transfection of CIITA but not 
upon expression of the CIITA (Δ132-301) deletion construct.  Flow cytometry.  HeLa cells were transfected with 
flag CIITA (Δ132-301) deletion construct or flag CIITA.  48hrs (A) or 72 hrs (B) following transfection, cells were 
trypsinized, washed and incubated with PE-labeled MHC II antibody.  Following antibody incubation, cells were fixed 
and MHC class II cell surface expression was measured by FACS-Canto.  (A, B-i) MHC II expression in cells trans-
fected with CIITA (light gray line) and MHC II expression in cells transfected with pcDNAcontrol (black line).  (A, B-
ii)  MHC II expression in cells transfected with CIITA (Δ132-301) (light gray line) and MHC II expression in cells 
transfected with pcDNA (black line).   Results shown are representative of 3 experiments.  (C) Transfection of dele-
tion and full length constructs of CIITA.  Western blot.  1/10
th
 of HeLa cells harvested for flow analysis were lysed 
in NP40.  Western blot analysis was performed to demonstrate expression of transfected constructs.  Results shown are 
representative of 3 experiments. 
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Thus binding of 19S ATPases to the ATPase binding domain, which lies within the CII-
TA P/S/T domain, is essential for both CIITA turnover and transactivation.  These data suggest 
proteolytic and non-proteolytic roles of 19S ATPases in CIITA mediated MHC class II transcrip-
tion. 
DISCUSSION 
Recruitment of CIITA to the MHC class II promoter is required for both constitutive and 
inducible expression of MHC class II genes.  Further evidence of the complex contributions of 
CIITA to the inflammatory response is that CIITA also plays crucial roles in transcriptional regu-
lation of additional diverse immune response genes including IL-4 (Sisk, Gourley et al. 2000), 
IL-10 (Yee, Yao et al. 2005), E-cathepsin (Yee, Yao et al. 2004), MMP-9 (Nozell, Ma et al. 
2004), plexin (Wong, Brickey et al. 2003) and Fas ligand (Gourley and Chang 2001).  Since the 
identification of CIITA as a multi-potent master regulator, many studies have focused on under-
standing the complex domain structure and functions of CIITA.  Despite this, due to the intricacy 
of CIITA structure and the roles CIITA plays in transcriptional regulation of multiple genes in 
various cell types, CIITA regulation remains enigmatic.  We and others have previously linked 
CIITA to the UPS through demonstration of CIITA mono-ubiquitination (Greer, Zika et al. 
2003) and poly-ubiquitination (Schnappauf, Hake et al. 2003), and through observation of func-
tional dependence of CIITA on 19S ATPases (Bhat, Turner et al. 2008; Koues, Dudley et al. 
2008; Agnieszka D.Truax 2009; Koues, Dudley et al. 2009).  Here we have identified a novel N-
terminal ATPase binding domain in CIITA and show that this domain is crucial for CIITA stabil-
ity and MHC class II expression.   
In mapping studies we observed the 19S ATPase Sug1 associated with CIITA truncations 
1-949aa, 1-444aa and 1-335aa but failed to bind truncation 1-224aa.   
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Figure 3.7: Supplementary data: CIITA truncation of 1-444aa associates with Sug1 independent of Sug1 AT-
Pase activity.  
Co-Immunoprecipitation (Co-IP) assays.  HeLa cells were co-transfected as indicated with flag tagged truncations of 
CIITA 1-224aa or 1-444aa and either myc Sug1 or a myc Sug1 ATPase mutant.  Cells were harvested, lysed in NP40 
buffer, precleared, and IP‟d with anti-myc antibody.  Western blot analysis was performed and the immunoprecipi-
tated (IP‟d) samples were immunoblotted (IB) using anti-flag antibody.  Lysate blots indicate expression of myc Sug1 
and flag CIITA constructs.  Results shown are representative of 3 experiments.  
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CIITA truncation 1-224aa lacks a majority of the proline-serine-threonine rich (P/S/T) region 
which is fully present in the truncations which bind Sug1.  These data indicated that while C-
terminal domains of CIITA, including the GBD, NLS2 and 3 and LRR domains, are not impor-
tant in interactions with Sug1; the P/S/T region is important for CIITA association with Sug1.   
CIITA has a proline rich region that lies within its P/S/T region, and transcription factors 
rich in proline residues often demonstrate increased DNA binding ability and activation potential 
(Mermod, O'Neill et al. 1989; Harton and Ting 2000).  However, CIITA is a non-DNA binding 
transcription factor with an N-terminal transcription activation domain (Steimle, Otten et al. 
1993; Zhou and Glimcher 1995; Kretsovali, Agalioti et al. 1998).  Although deletion of a part of 
the domain does not affect CIITA transactivity (Chin, Li et al. 1997), the P/S/T domain has been 
shown to be essential for interaction with other transcription factors and cofactors (Fontes, Jiang 
et al. 1997; Fontes, Kanazawa et al. 1999) and deletion of the entire domain reduces CIITA 
transactivity as measured by reporter assays (Chin, Li et al. 1997).  Therefore, the functional im-
portance of the proline rich region and the P/S/T domain of CIITA remains under investigation 
(Harton and Ting 2000).  We show here that the 19S ATPase Sug1, and the S7 and S6a repre-
sentative members of the additional 19S heterodimers, interacts within this proline rich region.  
Based on these observations, we have termed the region required for CIITA association with 19S 
ATPases the “ATPase binding domain.” 
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Figure 3.8: Supplementary data: The MHC class II antibody is specific.   
Flow cytometry.  HeLa cells were transfected with flag CIITA ATPase binding domain (Δ132-301) deletion construct 
or flag CIITA.  72 hrs following transfection, cells were trypsinized, washed and incubated with PE-labeled IgG con-
trol antibody.  Following antibody incubation, cells were fixed and PE cell surface staining was measured by FACS-
Canto. (i)  Hela cells transfected with CIITA (light gray line) and Hela cells transfected with pcDNA (black line).  (ii)  
Hela cells transfected with CIITA (Δ132-301) (light gray line) and Hela cells transfected with pcDNA (black line). 
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Lack of the ATPase binding domain significantly increases CIITA half-life, indicating 
that the binding of 19S ATPases plays important roles in CIITA turnover.  However, the CIITA 
that accumulates in the absence of the ATPase binding domain is transcriptionally inactive as 
overexpression of ATPase domain mutants fails to facilitate cell surface expression of MHC 
class II proteins.  We have previously shown the 19S ATPase Sug1 is essential for CIITA re-
cruitment to the MHC class II proximal promoter region and for MHC class II expression and 
have demonstrated critical roles for the 19S ATPases in regulating activating modifications to 
histones (Bhat, Turner et al. 2008; Koues, Dudley et al. 2008; Koues, Dudley et al. 2009; Truax, 
Koues et al. 2009).  Here we have identified a novel N-terminal ATPase binding domain within 
the PST domain that is crucial for 19S ATPase binding to CIITA, for MHC class II expression 
and for CIITA degradation.  Together these observations suggest proteolytic and non-proteolytic 
roles for 19S ATPases in CIITA mediated MHC class II transcription.    
Studies in yeast have demonstrated that physical interaction of 19S ATPase subunits with 
the activation domain of Gal4 leads to destabilization of Gal4 from the promoter (Ferdous, 
Sikder et al. 2007).  This “stripping” activity of the ATPases, but not binding of a larger 19S 
complex, was rendered inactive when Gal4 was mono-ubiquitinated (Archer, Burdine et al. 
2008), and suggests regulatory binding of a 19S complex to activation domains.  Mutation analy-
sis indicated that ubiquitination of lysine residues between the CIITA P/S/T domain and GBD 
domain is not required for CIITA –Sug1 interactions.  These data suggest the possibility that 
ATPase binding in the nearby ATPase binding domain is indicative of association of a larger 19S 
complex whose function, not binding, is modulated by the ubiquitination status of local lysine 
residues.   
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One scenario in which the 26S could regulate CIITA in a bimodal fashion is as follows:   
Mono-ubiquitinated CIITA is recruited to the MHC class II promoter where, aided by 19S     
ATPase recruitment of chromatin remodeling enzymes, CIITA stably binds the enhanceosome 
complex and the 19S complex and drives MHC class II transcription.  Although 19S ATPases 
are simultaneously localized to the MHC class II promoter, mono-ubiquitination protects CIITA 
from stripping by the 19S ATPases.  Following poly-ubiquitination, protection from 19S strip-
ping is lost and CIITA is pulled from the enhanceosome complex and degraded by a promoter 
assembled 26S proteasome.  In this scenario if 19S binding to CIITA is blocked, as seen in    
ATPase binding mutants, CIITA exhibits enhanced stability as it is protected from the stripping 
and degradative activities of the 19S.  Although protected, CIITA that does not bind the 19S 
ATPases is inactive; indicating the 19S ATPase binding domain of CIITA stabilizes CIITA asso-
ciation with the enhanceosome complex via the promoter localized19S.  Thus, the interactions 
that tether mono-ubiquitinated CIITA to the 19S proteasome initially drive CIITA transactivation 
and eventually target CIITA degradation.  
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SUMMARY 
Major histocompatibility (MHC) class II molecules are cell surface glycoproteins that 
present extracellular antigens to CD4
+
 T cells and are essential for initiation of the adaptive im-
mune response.  MHC class II expression requires recruitment of a master regulator, the class II 
transactivator (CIITA), to the MHC class II promoter.  Post-translational modifications of CIITA 
play important roles in modulating CIITA mediated transcription of various genes in different 
cell types.  We and others have previously linked regulation of CIITA to the ubiquitin protea-
some system (UPS) by demonstrating that mono-ubiquitination of CIITA dramatically increases 
its transactivity whereas poly-ubiquitination leads to CIITA degradation.  Here we have identi-
fied three degron proximal lysine residues, K315, K330 and K333, and a phosphorylation site, 
S280, located within the CIITA degron, that regulate CIITA ubiquitination, stability and MHC 
class II expression.  Together, these findings contribute to the developing post-translational mod-
ification code for CIITA.  
 
BACKGROUND 
MHC class II proteins present processed exogenous antigens on the cell surface to acti-
vate CD4
+
 T cells (Matheux and Villard 2004) and are thus critical contributors to both cell and 
antibody mediated immune responses (Glimcher and Kara 1992).  In addition to eliciting patho-
gen mediated immune responses, MHC class II molecules play important roles in anti-tumor 
immunity as tumor specific CD4
+
 T cells recruit and activate CD8
+
 T cells at tumor sites (Wang 
2003).   Because MHC class II is a critical regulator of both pathogen and tumor mediated adap-
tive immune responses, its expression is tightly regulated (Benoist and Mathis 1990), and this 
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regulation is primarily at the level of transcription.  CIITA is a non-DNA binding co-factor re-
quired for initiation of MHC class II gene transcription (Masternak, Muhlethaler-Mottet et al. 
2000).  CIITA is expressed from three distinct promoters, (pI, pIII and pIV), which direct the 
synthesis of CIITA isoforms I, III and IV to ensure CIITA expression in different cell types un-
der different conditions (Muhlethaler-Mottet, Otten et al. 1997).  Isoform I (IFI) is expressed 
from pI in dendritic cells and macrophages; IF III is expressed from pIII in B cells and is upregu-
lated in response to IFN- ; and IF IV is expressed from pIV in all nucleated IFN-γ induced cells 
(Muhlethaler-Mottet, Otten et al. 1997; Piskurich, Linhoff et al. 1999).  CIITA is not only essen-
tial for MHC Class II transcription, but also plays crucial roles in transcriptional regulation of 
additional diverse immune response genes including IL-4 (Sisk, Gourley et al. 2000), IL-10 
(Yee, Yao et al. 2005), E-cathepsin (Yee, Yao et al. 2004), MMP-9 (Nozell, Ma et al. 2004), 
plexin (Wong, Brickey et al. 2003) and Fas ligand (Gourley and Chang 2001).  As expected for a 
critical regulator of diverse inflammatory genes, dysregulated expression and activity of CIITA 
is implicated in disease including head and neck cancers (Meissner, Whiteside et al. 2009), small 
cell lung cancer (Yazawa, Kamma et al. 1999), Erwings sarcoma (Dagmar, Alfons et al. 2009), 
autoimmune Adisson‟s disease (Skinningsrud, Husebye et al. 2008), artherosclerosis (Buttice, 
Miller et al. 2006), and many others.  However, due to the complex domain structure and distinct 
roles of CIITA in transcriptional regulation of multiple genes in various cell types, CIITA post-
translational regulation remains enigmatic.  
Post-translational regulation of CIITA is a crucial regulatory point because functional 
CIITA requires multiple post-translational modifications (Cressman, Chin et al. 1999; 
Spilianakis, Papamatheakis et al. 2000; Cressman, O'Connor et al. 2001; Sisk, Nickerson et al. 
2003; Satoh, Toyota et al. 2004; Drozina, Kohoutek et al. 2006) including phosphorylation,   
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ubiquitination, and acetylation (Cressman, Chin et al. 1999; Spilianakis, Papamatheakis et al. 
2000; Cressman, O'Connor et al. 2001; Sisk, Nickerson et al. 2003; Satoh, Toyota et al. 2004).  
Amongst these, phosphorylation of CIITA is critical for CIITA transactivity, nuclear localiza-
tion, oligomerization, and for interactions with transcription factors and co-factors (Li, Harton et 
al. 2001; Sisk, Nickerson et al. 2003; Greer, Harton et al. 2004; Xu, Harton et al. 2008).  CIITA 
ubiquitination is equally important as mono-ubiquitinated CIITA displays enhanced transactivity,  
association with the MHC class II enhanceosome complex, and MHC class II transcription 
(Greer, Zika et al. 2003).  Poly-ubiquitinated CIITA has been shown to be degraded by the ubi-
quitin-proteasome pathway (Schnappauf, Hake et al. 2003).  While ubiquitination is a known 
regulator of CIITA, sites of ubiquitination in CIITA remain to be identified, in part due to CII-
TA‟s large size and multiple potential ubiquitination sites of 42 lysine residues.   
We identify here three lysine residues, K315, K330 and K333, proximal to the degron se-
quence in CIITA isoform III as sites of mono-ubiquitination.  Mutating these lysine residues to 
arginine reduces CIITA mono-ubiquitination, protein stability, transactivation and MHC class II 
expression.  We also identify a regulatory phosphorylation site at serine 280 within the CIITA 
degron as a gatekeeper of CIITA mono-ubiquitination.  A mutant that combines a loss of phos-
phorylation at serine 280 with a loss of ubiquitination at the degron proximal lysine residues re-
stores MHC class II expression beyond that of wild type CIITA, indicating that regulated mono-
ubiquitination at these lysine residues is essential for CIITA stability and transactivity.  These 
findings identify novel sites in CIITA isoform III that regulate transactivation and CIITA me-
diated MHC class II expression.   
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MATERIALS AND METHODS 
Cell culture:  HeLa cells (human epithelial) from ATCC (Manassas, VA) were maintained using 
high-glucose Dulbecco modified Eagle (DMEM) medium (Mediatech Inc., Herndon, VA) sup-
plemented with 10% FCS, 50U/ml of penicillin, 50μg/ml of streptomycin and 2mM of L-
glutamine.  The cells were maintained at 37°C with 5% CO2.   
Plasmids:  Full length Flag-CIITA, truncation mutants Flag-CIITA 1-335aa, pCDNA3, HA-
Mono-Ubiquitin (HA-Mono-Ub) and HA-WT-Ubiquitin (HA-WT-Ub) plasmids were kindly 
provided by Dr. J. Ting.  The HLA-DRA luciferase reporter construct was described previously 
(Bhat, Turner et al. 2008).  The following site specific mutants: full length Flag-CIITA K1R 
(K315R), Flag-CIITA K2R (K330, 333R), Flag-CIITA K3R (K315, 330, 333R), Flag-CIITA 
K3R-S280A, Flag-CIITA S280A and truncation mutant Flag-CIITA 1-335aa K3R (K315, 330, 
333R) were generated using QuickChange Lightening site-directed mutagenesis kit (Stratagene, 
La Jolla, CA).  Specific primers with desired mutations were designed using Stratagene‟s primer 
design tool and mutagenesis reactions were performed as per the manufacturer‟s protocol.  Mu-
tagenesis was confirmed by sequence analysis and expression analyzed by western blot.  
N-terminal fusion of Mono-ubiquitin to CIITA and CIITA K3R.  N-terminal fusions of mono-
ubiquitin to full length Flag-CIITA or Flag-CIITA K3R were generated using HA-Mono-Ub and 
Flag-CIITA or Flag-CIITA K3R constructs and QuickChange Lightening site-directed mutage-
nesis kit (Stratagene, La Jolla, CA).  Unique restriction sites for AgeI were engineered between 
the Flag-tag and CIITA or CIITA K3R using specific primers.  Unique restriction sites for AgeI 
were engineered upstream and downstream of the mono-Ub gene using specific primers.  Inser-
tion of restriction sites were confirmed by sequencing.   Positive clones were subjected to restric-
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tion (RE) digestion with AgeI for 4hrs at 37°C and were heat inactivated for 10 minutes at 65°C.  
Appropriately sized DNA fragments were gel purified using QIAquick gel extraction kit as per 
the manufacturer‟s protocol (Qiagen, Valencia, CA).  The RE digested CIITA or CIITA K3R 
were ligated with RE digested fragment of mono-Ub over-night at 16°C and heat inactivated for 
10 minutes at 65°C.  The ligated mixture was transformed into Top 10 cells and plated on antibi-
otic selective plate.  DNA isolated from selected colonies was sequenced for insertion of mono-
Ub gene between the Flag-tag and CIITA or CIITA K3R.  Directionality of the construct was 
confirmed by DNA sequencing.   
Transient transfection and luciferase reporter assays:  HeLa cells were plated at 5x10
4
 
cells/well density (60% confluency) in 6-well plates and were incubated for 18 hrs at 37°C.  Fol-
lowing adhesion, cells were co-transfected as indicated with HLA-DRA and pcDNA, Flag-
CIITA, Flag-CIITA K1R, Flag-CIITA K2R, Flag-CIITA K3R, Flag-Mono-Ub-CIITA or Flag-
Mono-Ub-CIITA K3R plasmids using Fugene 6 (Roche, Indianapolis, IN) according to the man-
ufacturer‟s instructions.  Eighteen hrs following transfection, cells were lysed with 100μl of 1x 
cell culture lysis reagent (Promega, Madison, WI) supplemented with complete EDTA-free pro-
tease inhibitors (Roche).  Following addition of cell lysis reagent, cells were scraped and the 
lysed cell suspension was centrifuged for 2 minutes at 12,000 rpm (Thermo electron 851, Ther-
mo INC, Needham Heights, MA) at 4°C and luciferase assays were performed using Lmax II
384
 
(Molecular Devices, Sunnyvale, CA) according to the manufacturer‟s instructions.  Luciferase 
readings were normalized to protein content in the lysates by Bradford Assay.  Western blots 
were performed to confirm equal expression of expressed plasmids.  
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RNA expression:  HeLa cells were plated at a cell density of 8x10
5
 cells/plate. Following adhe-
sion, cells were transfected with pcDNA, Flag-CIITA, Flag-CIITA K1R, Flag-CIITA K2R, Flag-
CIITA K3R or Flag-CIITA S280A plasmids using Fugene 6.  Cells were stimulated with interfe-
ron γ and 18 hrs post-stimulation, cells were harvested, washed with cold PBS, centrifuged at 
3,000 rpm at 4°C for 5 minutes, and 9/10
th
 of the cells were used to extract RNA.  Total RNA 
was prepared with 1ml of TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufac-
turer‟s instructions.  RNA was reconstituted in 30μl DEPC water (MP Biomedical, LLC, Aurora, 
OH) and stored at -80°C.  The Omniscript reverse transcription kit (Qiagen) was used to reverse 
transcribe 1μg of RNA into cDNA.  Gene specific antisense primers (Sigma, Saint Louis, MO) 
were used for reverse transcription (RT).  PCR was performed using a Mastercycle thermal cyc-
ler (Eppendorf, Hauppauge, NY).  Real-time PCR reactions were carried out on an ABI prism 
7900 (Applied Biosystems, Foster City, CA) using primers and probes for MHC-II (Bhat, Turner 
et al. 2008; Koues, Dudley et al. 2008) and GAPDH (Medhurst, Harrison et al. 2000).  GAPDH 
RNA was used to normalize mRNA values. Presented values from real-time PCR reactions were 
calculated on the basis of standard curves generated for each gene, were run in triplicate reac-
tions and were analyzed using the SDS 2.0 program. 1/10
th
 of cells were lyzed in 100 µl of 1% 
Nonidet P-40 buffer supplemented with complete EDTA-free protease inhibitors (Roche) on ice.  
Lysates were centrifuged and Bradford assays were performed to determine total protein content 
in the lysates.  Western blots confirmed equal expression of expressed plasmids.  
Ubiquitination assay:  HeLa cells were plated at a cell density of 8 x10
5
 in 10cm tissue culture 
plates.  Following adhesion, cells were co-transfected with 1-224aa, 1-335aa truncation mutants 
of CIITA, Flag-CIITA, Flag-CIITA 1-335aa K3R, Flag-CIITA K3R or Flag-CIITA S280A and 
HA-Mono-Ub or HA-WT-Ub.  Cells were treated with MG132, proteasome inhibitor, for 4hrs, 
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harvested, and lysed in 1% Nonidet P-40 buffer supplemented with complete EDTA-free pro-
tease inhibitors (Roche) on ice. Lysates were centrifuged, normalized for protein concentration, 
pre-cleared with 50 μl mouse IgG (Sigma-Aldrich) and immunoprecipitated with 30µl of anti 
Flag-agarose beads (Sigma-Aldrich).  Immune complexes were denatured with Leammli buffer, 
boiled and separated by SDS-PAGE gel electrophoresis.  Gels were transferred to nitrocellulose 
and individually immunoblotted with anti-HA monoclonal antibodies (Sigma-Aldrich).  HRP 
conjugates were detected with Immobilon Western Chemiluminescent substrate (Milipore) to 
determine in vivo ubiquitination patterns of various CIITA constructs.  Bradford assays were 
used to normalize for protein and equal loading was determined in non-immunoprecipitated ly-
sates. 
Half-life assay:  HeLa cells were plated at a cell density of 8 x10
5
 in 10 cm tissue culture plates.  
Following adhesion, cells were transfected with 5μg of Flag-CIITA, Flag-CIITA K3R, Flag-
CIITA S280A or Flag-CIITA K3R-S280A.  Transfected cells were treated with 100µM cyclo-
heximide (Sigma-Aldrich) for 0-20 hrs.  Following cycloheximide treatment, cells were lysed in 
1% Nonidet P-40 buffer supplemented with complete EDTA-free protease inhibitors (Roche) on 
ice.  Lysates were centrifuged and normalized for protein concentration.  As controls, HeLa cells 
were transfected with Flag-CIITA (Δ132-301) deletion construct or Flag-CIITA construct and 
treated with 100µM cycloheximide and MG132 (EMD Biosciences, San Diego, CA) for 8 hrs to 
block new protein synthesis and protein degradation.  Proteins were denatured with Leammli 
buffer, boiled and separated by SDS-PAGE gel electrophoresis.  Gels were transferred to nitro-
cellulose and individually immunoblotted with anti-Flag antibodies (Sigma-Aldrich).  HRP con-
jugates were detected with Immobilon Western Chemiluminescent substrate (Milipore) to deter-
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mine half-life of CIITA constructs.  Proteins were normalized by Bradford assay and equal load-
ing was determined in lysates.  
Flow cytometry:  HeLa cells were plated at a cell density of 8 x10
5
 in 10cm tissue culture 
plates.  Following adhesion, cells were transfected with Flag-CIITA, Flag-CIITA K1R, Flag-
CIITA K2R, Flag-CIITA K3R, Flag-CIITA S280A or Flag-CIITA K3R-S280A.  Seventy two 
hrs following transfection, cells were trypsinized and washed with PBS.  Following the wash, 
9/10
th
 of the cells were resuspended in incubation buffer (0.5% bovine serum albumin in PBS 
w/v) and 10µg Phycoerythrin (PE)-labeled anti-human HLA-DR (clone L243, Biolegend, San 
Diego, CA) antibody or PE mouse IgG2a κ isotype control antibody (Biolegend) was added to 
the cell suspension and rotated at 4°C.  Following antibody incubation, cells were washed twice 
with PBS, fixed with 2% paraformaldehyde and stored at 4°C.  MHC class II cell surface expres-
sion was measured by FACS-Canto (Becton Dickinson, San Jose, CA) and analyzed using Flow-
Jo.  All samples were analyzed using 10,000 events per sample.  1/10
th
 of the HeLa cells har-
vested for flow analysis were lysed in 1% Nonidet P-40 buffer supplemented with Complete 
EDTA-free protease inhibitors (Roche) on ice.  Proteins were denatured with Leammli buffer, 
boiled and separated by SDS-PAGE gel electrophoresis.  Gels were transferred to nitrocellulose 
and individually immunoblotted with anti-Flag antibodies (Sigma-Aldrich).  HRP conjugates 
were detected with Immobilon Western Chemiluminescent substrate (Millipore) to determine 
expression of CIITA constructs.  Proteins were normalized by Bradford assay and equal loading 
was determined in lysates.   
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RESULTS 
Mutating serine 280 in the CIITA degron reduces CIITA ubiquitination and enhances 
CIITA half-life.  
CIITA is large protein with four functional domains, an N-terminal acidic activation do-
main (AAD) required for CIITA transactivity, a proline/serine/threonine rich (P/S/T) domain re-
quired for binding to factors and cofactors, a GTP-binding domain (GBD), and a C-terminal leu-
cine rich region (LRR) required for localization and oligomerization (Masternak, Muhlethaler-
Mottet et al. 2000; Cressman, O'Connor et al. 2001; Tosi, Jabrane-Ferrat et al. 2002) (figure 
4.1A, top panel).  The P/S/T domain of CIITA isoform 1 (IF1) contains a degron (Drozina, 
Kohoutek et al. 2006), a sequence which typically targets proteins for ubiquitination at proximal 
lysine residues and degradation (Barbash, Egan et al. 2009).  CIITA IF1 serine 357 lies within 
the degron sequence and is phosphorylated by ERK1/2 prior to IF1 ubiquitination (Drozina, 
Kohoutek et al. 2006).  Our sequence analysis revealed a degron is also present in CIITA isoform 
III (IF3), so we first determined if the conserved serine at position 280 is important for CIITA 
IF3 ubiquitination and stability.  CIITA IF3 serine 280 was mutated to alanine using site directed 
mutagenesis (figure 4.1A, bottom panel) and in vivo ubiquitination assays were performed.  
Expression of WT-CIITA or CIITA S280A with mono-ubiquitin in HeLa cells demonstrated that 
CIITA S280A was less mono-ubiquitinated than WT-CIITA (figure 4.1B).  Densiometric quan-
titation revealed a 50% decrease in CIITA S280A mono-ubiquitination in comparison to that of 
WT-CIITA (figure 4.1C).  Half-life assays indicated CIITA S280A is more stable than WT-
CIITA (figure 4.1D, top panel) while transfection controls using a combined 8hr treatment of 
cycloheximide and the proteasome inhibitor MG132 equally reconstituted expression WT-CIITA 
and CIITA S280A (figure 4.1D, bottom panel).  
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Figure 4.1:  Mutating serine 280 in the degron of CIITA isoform III reduces CIITA ubiquitination and en-
hances CIITA half-life.  
(A) Schematic representation of domain structure of CIITA.  CIITA is an 1130 amino acid protein with four func-
tional domains: an N-terminal transcriptional acidic activation domain (AAD), a proline/serine/threonine rich (P/S/T) 
domain, a GTP-binding domain (GBD), and a C-terminal leucine rich region (LRR).  CIITA has three nuclear locali-
zation sequences (NLS) dispersed through the length of the protein.  The P/S/T rich region of CIITA contains a pro-
teolytic signal sites termed a degron (D) (top panel).  Site-directed mutagenesis was performed to mutate serine 280 to 
alanine (flag-CIITA S280A, bottom panel).  (B)  Mutating serine 280 to alanine reduces CIITA ubiquitination.  
Ubiquitination assay.  HeLa cells were co-transfected with flag-WT-CIITA or flag-CIITA S280A and HA-Mono-
Ubiquitin (HA-Mono-Ub) or HA-WT-Ubiquitin (HA-WT-Ub).  Cells were treated as indicated with proteasome inhi-
bitor MG132 for 4hrs prior to harvesting. Cells were harvested, lysed, precleared and immunoprecipitated (IP‟d) with 
anti-flag antibody to pull down CIITA and bound proteins.  Western blots were performed and IP‟d samples were 
immunoblotted (IB) using anti-HA antibody to detect ubiquitinated CIITA.  Lysate controls demonstrate expression 
of Flag-CIITA.  Results shown are representative of 3 experiments.  (C)  Densitometric quantitation.  Western blots 
of in vivo ubiquitination assays were quantified using Multi-Gauge V3.1 and graphed as shown.  Results shown are 
representative of 3 experiments.  (D)  Mutating serine 280 to alanine increases CIITA half life.  HeLa cells were 
transfected with flag-WT-CIITA or flag-CIITA S280A.   Following transfection, cells were treated with cyclohex-
imide for 0-20 hrs. Following cycloheximide treatment, cells were harvested and western blot analysis was performed 
to determine the half-life of transfected CIITA (top panel).  As transfection and degradation controls, HeLa cells 
transfected with flag-WT-CIITA or flag-CIITA S280A were treated with cycloheximide and proteasome inhibitor 
MG132 for 8hrs (bottom panel).  Results shown are representative of 3 experiments.   
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Despite its increased stability, CIITA S280A is less active than WT CIITA. 
We have recently identified a novel N-terminal ATPase binding domain in CIITA that 
lies within the P/S/T region of CIITA and encompasses a majority of the degron.  Absence of 
this domain increases CIITA half-life, but dramatically decreases MHC class II surface expres-
sion indicating roles for the ATPase binding domain in regulating CIITA transactivation (Bhat, 
Truax et.al. 2009 in revision, Journal of Immunology and Cell Biology).  As mutating serine 280 
to alanine reduces CIITA mono-ubiquitination and enhances CIITA half-life, we next determined 
if this mutation affected CIITA mediated MHC class II transcription.  MHC class II mRNA le-
vels were measured in HeLa cells transfected with WT-CIITA or with CIITA S280A, and either 
untreated or stimulated with IFN-γ.  We observed that in unstimulated cells, expression of WT-
CIITA resulted in increased MHC class II expression as compared to pcDNA or CIITA S280A 
transfected cells.  Upon IFN-γ stimulation, endogenous MHC class II transcript levels were in-
creased, and expression of WT-CIITA further enhanced transcript levels.  However, expression 
of the CIITA S280A did not significantly increase endogenous MHC class II transcript levels 
beyond that of IFN-γ stimulation alone (figure 4.2A) despite equal expression of CIITA S280A 
in both experiments (figure 4.2B).  MHC class II cell surface expression was similarly reduced 
by the CIITA serine 280 to alanine mutation in unstimulated HeLa cells (figure 4.2C).  
 
CIITA is significantly ubiquitinated downstream of S280 and the degron sequence. 
Gene transcription involves highly coordinated and sequential post-translational modifi-
cations of activators with activator phosphorylation frequently preceding mono-ubiquitination.   
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Figure 4.2:  CIITA S280A is less active than WT CIITA.   
(A)  Mutating CIITA serine 280 to alanine decreases MHC class II mRNA expression levels.  mRNA quantifi-
cation.  HeLa cells were transfected flag-CIITA or flag-CIITA S280A or pcDNA as indicated and were stimulated 
with IFN-γ for 18hrs or left untreated.  Cells were harvested, RNA was extracted and cDNA was prepared and quan-
tified by Real-time PCR.  Results shown are an average of 3 experiments (top panel).  Western blots.   1/10
th
 of the 
cell volume was lysed in NP40 to confirm expression of flag-CIITA and flag-CIITA S280A (bottom panels).  (B) 
Mutating CIITA serine 280 to alanine decreases MHC class II surface expression.  Flow cytometry.  HeLa cells 
were transfected as indicated with flag-CIITA or flag-CIITA S280A mutant or pcDNA.  72hrs following transfec-
tion, cells were trypsinized, washed and incubated with PE-labeled anti-human HLA-DR antibody.  Following anti-
body incubation, cells were fixed and PE cell surface staining was measured by FACS-Canto.   
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Serine phosphorylation in the CIITA isoform I degron has been shown to precede CIITA 
mono-ubiquitination and subsequent poly-ubiquitination (Drozina, Kohoutek et al. 2006).  To 
identify the lysine resides targeted for ubiquitination, we generated two CIITA truncation mu-
tants:  CIITA 1-224aa that lacked the entire degron and proximal downstream lysines, and CII-
TA 1-335aa that contained the entire degron and the lysine residues in close proximity to the de-
gron (figure 4.3A) and compared them to ubiquitination of WT-CIITA (figure 4.3B).  In vivo 
ubiquitination assays indicate low level mono-ubiquitination of CIITA 1-224aa compared to the 
robust monoubiquitination seen in CIITA1-335aa (figure 4.3B, compare lanes 2 and 5) and in 
WT-CIITA (figure 4.3B, compare lanes 2 and 8).  Importantly, CIITA 1-335aa contains only 3 
additional lysine residues more than CIITA 1-224aa; compared to WT-CIITA which contains an 
additional 35 lysine residues more than CIITA 1-224aa and 32 more lysine residues than CIITA 
truncation 1-335aa.  As the difference of 3 lysine residues between the two CIITA truncations 
results in a substantial difference in their levels of mono-ubiquitination (figure 4.3C), these 3 
lysine residues likely serve as sites for prominent CIITA mono-ubiquitination.  
 
Mutating degron proximal lysines 315, 330 and 333 to arginine reduces CIITA mono-
ubiquitination and half-life. 
Ubiquitination assay of CIITA truncations indicate residues located between amino acids 
224 and 335 of CIITA may serve as sites for mono-ubiquitination.  As lysine residues proximal 
to degrons are preferentially targeted for ubiquitination by E3 ligases (Barbash, Egan et al. 
2009), we sought to further determine the ubiquitination status of  residues K315, K330 and 
K333.  When we first performed ubiquitination assay to determine the effect of lysine mutations  
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Figure 4.3:  CIITA is highly ubiquitinated downstream of the N-terminal degron.   
(A) Schematic representation of CIITA truncation mutants.  Full length flag-CIITA was used to generate trunca-
tion constructs flag-CIITA 1-224aa and flag-CIITA 1-335aa.  (B) CIITA is ubiquitinated between residues 225 
and 335.  Ubiquitination assay.  HeLa cells were transfected with the 1-224aa or 1-335aa truncation mutants of CII-
TA or WT-CIITA, and HA-Mono-Ubiquitin (HA-Mono-Ub) or HA-WT-Ubiquitin (HA-WT-Ub).  Cells were treated 
as indicated with the proteasome inhibitor MG132 for 4hrs prior to harvesting.  Following lysis, cells were IP‟d with 
anti-Flag antibody and IP‟d samples were IB‟d with anti-HA antibody (top panels).  Lysates confirm expression of 
Flag-CIITA (bottom panels).  Results shown are representative data of 3 experiments.  (C)  Densitometric quantita-
tion.  Western blots from in vivo ubiquitination assays were quantified using Multi-Gauge V3.1 and graphed.  Re-
sults shown are representative data of 3 experiments.   
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on CIITA ubiquitination using full length CIITA (flag-CIITA K315,330,333R) (figure 4.4A), we 
observed a slight decrease in mono-ubiquitination (Supplemental figure 4.7A-B).  The small 
difference can be attributed to the fact that full length CIITA has 39 additional lysine residues 
which may serve as ubiquitination sites (Greer, Zika et al. 2003) .  When we performed ubiquiti-
nation assays comparing CIITA1-335 to the triple lysine mutant CIITA 1-335 K315, 330, 333R, 
we observed dramatic and quantifiable decrease in mono-ubiquitination (figure 4.4B-C).  To-
gether, these data indicate the three degron proximal lysine residues are targets for mono-
ubiquitination, and highlight the fact that other lysine sites downstream of these lysines may 
serve as sites for mono-ubiquitination if lysines 315, 330, and 333 are unavailable for ubiquitina-
tion.   
  Mono-ubiquitination has been shown to protect target proteins from the “stripping” ac-
tivity of 19S proteasomal ATPases, thus preventing transcription factor degradation and increas-
ing transactivation potential (Archer, Burdine et al. 2008; Archer, Delahodde et al. 2008).  If de-
gron proximal lysine residues K315, K330 and K333 serve as sites for protective mono-
ubiquitination, then mutating the three lysine residues to arginine may render them susceptible to 
rapid degradation and increased vulnerability to the “stripping” activity of 19S proteasomal   
ATPases.  Indeed, cycloheximide chase assays indicate the CIITA K3R mutant has a shorter 
half-life than WT-CIITA (figure 4.4D, top panels).  Transfection controls using a combined 8 hr 
treatment of cycloheximide and the proteasome inhibitor MG132 equally reconstituted expres-
sion WT-CIITA and CIITA K3R, further indication that CIITA degradation requires a functional 
26S proteasome. 
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Figure 4.4:  Mutating CIITA lysines 315, 330 and 333 to arginine reduces CIITA mono-ubiquitination and 
half life.  
(A) Schematic representation of CIITA lysine mutants. Site-directed mutagenesis was performed to mutate ly-
sine residues 315, 330 and 333 to arginine.  Mutants generated were flag-CIITA K1R (K315R), flag-CIITA K2R 
(K330, 333R) and flag-CIITA K3R (K315, 330, 333R).  (B)  Mutating lysine residues K315, K330 and K333 to 
arginine reduces CIITA mono-ubiquitination.  Ubiquitination assay.  HeLa cells were transfected with flag-
CIITA 1-335 or flag-CIITA 1-335 K3R, and HA-Mono-Ubiquitin (HA-Mono-Ub) or HA-WT-Ubiquitin (HA-WT-
Ub).  Cells were treated as indicated with the proteasome inhibitor MG132 for 4hrs prior to harvesting.  Lysed cells 
were IP‟d with anti-flag antibodies and IB‟d with anti-HA antibodies (top).  Lysate controls demonstrate expression 
of Flag-CIITA (bottom).  Results shown are representative data of 3 experiments.  (C)  Densitometric quantita-
tion.  Western blots from ubiquitination assays were quantified using Multi-Gauge V3.1 and graphed.  Results 
shown are representative data of 3 experiments.  (D)  Mutating lysine residues K315, K330 and K333 to arginine 
decreases CIITA half-life.  HeLa cells were transfected with flag-CIITA or flag-CIITA K3R.   Following transfec-
tion, cells were treated with cycloheximide for 0-20 hrs, harvested and IB‟d to determine the half-life of transfected 
CIITA (top panel).  As transfection and degradation controls, HeLa cells transfected with flag-WT-CIITA or flag-
CIITA K3R were treated with cycloheximide and proteasome inhibitor MG132 for 8hrs (bottom panel).  Results 
shown are representative of 3 experiments.   
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Mutating CIITA lysines 315, 330 and 333 to arginine reduces CIITA transactivity, MHC 
class II mRNA levels and MHC class II surface expression. 
Mono-ubiquitination of CIITA has previously been shown to enhance CIITA transactivi-
ty and MHC class II expression (Greer, Zika et al. 2003).  As mutating lysine 315, 330 and 333 
to arginine reduces CIITA mono-ubiquitination and half-life, we next wanted to know if these 
mutations also affected CIITA mediated MHC class II transcription.  To address this, we per-
formed luciferase reporter assays to measure CIITA transactivity.  Results from reporter assays 
indicated that expression of WT-CIITA dramatically increases transactivation from a MHC class 
II HLA-DRA reporter construct.  However, expression of any of the CIITA lysine mutants:  CII-
TA K315R, CIITA K330, 333R, and CIITA K315, 330, 333R resulted in dramatic decreases in 
CIITA transactivation (figure 4.5A, top).  Western blots of transfection controls demonstrated 
expression of each of the indicated flag-tagged constructs (figure 4.5A, bottom).   
We next tested if endogenous MHC class II transcript levels were similarly affected by 
the degron proximal lysine mutations.  MHC class II mRNA levels were measured in HeLa cells 
transfected with WT-CIITA, CIITA K315R, CIITA K330,333R or CIITA K315,330,333R and 
either left untreated or stimulated with IFN-γ.  In unstimulated HeLa cells, expression of WT-
CIITA resulted in an increase in MHC class II transcript levels as compared to cells transfected 
with any of the CIITA degron proximal lysine mutants (figure 4.5B, top left panel).  When 
HeLa cells were stimulated with IFN-γ, endogenous MHC class II transcript levels increased and 
were further enhanced by expression of WT-CIITA.  However, expression of the degron proxim-
al lysine mutants failed to significantly enhance MHC class II transcript levels beyond levels 
seen in cells stimulated with IFN-  and transfected with the pCDNA control (figure 4.5B, top 
right panel).  
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Western blots of transfection controls demonstrate expression of each of the indicated 
flag-tagged constructs (figure 4.5B, bottom).  MHC class II cell surface expression was similar-
ly reduced by the CIITA lysine to arginine mutations in unstimulated HeLa cells (figure 4.5C).  
Figure 4.5:  Mutating lysines 315, 330 and 333 to arginine reduces CIITA transactivity, MHC class II mRNA 
levels, and MHC class II surface expression.  
(A)  Mutating CIITA lysine residues K315, K330 and K333 to arginine reduces CIITA transactivity.  Luciferase 
reporter assays.  HeLa cells were transfected with flag-CIITA, flag-CIITA K1R, flag-CIITA K2R, flag-CIITA K3R or 
pcDNA and HLA-DRA-Luciferase reporter  Luciferase readings were normalized to total protein concentration. Re-
sults shown are an average of 3 experiments (top panel). Expression of flag-CIITA, flag-CIITA K315R, flag-CIITA 
K330,333R and flag-CIITA K315,330,333R.  Western blot.   Lysates IB‟d with anti-flag antibodies confirm expres-
sion of flag-tagged constructs.  Results shown are representative of 3 experiments (bottom panels).  (B)  Mutating 
CIITA lysine residues K315, K330 and K333 to arginine reduces MHC class II mRNA levels.  mRNA quantifica-
tion. HeLa cells were transfected with flag-CIITA, flag-CIITA K1R, flag-CIITA K2R, flag-CIITA K3R or pcDNA.  
Following transfection, cells were left untreated or were stimulated with IFN-γ for 18hrs.  Cells were harvested,RNA 
extracted, and cDNA was prepared and quantified by Real-time PCR.  Results shown are an average of 3 experiments 
(top panel).  Expression of flag-CIITA, flag-CIITA K315R, flag-CIITA K330,333R and flag-CIITA 
K315,330,333R.  Western blot.   1/10
th
 of the cell volume was lysed and IB‟d with anti-flag antibodies to confirm ex-
pression of flag-tagged constructs.  Results shown are representative of 3 experiments (bottom panels).  (C) Mutating 
CIITA lysine residues K315, K330 and K333 to arginine reduces MHC class II surface expression.  Flow cyto-
metry.  HeLa cells were transfected with flag-CIITA, flag-CIITA K315R, flag-CIITA K330,333R , flag-CIITA 
K315,330,333R or pcDNA.  72 hrs following transfection, cells were trypsinized, washed and incubated with PE-
labeled anti-human HLA-DR antibody.  Following antibody incubation, cells were fixed and PE cell surface staining 
was measured by FACS-Canto. (i)  HeLa cells transfected with flag-CIITA (light gray line) and HeLa cells transfected 
with pcDNA (black line).  (ii)  HeLa cells transfected with flag-CIITA K315R (light gray line) and HeLa cells trans-
fected with pcDNA (black line).  (iii)  HeLa cells transfected with flag-CIITA K330,333 R (light gray line) and HeLa 
cells transfected with pcDNA (black line).  (iv)  HeLa cells transfected with flag-CIITA K315,330,333R (light gray 
line) and HeLa cells transfected with pcDNA (black line).   
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As mutating the degron proximal lysine residues to arginine reduces CIITA mono-ubiquitination 
and also affects CIITA mediated MHC class II transcription and surface expression, we next ge-
netically fused mono-ubiquitin to the N-terminus of CIITA and CIITA K3R constructs in order 
to overcome the lack of mono-ubiquitination at the degron proximal lysine residues in hopes of 
resuscitating CIITA activity in the lysine mutants.  However, luciferase reporter assays using 
these fusion constructs demonstrated substantial decreases in CIITA transactivation when either 
WT CIITA (Mono-Ub-CIITA) or CIITA K315, 330, 333R (Mono-Ub-K315, 330, 333R) was 
fused to mono-ubiquitin (supplementary figure 4.8A).  Western blot analysis of lysates isolated 
from cells transfected with these fusion-constructs demonstrated CIITA was rapidly degraded 
when fused with mono-Ub as indicated by the formation of a smear as compared to a single band 
for WT-CIITA (supplementary figure 4.8B).  Minimally, these data indicate CIITA fragmenta-
tion, and likely rapid degradation, of ubiquitin-fused CIITA.   
 
Mutating Serine 280 to alanine in the triple lysine mutant restores MHC class II surface 
expression. 
Although multiple sites in CIITA can be targeted for mono-ubiquitination, our results 
suggest that degron proximal lysine residues, K315, K330, and K333, are important regulatory 
targets for CIITA mono-ubiquitination and CIITA stability and for MHC class II expression.  
Serine 280 within the degron of CIITA regulates CIITA half life and plays important roles in re-
gulating CIITA ubiquitination, mostly likely affecting access to degron proximal lysine residues.  
To determine the effects of combining the degron proximal serine and lysine mutations, we mu-
tated serine 280 to alanine in CIITA K315, 330, 333R (figure 4.6A).  The CIITA S280AK315, 
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330, 333R mutant restored MHC class II surface expression to a level beyond that seen in cells 
transfected with WT CIITA, indicating the importance of an initiating phosphorylation event to 
properly regulate ubiquitination and CIITA mediated MHC class II expression.  
 
DISCUSSION 
CIITA, the master regulator of MHC Class II genes, has been implicated in disease de-
velopment due to its function as a multi-potent transactivator of various critical immune genes 
(Sisk, Gourley et al. 2000; Gourley and Chang 2001; Wong, Brickey et al. 2003; Nozell, Ma et 
al. 2004; Yee, Yao et al. 2004; Yee, Yao et al. 2005).  How CIITA is able to wear multiple hats 
and modulate this wide variety of genes in a cell and tissue specific manner remains under inves-
tigation.  Post-translational modifications of CIITA are major players in modulating CIITA ac-
tivity as they fine-tune CIITA transactivity in response to various cellular stimuli.  Here we have 
sought to identify essential ubiquitination sites in CIITA and to link ubiquitination to a phospho-
rylation event. 
The process of protein ubiquitination is a complex enzymatic cascade involving covalent 
attachment of a ubiquitin moiety to an internal lysine residue.  Although E3 ligases can target 
different lysine residues for ubiquitination, its known that lysine resides proximal to degron sites 
are preferentially targeted (Barbash, Egan et al. 2009).   
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Figure 4.6:  Combining CIITA mutations of S280A with K315, 330, 333R rescues CIITA.  
(A) Site directed mutagenesis of serine 280 to alanine in the K315, 330, 333R lysine mutant of CIITA.  Gen-
eration of flag-CIITA S280AK315,330,330R.  (B) Mutating serine 280 to alanine in the triple lysine mutant 
stabilizes MHC class II surface expression.  Flow cytometry.  HeLa cells were transfected with flag-CIITA, flag-
CIITA K315,330,333R, flag-CIITA S280A, flag-CIITA S280AK315,330,333R or pcDNA.  72 hrs following trans-
fection, cells were trypsinized, washed and incubated with PE-labeled anti-human HLA-DR antibody.  Following 
antibody incubation, cells were fixed and PE cell surface staining was measured by FACS-Canto.  (i)  HeLa cells 
transfected with flag-CIITA (light gray line) and with pcDNA (black line).  (ii) HeLa cells transfected with flag-
CIITA K315,330,333R (light gray line) and with pcDNA (black line).  (iii) HeLa cells transfected with flag-CIITA 
S280A (light gray line) and with pcDNA (black line).  (iv) HeLa cells transfected with flag-CIITA 
S280AK315,330,333R (light gray line) and pcDNA (black line).   
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Studies have shown that mutation of threonine 286 in the degron sites of cyclin D1 leads 
to loss of phosphorylation dependent ubiquitination.  This loss of ubiquitination results in accu-
mulation of cyclin D1 and has been attributed to development of various cancers including en-
dometrial cancer, ductal breast carcinoma, head and neck, prostrate and lung cancer (Moreno-
Bueno, Rodriguez-Perales et al. 2003).  Furthermore, CIITA isoform I transactivity has been 
demonstrated to be dependent on ubiquitination that proceeds phosphorylation of S357 in its de-
gron (Drozina, Kohoutek et al. 2006).  In a recent study, we identified a novel N-terminal      
ATPase binding domain in CIITA that encompasses a majority of the degron (Bhat, Truax et.al. 
2009, in revision, The Journal of Immunology and Cell Biology).  Absence of the ATPase bind-
ing domain increases CIITA half-life, but dramatically decreases MHC class II surface expres-
sion, indicating roles for the ATPase binding domain in regulating CIITA transactivation.  These 
observations point to the fact that phosphorylation of residues in the degron site may be modulat-
ing CIITA transactivity via ubiquitination.  Here we have identified a conserved serine residue 
within the degron of CIITA isoform III that regulates CIITA.  Mutating serine 280 to alanine 
blocks phosphorylation, reduces CIITA ubiquitination, and stabilizes the protein.  Despite in-
creased accumulation of CIITA, the S280A mutation decreases CIITA mediated MHC class II 
expression.  Previous studies have shown that mono-ubiquitination of CIITA enhances its trans-
activity and MHC class II expression (Greer, Zika et al. 2003).  Together, these data indicate that 
phosphorylation at serine 280 is required for CIITA mono-ubiquitination and subsequent CIITA 
mediated MHC class II expression.  Recent studies have identified serine residues in the CIITA 
degron and P/S/T domain that are targets of phosphorylation by ERK1/2 (Greer, Harton et al. 
2004; Drozina, Kohoutek et al. 2006; Voong, Slater et al. 2008).  Future studies will determine if 
S280 is also a target of ERK1/2 mediated phosphorylation.   
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Figure 4.7:  Supplementary data: Mutating lysine residues K315, K330 and K333 to arginine in full length 
CIITA has modest effects on CIITA ubiquitination.   
(A) Ubiquitination assay.  HeLa cells were co-transfected with the flag-CIITA or flag-CIITA K3R and HA-Mono-
Ubiquitin (HA-Mono-Ub) or HA-WT-Ubiquitin (HA-WT-Ub).  Cells were treated with MG132, proteasome inhibi-
tor, for 4hours before harvesting. Cells were harvested, lysed in NP40, precleared and IP‟d with anti-Flag antibody 
to pull down proteins attached to CIITA.  Western blots were performed and the IP‟d samples were IB using anti-
HA antibody (for HA-Mono/WT-Ub).  Lysates were run to control for proper expression of HA-Mono/WT-Ub and 
Flag-CIITA.  The results are representative data of 3 experiments.  (B)  Densitometry and quantitation of data in 
B.  Western blots from in vivo ubiquitination assays were quantified using Multi-Gauge V3.1 and graphed as shown.  
Results shown are representative of 3 experiments.   
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Previous studies have linked activator phosphorylation and downstream, degron proximal 
mono-ubiquitination (Drozina, Kohoutek et al. 2006; Barbash, Egan et al. 2009).  E3 ubiquitin 
ligases have specificity to lysine residues in substrate proteins (Zheng, Schulman et al. 2002; 
Wu, Xu et al. 2003; Barbash, Egan et al. 2009) and lysine residues proximal to degron sequences 
are preferentially targeted for ubiquitination by E3 ligases (Barbash, Egan et al. 2009).  We have 
identified three lysine residues in CIITA isoform III, K315, K330 and K333, proximal to the de-
gron sequence as sites of mono-ubiquitination.  Mutating these lysine residues to arginine reduc-
es CIITA mono-ubiquitination and half-life, indicating that mono-ubiquitination at these residues 
stabilizes CIITA.  Additionally, these lysine mutations reduce CIITA transactivity, leading to 
reductions in MHC class II transcript levels and MHC class II surface expression.  In addition, 
we demonstrate the mono-ubiquitination events at the three lysine residues are interchangable; 
CIITA K315R, CIITA K330, 333R, and CIITA K315, 330, 333R all have similar effects on CII-
TA transactivity, indicating that these sites may serve as alternate sites for ubiquitination due to 
stearic hindrance.   
Mutating CIITA serine 280 to alanine in the triple lysine mutant restores MHC class II 
cell surface expression levels in excess of levels modulated by WT CIITA.  These data indicate 
mono-ubiquitination at these lysine residues is regulated by phosphorylation at serine 280 and 
that both events, phosphorylation and mono-ubiquitination, are crucial for CIITA stability and 
transactivity.  Based on our observations, we propose that phosphorylation of S280 is recognized 
by a specific E3 ligase that binds CIITA and mono-ubiquitinates proximal lysine residues K315, 
K330 or K333.  Mono-ubiquitination of these lysine residues protects them from the “stripping 
activity” of proteasomal ATPases, and thus protects CIITA from degradation, increases CIITA 
transactivation potential and upregulates MHC class II transcription.   
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Figure 4.8: Supplementary data: Genetically fusing Mono-ubiquitin to WT or triple lysine mutant of CIITA 
reduces its transactivity due to rapid degradation of fusion products.  
(A) Flag-mono-ubiquitin-CIITA and Flag-mono-ubiquitin-CIITAK315,330,333R  are rapidly degraded. 
Western blot.  HeLa cells were transfected with the flag-CIITA /flag-mono-ubiquitin-CIITA (left panel) or the flag-
CIITA / flag-mono-Ubiquitin-CIITA K3R (right panel).  Cells were harvested, lysed in NP40 and western blots 
were performed to check for expression of CIITA constructs.  (B) Flag-mono-ubiquitin-CIITA and Flag-mono-
ubiquitin-CIITAK315,330,333R are show lower transactivity as compared to flag-CIITA or flag- CII-
TAK315,330,333R. Luciferase reporter assays.  HeLa cells were co-transfected with flag-CIITA/flag-mono-
ubiquitin-CIITA (left panel), flag-CIITA K315,330,333R /flag-mono-Ubiquitin-CIITA K315,330,333R  (right pan-
el) or pcDNA (empty vector) and HLA-DRA-Luciferase reporter constructs.  Cells were harvested, lysed in cell 
lysis buffer and luciferase assay was performed using manufacturers‟ protocol.  Luciferase readings were norma-
lized to total protein concentration. Results are average of 2 experiments. 
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While previous studies have demonstrated ubiquitination to be a regulatory mechanism of 
CIITA transactivity, they have failed to map sites of ubiquitination in CIITA (Greer, Zika et al. 
2003; Schnappauf, Hake et al. 2003).  This report identifies ubiquitination sites for CIITA that 
regulate CIITA mediated MHC class II expression.  These findings will further our knowledge of 
the roles of post-translational modifications of CIITA in modulating CIITA activity and will 
provide novel tools for development of therapeutic strategies regarding the expression of CIITA 
and MHC class II.  
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CHAPTER 5 
 
CONCLUSIONS 
Eukaryotic transcription involves a complex interplay of multiple protein complexes 
which must be recruited to, and ultimately removed from, DNA.  Though intensive studies have 
been undertaken to elucidate the mechanisms involved, how cells perform the tasks required to 
initiate, maintain and terminate transcription remains largely enigmatic.  The ubiquitin protea-
some system (UPS), long known to be the master regulator of protein degradation, plays crucial 
roles in a multitude of cellular activities including transcription.  The UPS is known to regulate 
transcription by proteolytically degrading transcription factors, co-factors and chromatin remode-
ling enzymes; however, novel, non-proteolytic roles for the UPS in transcriptional regulation 
have only recently been investigated (Ciechanover, Shkedy et al. 1994; Hochstrasser 1996; 
Carrano, Eytan et al. 1999; Aviel, Winberg et al. 2000; Reinstein, Scheffner et al. 2000; Koepp, 
Schaefer et al. 2001; Haglund, Sigismund et al. 2003; Schnappauf, Hake et al. 2003; Coulombe, 
Rodier et al. 2004; Hegde 2004; Hernandez-Pigeon, Laurent et al. 2004; Kinyamu, Chen et al. 
2005; Auld and Silver 2006; Duncan, Piper et al. 2006; Huang, Kirkpatrick et al. 2006; Barbash, 
Egan et al. 2009).   
Initial observations indicating that the intact 26S proteasome, the 19S regulatory particle, 
and the 20S proteolytic core exist in both cytoplasmic and nuclear compartments in multiple cell 
types, including Xenopus laevis oocytes (Peters, Franke et al. 1994) demonstrated the 26S, 19S 
and 20S could exist separately and therefore might play independent roles in transcriptional 
regulation.  To date, subunits of the 19S and/or 20S proteasome have been shown to associate 
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with an excess of 6400 genes (Sikder, Johnston et al. 2006).  While the 26S proteasome is known 
to associate with RNA polymerase II (RNA Pol II) (Gillette, Gonzalez et al. 2004) and to be crit-
ical for efficient RNA Pol II mediated elongation (Ferdous, Gonzalez et al. 2001), specific inhi-
bition of 19S activity decreases elongation while inhibition of 20S activity increases elongation, 
indicating a balance between these two subunits and their activities may be important for tran-
scriptional regulation (Ferdous, Gonzalez et al. 2001; Ferdous, Kodadek et al. 2002; Gillette, 
Gonzalez et al. 2004).  While the role of the 19S proteasome in yeast gene transcription has been 
robustly investigated, only recently have publications highlighted the significance of the 19S in 
regulating mammalian transcription.  Highlights of these studies include observations that the 
19S proteasomal ATPase Sug1 interacts with various mammalian transcription factors including 
viral transcription factor E1A, tumor suppressor p53, HIV-1 transactivator Tat and retinoic acid 
receptor, and via these interactions, increases transcription of target genes (Ferdous, Kodadek et 
al. 2002; Rasti, Grand et al. 2006; Zhu, Wani et al. 2007; Ferry, Gianni et al. 2009).   
While the evidence for 19S involvement in mammalian transcription is enticing, it re-
mains unclear whether or not 19S subunits play independent roles in recruiting and stabilizing 
transcription factors at responsive promoters.  In order to more fully understand the roles of the 
proteasome system in regulating mammalian genes, we initially investigated the role of the 19S 
ATPase subunit Sug1 in regulating MHC class II transcription.  We chose this model system be-
cause MHC class II molecules are cell surface glycoproteins that serve as major determinants of 
the immune response (Kvist and Levy 1993).  Because MHC class II is a critical regulator of 
adaptive immune and anti-tumor responses (Glimcher and Kara 1992; Wang 2003), its expres-
sion is tightly regulated (Benoist and Mathis 1990).  MHC class II expression is regulated pri-
marily at the level of transcription by the master regulator, the class II transactivator, CIITA 
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(Masternak, Muhlethaler-Mottet et al. 2000).  Although much research has been performed to 
understand the transcriptional mechanisms of CIITA, how CIITA is recruited, stabilized and de-
graded at MHC Class II promoters remains unclear.  It was with this deficit of knowledge in 
CIITA and MHC class II regulation that we approached the hypothesis that 19S ATPases mod-
ulated mammalian transcription factor activity independent of proteolysis.   
Our initial observations were that proteasome inhibition decreases CIITA transactivity 
and MHC class II expression without affecting CIITA expression, and indicated non-proteolytic 
roles for the proteasome in regulating CIITA mediated MHC class II transcription.  The 19S 
ATPase Sug1 rapidly associates with the MHC class II proximal promoter within 4 hours of cy-
tokine stimulation and association correlated with CIITA recruitment to the MHC class II pro-
moter.  Furthermore, CIITA and Sug1 co-precipitate, suggesting the existence of a regulatory 
interaction between the two proteins.  Association of the 19S Sug1 subunit at the MHC class II 
promoter peaks between 4 and 24 hours following IFN-  stimulation, then declines and main-
tains reproducibly sustained binding for up to 95 hours.  It is interesting to note that the alpha 4 
subunit of the 20S core also associates with the MHC class II promoter following prolonged cy-
tokine stimulation.  Together, these observations indicate potential reassembly of the 26S protea-
some at the less transcriptionally active promoter.  CIITA association with the MHC class II 
promoter remains relatively stable up to 65 hours of IFN-γ stimulation, after which the CIITA 
promoter association rapidly declines.  These observations correlate promoter recruitment and 
assembly of a functional 26S proteasome with the loss of CIITA and are consistent with a role 
for the reconstituted 26S proteasome in mediating transcriptional termination by degrading pro-
moter bound CIITA.    
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 Chromatin immune precipitation (ChIP) assays indicate that the 19S proteasomal      
ATPase Sug1 and CIITA are recruited to the MHC class II proximal promoter region early dur-
ing cytokine stimulation.  In addition, we observed that these two proteins co-immunoprecipitate.  
Together, these studies indicate roles for Sug1 in regulating MHC class II transcription by con-
trolling CIITA promoter association.  When Sug1 expression is decreased via RNAi, the ability 
of CIITA to regulate MHC class II transcription and MHC class II transcript levels are also re-
duced.  However, CIITA expression remains stable in the absence of Sug1, indicating selectivity 
in transcriptional systems regulated by Sug1.  Despite sustained expression of CIITA, in the ab-
sence of Sug1, CIITA recruitment to the MHC class II promoter is diminished.  Reporter assays 
indicate that proteolytic function of the 26S proteasome is also required for efficient transcrip-
tional activation by CIITA, and therefore, for cytokine inducible MHC class II expression.  Ad-
ditonally, in Koues et.al., and Truax et.al., we demonstrated that additional 19S proteasomal  
ATPases bind the MHC class II promoter and play positive roles in regulating MHC class II 
transcription (Koues, Dudley et al. 2008; Koues, Dudley et al. 2009; Truax, Koues et al. 2009).  
In sum, these observations indicate that the proteasome functions both proteolytically and non-
proteolytically at promoter and coding regions of MHC class II during different stages of tran-
scription.  Although these observations clearly indicate a non-proteolytic role for 19S protea-
somal ATPases in CIITA mediated MHC class II gene expression, how CIITA is recruited, stabi-
lized and degraded from the promoter remains is unknown.   
CIITA is not only essential for MHC Class II transcription but also plays crucial roles in 
transcriptional regulation of additional diverse immune response genes including IL-4 (Sisk, 
Gourley et al. 2000), IL-10 (Yee, Yao et al. 2005), E-cathepsin (Yee, Yao et al. 2004), MMP-9 
(Nozell, Ma et al. 2004), plexin (Wong, Brickey et al. 2003) and Fas ligand (Gourley and Chang 
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2001).  Involvement of CIITA in transcriptional regulation of a diverse set of immune response 
genes clearly indicates that CIITA may play roles in disease development.  To date, CIITA has 
been implicated in the development of diverse diseases including multiple tumor types (Yazawa, 
Kamma et al. 1999; Dagmar, Alfons et al. 2009; Meissner, Whiteside et al. 2009) and autoim-
mune conditions (Drozina, Kohoutek et al. 2005).  Due to the role of CIITA in regulating the ex-
pression of multiple genes and in diverse disease development, intense studies have focused on 
understanding CIITA regulation.  However, these studies are limited in their findings due to the 
complex domain structure and the distinct roles of CIITA in transcriptional regulation of mul-
tiple genes in various cell types.  We and others have previously linked CIITA to the UPS 
through demonstration of CIITA mono-ubiquitination (Greer, Zika et al. 2003) and poly-
ubiquitination (Schnappauf, Hake et al. 2003), and o alsthrough our previous observation of 
functional dependence of CIITA on 19S ATPases (Bhat, Turner et al. 2008; Koues, Dudley et al. 
2008; Agnieszka D.Truax 2009; Koues, Dudley et al. 2009).  Continued study of the roles of 19S 
ATPases in modulating CIITA activity has helped us gain significant insight into CIITA regula-
tion.   
To this end, we mapped the association of 19S ATPases with CIITA.  We observed that 
CIITA interacts with the C-terminal domain of the 19S ATPase Sug1 and that this interaction is 
independent of the ATPase activity of Sug1.  We observed in co-immunoprecipitation experi-
ments that while C-terminal domains of CIITA, including the GBD, NLS2, and 3, and LRR, are 
not important in interactions with Sug1; the P/S/T region is critical for CIITA association with 
Sug1.  Deletion of part of the P/S/T domain does not affect CIITA transactivity (Chin, Li et al. 
1997), the P/S/T has been shown to be essential for interactions with other transcription factors 
and cofactors (Fontes, Jiang et al. 1997; Fontes, Kanazawa et al. 1999) and deletion of the entire 
148 
 
P/S/T domain reduces CIITA transactivity (Chin, Li et al. 1997).  Therefore, the functional im-
portance of the P/S/T domain of CIITA remains under investigation (Harton and Ting 2000).  
We show that the 19S ATPases Sug1, S7, and S6a, as representative members of the additional 
19S heterodimers, interact within the proline rich P/S/T region.  Based on these observations, we 
have termed the region required for CIITA association with 19S ATPases the “ATPase binding 
domain.” 
To further understand the functional importance of the ATPase binding domain, we per-
formed chase assays to determine CIITA stability upon loss of the 19S binding site.  Cyclohex-
imide chase assays suggested that lack of the ATPase binding domain significantly increases 
CIITA half-life, indicating that binding of 19S ATPases plays important roles in CIITA turnover.  
Although CIITA half-life is enhanced in the absence of the ATPase binding domain, flow cyto-
metric studies demonstrate that MHC class II cell surface expression is diminished.  These data 
indicate CIITA is transcriptionally inactive in the absence of the ATPase binding domain.  Thus, 
the N-terminal ATPase binding domain that lies within the PST domain is crucial for 19S      
ATPase binding to CIITA, for MHC class II expression and for CIITA degradation.  These ob-
servations further enumerate proteolytic and non-proteolytic roles for 19S ATPases in CIITA 
mediated MHC class II transcription.   
Thus far, our studies establish that 19S subunits of the 26S proteasome regulate CIITA 
transactivity, stability, and MHC class II expression via binding of 19S proteasomal ATPases to 
the ATPase binding domain of CIITA.  From previous studies in our lab (Greer, Zika et al. 2003) 
and others, we know that the subunits of the UPS work in concert with the ubiquitination status 
of proteins to determine protein fate and that mono-ubiquitination and non-canonical poly-
ubiquitination of proteins is linked to transcription regulation (Bres, Kiernan et al. 2003; Greer, 
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Zika et al. 2003; Gregory, Taniguchi et al. 2003; Li, Brooks et al. 2003; Kurosu and Peterlin 
2004; van der Horst, de Vries-Smits et al. 2006).  Previous studies have shown that transcription 
factors phosphorylation that precedes degron proximal mono-ubiquitination can play important 
roles in transcription factor transactivity and stability (Drozina, Kohoutek et al. 2006; Barbash, 
Egan et al. 2009).  These observations indicate phosphorylation of residues in the degron site 
may modulate CIITA transactivity via ubiquitination.  Studies have demonstrated that in CIITA 
isoform I phosphorylation of serine 357 in the degron precedes ubiquitination events that mod-
ulate transactivity (Drozina, Kohoutek et al. 2006).  We identify here a conserved serine residue 
within the degron of CIITA isoform III that regulates CIITA ubiquitination, protein stability and 
MHC class II expression.  Mutating serine 280 to alanine blocks phosphorylation, reduces CIITA 
ubiquitination, and stabilizes the protein.  Despite increased accumulation of CIITA, the S280A 
mutation decreases CIITA mediated MHC class II expression.  Previous studies have shown that 
mono-ubiquitination of CIITA enhances its transactivity and MHC class II expression (Greer, 
Zika et al. 2003).  Together, these data indicate that phosphorylation at serine 280 is required for 
CIITA mono-ubiquitination and subsequent CIITA mediated MHC class II expression.   
Although, ubiquitination of CIITA has been shown to modulate its transactivity, the sites 
of ubiquitination in CIITA have not been identified (Greer, Zika et al. 2003; Schnappauf, Hake et 
al. 2003).  Here we have identified three degron proximal lysine residues in CIITA isoform III, 
K315, K330 and K333 that serve as sites for mono-ubiquitination.  Mutating these lysine resi-
dues to arginine reduces CIITA mono-ubiquitination and half-life, indicating that mono-
ubiquitination at these residues stabilizes CIITA.  Additionally we observed that the lysine mu-
tants show reduced CIITA transactivity, leading to reductions in MHC class II transcript levels 
and MHC class II cell surface expression.  Thus, mono-ubiquitination at these lysine residues 
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plays important roles in regulating CIITA transactivity.   In addition, our data demonstrate the 
mono-ubiquitination events at the three lysine residues are interchangable; CIITA K315R, CIITA 
K330, 333R, and CIITA K315, 330, 333R all have similar effects on CIITA transactivity, indi-
cating that these sites may serve as alternate sites for ubiquitination.  Ours is the first report to 
identify ubiquitination sites for CIITA that regulate CIITA mediated MHC class II expression.  
Finally, mutation of CIITA serine 280 to alanine in the triple lysine mutant resulted in a restora-
tion of MHC class II cell surface expression, indicating that mono-ubiquitination at these lysine 
residues is likely regulated by phosphorylation at serine 280, and that both events are crucial for 
CIITA stability and transactivity.   
Based on our observations, we propose the following scenario in which the UPS regulates 
CIITA mediated MHC class II transcription:  Upon cytokine stimulation, CIITA is phosphory-
lated at S280.   Phosphorylation of S280 is recognized by a specific E3 ligase that binds CIITA 
and mono-ubiquitinates the proximal lysine residues K315, K330 or K333.  Mono-ubiquitinated 
CIITA and 19S ATPases are recruited to the MHC class II promoter where, aided by 19S      
ATPases, CIITA orchestrates the assembly of PTEFb and other transcription factors including 
chromatin remodeling enzymes.  CIITA stably binds the enhanceosome complex and the 19S 
complex and drives MHC class II transcription.  Although 19S ATPases are simultaneously loca-
lized to the MHC class II promoter, mono-ubiquitination protects CIITA from stripping by the 
19S ATPases, increases CIITA transactivation potential, and upregulates MHC class II transcrip-
tion.  The APIS complex of the 19S proteasome then disassociates from CIITA and proceeds to 
regulate transcription elongation.  Following prolonged cytokine stimulation, CIITA is poly-
ubiquitinated by E3 ligases, protection from 19S stripping is lost, CIITA is pulled from the en-
hanceosome complex, and CIITA is degraded by a promoter assembled 26S proteasome   
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  Figure 5.1: Ubiquitin and the 26S proteasome modulate CIITA transactivity and MHC class II expression 
 Upon cytokine stimulation, CIITA is phosphorylated at S280 which allows mono-ubiquitination of lysines 315, 330, 
and 333.  Mono-ubiquitinated CIITA and the 19S ATPases are recruited to the MHC class II promoter where, aided by 
19S ATPases, CIITA orchestrates the assembly various transcription factors and cofactors.  Once bound, mono-
ubiquitinated CIITA stably binds both the enhanceosome complex and the 19S complex and drives MHC class II tran-
scription.  Although 19S ATPases are simultaneously localized to the MHC class II promoter, mono-ubiquitination 
protects CIITA from 19S ATPase mediated stripping. The APIS complex then disassociates from CIITA and proceeds 
to drive transcription elongation.  Subsequent prolonged cytokine stimulation drives assembly of the 26S proteasome 
at the MHC class II promoter.  Once CIITA is poly-ubiquitinated by E3 ligases, protection from 19S stripping is lost 
and CIITA is pulled from the enhanceosome complex and degraded by a promoter assembled 26S proteasome.  
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(Figure 5.1).  Thus, the interactions that tether mono-ubiquitinated CIITA to the 19S proteasome 
initially drive CIITA transactivation and eventually target CIITA degradation.   
These findings have enhanced our knowledge of the roles of UPS and of post-
translational modifications of CIITA in modulating CIITA activity and MHC class II expression 
and thus provide novel tools for development of therapeutic strategies to manipulate the expres-
sion of CIITA and MHC class II.   Our findings also bring to light an array of unanswered ques-
tions.  It will be of interest to identify the kinases and E3 ligase(s) involved in serine 280 phos-
phorylation and lysine 315, 330 and 333 ubiquitination.  Recent studies have identified serine 
residues in the CIITA degron and P/S/T domain that are targets of phosphorylation by ERK1/2 
(Greer, Harton et al. 2004; Drozina, Kohoutek et al. 2006; Voong, Slater et al. 2008), therefore, 
future studies will determine if S280 is also a target of ERK1/2 mediated phosphorylation.  Fur-
thermore, understanding the signaling pathway that leads to the post-translational modifications 
that modulate CIITA transactivity will link posttranslational modifications of CIITA to the in-
flammatory events that make necessary increased MHC class II cell surface expression.  Future 
studies will also address how the mono-ubiquitinated state of CIITA is maintained and identify 
deubiquitinating enzymes that target CIITA.  CIITA is a multi-potent transactivator that plays 
roles in regulating the expression of multiple genes and in disease development. 
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